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ABSTRACT
The level of sophistication associated with modern radiotherapy techniques such as
Intensity Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc
Therapy (VMAT) continues to increase, placing increasing demands on the current
Quality Assurance (QA) procedures that ensure patient safety. There is therefore a
significant need for real-time detectors that provide verification of IMRT and VMAT
during the delivery of a patient’s cancer treatment. Current QA procedures typically
involve a pre-treatment dosimetric verification to ensure that the linac is delivering the
dose map as specified by the computerised radiotherapy treatment plan calculation. A
transmission type detector consisting of a two dimensional (2D) array of silicon diodes,
“Magic Plate” (MP), is one potential candidate that would allow for online dosimetry in
real time, during the patient treatment. This is the focus of the studies presented in this
thesis.
The first part of this thesis is to demonstrate the potential performance characteristics of
a silicon diode array called the Magic Plate (MP) quality assurance system when
operated in dose mode (MPDM), as a dosimeter, i.e. on the patient couch embedded in a
solid water phantom at several depths and different beam energies. These characteristics
are then taken into account in the later chapters to compare with the reconstructed 2D
and /or three dimensional (3D) dose in a phantom at several depths.
The second part of this thesis demonstrates that for the two potential operational set-up
conditions (i.e. different build up) of the Magic Plate when operated in transmission
mode (MPTM) at different field sizes, treatment configurations and beam energies, the
sensor array (positioned upstream of the patient) minimally perturbs the radiation field
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(both in field and out of field). A beam perturbation of < 0.5 % increase in the skin dose
and < 0.5 % change in dose at depth in a solid water phantom is reported. This small
change demonstrates that the MPTM is suitable as an instrument for real-time
verification of VMAT and IMRT during patient treatment.
The third part of this work is to describe the characterisation of the radiation response of
MPTM. This mode of MP operation is designed to be used to sense the 2D energy
fluence maps of the modulated radiation beam. For the MPTM investigation two
potential operational set-up conditions have been studied:
(a) The bare MP array sandwiched between black plastic sheets, 80 µm thick, here in
referred to as “the bare MPTM”.
(b) The bare MP array with an additional 1 mm of solid water covering the entire array,
here in referred as “MPTM with 1 mm build up”.
In addition, the response of the MPTM was investigated for different field sizes and
different treatment configurations ranging from 1×1 cm2 to 40×40 cm2 defined by the
multi-leaf collimators (MLCs) only or MLCs and linac jaws. This study emphasises
how having the MLCs fully retracted or matching the shape of the linac jaws influences
the response of the MP operating in transmission mode. Moreover, to determine the
significance of the different electron contamination and photon scattering conditions
and the corresponding effect these conditions may have on the measured MPTM
response.
The last part of this thesis demonstrates that the 2D transmission response data can be
used to reconstruct the dose in 2D or 3D in real time along rays projected from the
photon source through each MP sensor element. Hence the dose can potentially be
reconstructed segment by segment or pulse by pulse for IMRT or VMAT treatment
deliveries.
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An algorithm has been developed, that predicts the dose in the patient/or and in the
phantom based on the measured intensity of the X-ray distribution in the beam using
MPTM. This can be checked against the planned dose and if they disagree the treatment
can be stopped automatically and immediately.
In transmission mode the MP is positioned in the block tray of a linac so that the central
detector of the array lies on the central axis of the radiation beam. The MPTM response
is proportional to the projected 2D dose map measured at a specific phantom depth, the
“sweet depth”. A single factor, for several irradiation field sizes and depths, is derived
to reconstruct the dose in the phantom along rays projected from the photon source
through each MPTM detector element. The performance of the sensor system and
reconstruction method for several square irradiation field sizes, as well as very
asymmetric irradiation field geometries, is investigated with reconstruction in solid
water phantom. It is demonstrated that for all field sizes using the above method, the
2D reconstructed and measured doses agree to within ± 2.48 % (2 standard deviation)
for all in-field MP detector elements.
Importantly also, is the direct confirmation that the sensor array, positioned upstream of
the patient, does not significantly perturb the irradiation field depth dose profile,
including the dose in the build-up region. The online monitoring and reconstruction may
also be applicable to other complex forms of radiotherapy including Stereotactic
Radiotherapy and Motion Adaptive Radiotherapy where real-time radiation treatment
monitoring through dose reconstruction is very important.
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CHAPTER 1

Introduction
For patients diagnosed with cancer, 52% would benefit from radiotherapy to optimise
their treatment outcome [1, 2]. Radiotherapy is a treatment that aims to deliver a
sufficient radiation dose to the tumour to guarantee tumour control as long as the
probability of serious side effects remains sufficiently low. As a result, the tumour
control probability (TCP) has to be balanced against the normal tissue complication
probability (NTCP). For some types of cancer, those probability curves are well defined
and it is established that the outcome of a radiotherapy treatment depends on doses that
do not vary by more than ± 5 % from the optimum. This accuracy requirement is
generally extended to all treatments, though some studies highlight the need for higher
accuracy in some situations [3, 4].
Currently, the use of in vivo dosimetry is recommended for some complex treatment
deliveries following recommendations by many national and international organisations
[5, 6]. More complex treatment techniques such as IMRT and VMAT introduce new
challenges and requirements. Increasing delivery precision from IMRT and VMAT is
accompanied by increases in treatment complexity which raises the potential risk of
accident due to a delivery error, hence online dosimeters used in vivo would be ideal.
Therefore the need to provide real-time dosimetry devices with high spatial resolution,
sensitivity and accuracy is essential. It is fundamentally difficult to place in vivo
1

dosimeters in situ. Hence non-invasive dosimetry monitoring systems have become an
attractive proposition to alert to any treatment delivery errors. QA systems currently
available are too bulky or interfere detrimentally with the radiotherapy treatment
delivery to be used during patient treatment [7, 8].
The Centre for Medical Radiation Physics (CMRP) at the University of Wollongong
(UoW), Australia, has developed a 2D silicon diode array dosimeter called the Magic
Plate (MP).The MP system is capable of providing real-time dosimetric and/or
transmission radiation response information to the radiation oncologist and
radiotherapist while the patient is being treated. The 2D array is different from other
commercially available 2D arrays with its unique packaging design which exhibits
advantages over conventional dosimeters. These benefits will be explored in this thesis.

1.1 Thesis objectives
This thesis demonstrates the real-time operation of an 11×11 semiconductor 2D diode
array MP, which is specifically designed to be sensitive to the energy fluence without
perturbing the radiation field incident on the patient. The array is therefore positioned
between the linac radiation source and the patient, and utilised as a transmission
detector during radiation treatment.
Real-time verification and 2D or 3D dose reconstruction on daily patient anatomy have
the potential to improve treatment delivery, safety and accuracy during patient
treatment. Recalculation of dose based on online fluence measurements with a
transmission detector attached to the linac head is one possible implementation. This
thesis provides a comprehensive analysis of the influence of the Magic Plate on
treatment beam characteristics. The main objectives of this thesis are the following:
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Objective 1: To demonstrate the potential performance characteristics of the MP
system when operated in dose mode (MPDM), i.e. in a phantom on the patient couch
placed under the linear accelerator treatment beam. Objective 1 of this thesis is to repeat
some of the work of Wong et al [9] at 6 MV (such as the field size dependence) and
then extend this work to 10 and 18 MV photon beams to assess the operation of the MP
in these significantly different radiation field environments (e.g. including neutrons
presence on 18 MV photon beam). The research performed in relation to objective 1 is
outlined in Chapter 4 and describes the following characterisation measurements of the
MPDM that were carried out such as: response to different field sizes, dose beam
profiles derivation, the water equivalent depth (WED) for surface dosimetry and the
response of the diode array for different frequency of the linac pulses.

Objective 2: To demonstrate the performance characteristics of the MPTM system
upstream of the patient. Of particular interest is to quantitatively study the effect of
packaging of the MP (with and without 1 mm build-up/filtering material on the top of
the MP) on response of the MPTM for different field sizes and photon beam energies.
Any beam perturbation effects, leading to changes in the skin dose and/or the
percentage depth dose (PDD) (both in and out of field) are examined. In addition, the
effect on the 3D dose distribution measured by the Delta4® QA system was also
investigated. The transmission factor for both of these MPTM setups in the central axis
was performed. This is performed in Chapter 5.

Objective 3: To describe the characterisation of the radiation response of the MPTM.
This mode of MP operation is designed to be used to verify the dose from IMRT and
VMAT treatment delivery, in real-time by measuring the 2D energy fluence map of the
3

modulated radiation beam. A demonstration of this concept is performed in Chapter 6.
However, direct verification of a VMAT or IMRT plans not form a part of this thesis.
Important parameters related to this concept are studied for the MPTM including
linearity of response, reducibility, uniformity, the effect of forward scattered electrons
from the jaws on the array detector response, the response of the array with different
dose rates, energy response, and back scattering effect.

Objective 4: To demonstrate how the 2D transmission response data can be used to
reconstruct the dose in 2D or 3D in real-time along rays projected from the photon
source through each sensor element. As it can be performed in real-time, dose can be
reconstructed segment by segment or pulse by pulse for IMRT and/or VMAT
treatments deliveries. This is performed in Chapter 7 and Chapter 8.
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CHAPTER 2
Literature Review
This chapter aims to provide an extensive background on modern QA detector
technologies, specifically for the treatment of IMRT and VMAT.

2.1

Cancer Data

Cancer is defined as the uncontrolled malignant growth (cell division beyond normal
limits) of a group of cells caused by a series of changes in the genome [10, 11].
According to a study released by the Australian Institute of Health and Welfare,
(Canberra) and the Australasian Association of Cancer Registries (AIHW & AACR,
2015); 126,800 (69,790 males and 57,010 females) new cases of cancer were estimated
in Australia in 2015, and cancer is the cause of approximately 3 in every 10 deaths
registered in Australia [12]. This makes cancer the second most common cause of death
behind cardiovascular disease. The five most common types of cancer diagnosed and
reported were prostate cancer among males (with 17,250 cases diagnosed), bowel
cancer ( 17,070 cases), breast cancer in females ( 15,740 cases), melanoma of the skin (
12,960 cases), and finally lung cancer (11,880 cases) [12]. However, the number of
deaths has fallen for most cancer sites due to the development of treatments and the
early detection of cancer.
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2.2

Review of Radiation Therapy

Radiotherapy is a complex procedure that uses a dose of ionising radiation to the
tumour. Beams may be composed of different particles, including; electrons, photons
(X-rays) or protons [13]. The use of X-rays delivered by linear accelerators dominates
the delivery methods.
In practice, radiotherapy can be used alone or in combination with other treatments,
such as chemotherapy or surgery, to treat cancers such as lung cancer and breast cancer
[1]. The objective of optimal radiotherapy is to damage the DNA of tumour cells
causing cell death and minimise the damage to the healthy normal tissue [13]. Research
carried out by the Collaboration for Cancer Outcomes Research and Evaluation
(CCORE) assessed that 52.3% of all cancer patients would benefit from radiation
therapy treatment [14]. Hence, approximately one in every two cancer patients would
benefit from radiation therapy referral.
There are several methods used to deliver radiation to the patient. The most common
type of radiotherapy is external beam radiation therapy (EBRT), which predominately
uses medical linear accelerators [15, 16]. In this method the beam of radiation comes
from outside the body, and is directed towards a target inside the body [17]. Other
delivery methods include internal radiation therapy (otherwise known as brachytherapy
[17]) and radioisotope therapy (or unsealed source radiotherapy) but these are outside
the scope of this thesis.
One significant enhancement in EBRT came in the early 1970s with the use of X-ray
transmission computed tomography (CT scanning) in clinical diagnostic radiology [18].
Since then CT scanning has been applied to radiotherapy planning to describe the
geometry and electron density of tissue in the region that should be irradiated. It has
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been used in tumour localisation, and provides detailed information about surrounding
healthy tissue [18].
The conventional approach of 3D conformal radiation therapy involves the
combination of several irregularly shaped fields at different gantry angles. It can reduce
toxicity to the neighbouring healthy tissue when delivering radiation to the deep seated
tumours [16, 19, 20]. Irregularly shaped radiation beams were historically delivered by
using blocking material. However the introduction of MLCs which facilitates the use of
fast field shaping enabled practical implementation of 3D conformal radiation therapy
[1, 19]. Three-dimensional conformal radiation therapy (3D CRT) uses MLCs to define
irregular shaped field boundaries, where multiple radiation beams can be used that each
have been custom shaped to conform the dose to the tumour guided by the 3D CT
images [19]. In 3D conformal radiation therapy the field shape covers the beam’s eye
view projection of the target volume from each gantry angle and it represents a change
from traditional methods which did not spare normal structures adequately [19].
IMRT represents a sub-set and new generation of 3D conformal radiation therapy [19,
21]. Brahme et al (1982) published their paper which has been considered as the key
theoretical article on IMRT [22, 23]. They introduced the problem of treatment planning
as an inverse problem, contrasting it to forward planning which had been previously
used. IMRT delivery increased the dose gradient between the tumour and the
surrounding healthy organs [24].The historical development and modern practice of
IMRT delivery methods was reviewed and studied in greater detail by Webb [23].
Radiotherapy delivery has thus become more precise, and the margin of error has been
reduced [25]. However, there still remains problem that patient organs can move during
the treatment delivery. The major challenge in the delivery of the desired dose by using
highly conformal radiation therapy is intra-fractional tumour motion (i.e. tumours in the
7

thorax) due to respiration [26]. Radiation therapy delivery has been further developed to
overcome these problems and they are addressed by a new technique called motion
adaptive radiation therapy, where imaging systems determine the tumour position and
the radiation beam is adapted to the dynamically changing tumour position [27, 28].
This allows the control of the irradiation of the tumour to be maximised without
increasing treatment side effects. An even more recently available technique on linear
accelerators is the use of real-time imaging for organ motion tracking by dynamic multileaf collimator (DMLC) tracking. In DMLC tracking, each leaf that shapes the radiation
beam has its position optimised in real-time to continuously align the radiation beam
with the tumour. Several studies have made a significant step to minimising treatment
time and reducing the radiation dose to the normal tissue due to respiratory motion by
using the DMLC tracking technique. [27, 29-32]. Several methods exist to overcome
organ motion (such as by the respiratory gating technique) that can lead to longer
treatment times and are undesirable. Sawant et al (2008), Keall et al (2000), Falk et al
(2010) and others have been focusing on many features of DMLC tracking such as
tumour position, motion production, four-dimensional (4D) imaging, planning, and
accurately targeting treatment. This advanced treatment needs a suitable QA dosimetry
tool for routine clinical practice, one with an ability to imitate the moving organ in a
tissue equivalent phantom. Several papers have been published on the dosimetric
verification of DMLC technology and also for tracking movable organs [25, 27, 31, 3338].
In vivo dosimetry refers to a process of direct radiation dose measurement in a patient
which occurs either during diagnostic examination or radiation treatment. The process
of in vivo dosimetry may be performed either noninvasively with the dosimeter
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positioned upon the entrance or exit patient surface or invasively through implantation
of the dosimeter at a point of interest.
In radiotherapy in vivo dosimetry is performed noninvasively as a part of quality
assurance programs. Indirect comparison between the dose that was prescribed and the
dose that was delivered for a particular treatment field can be facilitated by in vivo QA
programs. This provides additional protections against major setup faults and errors in
calculation or transcription which were overlooked during the patient’s primary
examinations [39-44]. In a perfect scenario, in vivo dosimetry protocols provide
evidence that the treatment was conveyed correctly, in accordance with the user
specified tolerances.
The high accuracy maintained in dose delivery that is expected from complex and
conformal radiotherapy treatments can be supported by in vivo dosimetry [45, 46].
Access to thermoluminescent detectors (TLDs) or other in vivo systems by clinics is
highly recommended by the AAPM TG 40 (Comprehensive QA for radiation
Oncology)[5] .Without increasing the duration of the treatment session, a clear and
precise in vivo dosimetry program should be able to identify most faults.
Patients undergoing radiotherapy treatments at multiple facilities experienced 120
treatment faults that exceeded the 5% threshold, identified by in vivo dosimetry
systems, in a review administrated by the International Atomic Energy Agency (IAEA)
[6]. The conclusion of the review identified that in a recent case in Panama a well
placed in vivo dosimetry program might have mitigated or prevented the overexposure
of 28 patients. It was a recommendation of the report that adoption of in vivo dosimetry
be encouraged in the departments of radiotherapy, however, appropriate planning and
preparation for the implementation of such programs is necessary [6].
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In vivo dosimeters used for performing measurements of entrance and exit dose are
generally positioned upon the patient’s skin. The measurement of entrance dose enables
detection of errors in delivery which may be attributed to human error or equipment
malfunction. The exit dose allows for detecting additional dose delivery uncertainties
caused by heterogeneities in tissue (e.g. air cavities, bone etc.). The measured and
calculated doses are then compared for both cases. If the difference between these doses
exceeds the user specified range, the result may be used to detect and identify numerous
serious faults upon further investigation. Reports from other publications have also
stated that faults in the calibration of some machines were identified using in vivo
dosimetry[47]. The institution and the guidelines of the in vivo dosimetry program
determines the accepted range between the measured and calculated dose, nevertheless,
a ± 5% uncertainty limit has been suggested by some publications for all entrance dose
measurements executed [42, 47-49].

2.2.1 Intensity modulated radiation therapy (IMRT)
IMRT is an advanced radiation treatment delivery technique [9, 19]. IMRT is delivered
as a sequence of many small beam segments per fixed gantry angle that enter the body
from several gantry angles (different directions) [17]. With these multiple beams (or
segments) the intensity of radiation of each field can be modulated to achieve a high
dose to the tumour while sparing the surrounding healthy tissue. The sum of these
multiple beams or segments can produce a non-uniform radiation field. The intensity of
the radiation is modulated or more precisely the dose map is changed by using a MLC,
which consists of individual leaves of a high atomic number material, such as tungsten,
which can move in and out in real-time in the field to create a structure of complex field
shapes or beam apertures. Since IMRT allows for the modulation of dose inside of each
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field, this requires a highly sophisticated computing application which can perform
optimisations for a number of beam gantry angles in order to plan an optimum dose to
the tumour. This is called ‘inverse treatment planning’. Many papers and books have
studied inverse treatment planning in detail and many references to it can be found in
the literature [50-55].
There are two techniques that are generally used to deliver static gantry IMRT dose
distributions, “step and shoot” and “dynamic sliding window” deliveries. Both of these
techniques deliver an IMRT beam with fixed (static) angles [56].
In a step-and-shoot delivery, the beam of radiation is only delivering dose when the
MLC leaves are stationary (fixed) (i.e. shoot). Whenever the leaves are changed from
one segment to another, (i.e. step) the radiation beam is held off. On the other hand, in
the dynamic sliding window delivery technique the radiation beam is on all the time
when the leaves of the MLC are swept across the field [56, 57].
The safe clinical implementation of IMRT requires at least two systems before actual
clinical use: The first one is the treatment planning computer system which can
calculate the non-uniform fluence maps from multiple beam angles to deliver a high
dose to the tumour while delivering a low dose to healthy organs. The second system is
to deliver the non-uniform fluence as planned. Both of these systems must be tested and
commissioned before clinical use and the QA programme should be performed for pretreatment, daily, monthly, and yearly verifications [58].

2.2.2 Volumetric modulated arc therapy (VMAT)
The intensity modulated arc therapy (IMAT) technique was presented in a paper by Yu
in 1995 [59]. In this technique the MLC can be used dynamically to shape and reshape
the field segments during gantry rotation (with a single arc) while the radiation dose is
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being delivered to the patient. VMAT is similar to IMRT. However while IMRT is a
static gantry delivery, in VMAT the gantry of the linear accelerator (linac) rotates [58,
60]. In VMAT the dose is generally delivered to the entire planning target volume
(PTV) in a single or double rotation. Linear accelerators now have the capability to
deliver VMAT, where MLC segments, dose rate, and gantry speed are varied
simultaneously while the gantry is rotating. The two variables; gantry speed and dose
rate are the enhancements that differentiates VMAT from IMAT and this significantly
speeds up the treatment delivery. VMAT uses all angles that are available in the inverse
plan, which can produce a better conformal dose distribution than IMRT [61, 62].
Studies have recommended that VMAT can be used as effectively as IMRT for different
and complicated treatment sites, such as for head and neck treatments [60, 62, 63].
The main advantage of VMAT compared to IMRT is that the former shortens the
treatment time which may play a role in reducing both patient discomfort and intrafraction motion, and provide faster delivery than IMRT. One drawback of VMAT
verification is that the dose verification is slightly more difficult, as there is one extra
parameter; gantry rotation. In addition, dosimeters may display an angular dependence
which must be corrected for, increasing the difficulty of verification techniques [62].

2.2.3 Stereotactic Radiotherapy/Radiosurgery
Stereotactic radiotherapy has been under development for over 50 years; however, this
form of treatment has only been used in radiation oncology for the past 15 years [64].
Grosu et al. state that stereotaxy is that method where a point is defined in the patient’s
body by a 3D external coordinate system [64]. Stereotactic radiosurgery (SRS) is a
single fraction of radiation therapy with a combination of a stereotactic apparatus and
several narrow beams delivered to treat intracranial lesions [65]. The use of SRS has
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spread to other clinical sites due to its high geometrical precision and its ability to be
applied to treat small tumours [64, 66].
Stereotactic body radiation therapy (SBRT) is a very similar technique to SRS but is
used for targets that are outside the brain and the spine. SBRT is most commonly used
for targets in the lung, spine, liver, pancreas and kidney. In modern terminology, the
term Stereotactic ablative radiation therapy (SABR)/SBRT is proposed to an external
beam radiation therapy treatment that delivers a high dose of radiation with high
geometric precision to an extra-cranial target. As this is performed with only one or few
fractions and involves steep dose gradients, specialised planning and treatment delivery
techniques are needed, with associated specific QA requirements [67]. A course of one
to five fractions is typically delivered in SBRT[68].
Recently, small irregular fields of X- rays have been shaped to irregular targets, with a
high radiation dose delivered within a single session [66]. Therefore, accurate dosimetry
is very important as the position and the dimensions of the field must be precisely
matched and an accurate dose delivered to the target [69].

2.3

Current quality assurance and dosimetric verification

2.3.1

Introduction

The complexity of the IMRT delivery system requires the verification of the dose
delivery [23]. Therefore, the successful clinical implementation of IMRT requires
verifying the consistency between the dose calculated and the dose delivered to the
patient [70]. Treatment plans generally are not implemented clinically until the
calculated dose distribution is verified by an independent method. The treatment plan
can be verified by performing a true in vivo test where detectors are placed on the
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patient. Measurement of the dose to patient skin is viable but is labour intensive and
increases dose to patient skin. Another way to verify the dose indirectly is to irradiate a
phantom and compare the dose distribution results with those computed from the
treatment planning system (TPS) for that particular phantom [71].
The quantification of any major modifications between measurements and calculated
dose distributions can be gained by superimposing TPS calculated doses and measured
doses. This method is commonly employed to ascertain the agreement between the
delivered dose distribution and the planned dose distribution [72] and weather there is
any difference between dose maps in terms of measured and calculated dose, this
difference can also be used to indicate the appropriateness between measured and
calculated dose distributions [73]. These maps are sensitive to small spatial shifts that
may be due to mistakes in experimental set up or calculation or delivery errors. Small
shifts produce large dose differences between the calculated dose and the measured
dose, especially in the steep dose gradient region where the dose changes rapidly [74].
One important factor for dosimetric verification is the selection of the best dose
measurement instruments. There are several types of detectors; for example, there are
point dose measurement systems, such as: ionisation chambers, TLDs, and diode
detectors which can be used clinically for point measurements. For IMRT, a point dose
measurement cannot give adequate information for dose distributions as it is not able to
verify the IMRT plan at multiple points or in a plane. As mentioned above, IMRT is a
complicated technique where the dose drop-off is very large in small spatial
displacement, especially at the edge of the target [19, 72]. Therefore, to precisely verify
an IMRT plan in 2D or 3D the data would ideally be sampled with a high spatial
resolution in real-time over some measurement volume [75]. This can be achieved with
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2D or 3D dose verification techniques such as: film, detector arrays (for example
Delta4® system), and gel dosimetry.

2.3.2 Point dose verification systems
Main stream in vivo dosimetry systems currently available for megavoltage (MV)
photon radiotherapy are restricted to point dose detector technologies such as diodes
[44, 76] , TLDs [77] and metal oxide field effect transistors (MOSFETs) dosimeters
[42, 46, 78]. These point dose measurement techniques while being very valid and
useful, can be labour intensive and provide inadequate information with the dose only
being determined at a single point [79]. Notwithstanding their limitations, these existing
techniques are widely used in many facilities.

2.3.2.1

Ionisation chamber (IC)

Ionisation chambers are the standard and most commonly used dosimeter in
radiotherapy and in diagnostic radiology for the determination of a point measurement
of radiation dose [80]. An ionisation chamber measures the number of ion pairs
generated in a volume of air (gas) due to beam interaction [17, 80, 81]. Ionisation
chambers come in various shapes and sizes depending on specific requirements and
purposes and include the free air ionisation chamber [82], thimble chamber [83],
condenser chamber, farmer chamber, extrapolation chamber, parallel-plate chamber,
and waterproof chamber [17]. For dose verifications, ionisation chambers are inserted
inside a phantom and the measurement of the absorbed dose is attained.
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Figure 2.1: The electric equilibrium in a free air chamber.

When an X-ray beam is passing through air, interactions occur between the photons in
the beam and the atoms of the gases. The interactions depend on the magnitude of
energy that the photons possess. The interactions of photons with matter include;
photoelectric effect, Compton effect, or pair production. Electrons are produced by one
of these interactions, these high speed electrons generate further ionisations along their
paths. An electric field within the chamber is produced by the application of a large
voltage (100V– 400V) across the ion collection plates (cathode and anode). The positive
charges are attracted to the negative plate (cathode) and the negative charges move to
the positive plate (anode). This creates a current and the charge can be collected of
either sign and measured by an electrometer [17] (as shown in Figure 2.1). Several
papers discuss the conversion from ionisation to dose and the protocols that deal with
this process [84-86].
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Usually the ion chambers are not sealed, so an ion chambers response will be affected
by atmospheric conditions such as temperature and pressure. Therefore, the density of
air in the chamber volume depends on these atmospheric conditions. Thus, the density
of the air in the chamber volume will increase as the temperature decreases or pressure
increases. The chamber reading for a given exposure will increase as the temperature
decreases or as the pressure increases. For this reason, corrections are important and
TG-51 or TRS-398 recommendations (clinical reference dosimetry of high-energy
photon and electron beams protocol or protocols for the dosimetry of high-energy
photon and electron beams: a comparison of the IAEA TRS-398 and previous
international codes of practice) should be performed [58, 85, 87].
The ionisation chamber has many advantages in clinical use, such as: it is accurate and
precise, and recommended for beam calibration, with necessary the corrections well
understood; it offers long term stability, relative ease of use and instant, direct readout
[88]. The disadvantages with ionisation chambers are the necessity for positioning of
the ionisation chamber in a high dose and low gradient region in IMRT dose
distribution during creation of the phantom plan for verification. Furthermore, the
corresponding phantom needs to be setup on the treatment couch for measuring the
delivered dose. Both procedures are time consuming. It has also several disadvantages,
such as: limitations in physical dimension due to the finite size of the air volume
required for sufficient signal; its requirements for connecting cables, a high voltage
power supply; and the necessity for many corrections for high energy beam dosimetry
[15, 89]. For instance, when an ion chamber is used in IMRT where high dose gradients
exist, the ionisation chamber tends to overestimate the penumbra width due to its large
volume. Therefore, it does not accurately represent areas with high dose gradient fall-off
[90]. Moreover, small fields also are a challenge due to the volume averaging of the
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dose [91-94]. Recently, the design of the ionisation chambers has been improved to
make them as small as possible, however, these small chambers are still big compared
to some solid state dosimeters [95].

2.3.2.2

Thermoluminescence detectors (TLDs)

Thermoluminescence has been used for almost 100 years [68, 77]. TLDs are small
devices that are used to measure a dose delivered to a point [96]. They are constituted
by phosphors, such as a lithium fluoride (LiF:Mg,Ti,Na) or calcium fluoride
(CaF2:Mn,Dy) [17, 97]. TLDs operate by the solid-state phenomenon known as
thermoluminescence. Thermoluminescence is the emission of light from an insulator or
semiconductor when it is heated [96, 98]. When radiation interacts with the crystal it
causes electrons in the crystal’s atoms to elevate to higher energy states, where they are
trapped, due to the impurities in the crystal, until heated. When the crystal is heated the
electrons will be dropped back to their ground state, liberating photons of energy equal
to the energy difference between the ground state and the trapped state. These photons
are counted using photomultiplier tubes, and the number of photons counted is
proportional to the quantity of radiation striking the phosphor.
The TLDs response can be affected by many factors, such as: time, previous thermal or
radiation history, the nature of storage between exposure , readout, and the surrounding
gas during the readout process [17, 88]. There are many TLD phosphors available and
the most commonly used are lithium fluoride (LiF: Mg,Ti,Na), lithium borate (Li2B4O7 :
Mn,Cu), and calcium fluoride (CaF2: Mn,Dy) [97, 99]. Lithium fluoride dosimeters are
available in the form of powder, chips, and rods. TLD dosimetry for radiotherapy
treatment has a wide range of applications [100]. Firstly, it can determine the dose in
difficult treatment geometries; secondly, the dose to critical organs can be recorded and
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finally, it can be used to monitor special treatments; such as a total body irradiation.
TLDs offer a lot of advantages and disadvantages in clinical use [101, 102]. Some of the
advantages of TLDs are that they are generally small detectors and offer close tissue
equivalence, which make them useful for different applications in medicine [17]. In
addition, no cables are required during measurement (unlike ion chamber
measurements). They are also reusable, cheap, and multiple measurements can be
performed at the same time. However, they also have disadvantages such as: their small
physical size may make them difficult to handle; they are less accurate than an
ionisation chamber; a long time is necessary for annealing the material after exposure;
they cannot provide real-time dosimetry and expensive readout equipment is required
[81].

2.3.2.3

Semiconductor diode dosimetry

Semiconductor materials are attractive as radiation detectors and have been studied for
over 125 years [103]. The silicon semiconductor diode has been used as a radiation
detector for over 30 years [46]. In medical radiation detection there are several types of
semiconductor devices that can be used [68, 104]. Semiconductor diodes are more
sensitive than ionisation chambers. This allows for the production of small size diodes
that makes them very useful for measuring steep dose gradients in regions such as the
beam penumbra. Most semiconductor devices are used as active radiation detectors,
because they can allow real-time dose readout.
A silicon diode is a p-n junction. Pure silicon is lightly doped with phosphorus to
produce n-type semi-conductor material (called ‘donor’) or with boron to produce ptype (called ‘acceptor’) semi-conductor material. Each donor impurity can contribute a
free electron to the silicon and therefore comprise ‘donor atoms’; the majority of
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carriers in n-type silicon are electrons, while ‘holes’ (acceptor atoms) are the minority
carriers. In p-type silicon the reverse is true: ‘holes’ in the form of acceptor atoms are
the majority carriers while donor atoms with their donor electrons are the minority
carriers. Both n-type and p-type diodes are commercially available [46]. Silicon sections
heavily doped with impurities of the opposite type are implanted on the surface region
to create a p-n junction. Charge collection in a semiconductor diode is very different to
that in ionisation chambers. Ionisation chambers require a high voltage supply; the
intrinsic electric field across the p-n junction makes charge collection possible within
the diode without application of an external bias. Many books and articles have
discussed the principle operation of the silicon diode as a radiation detector [17, 68, 80,
81, 103, 104].
At the p-n junction, the majority carriers of each side diffuse to the opposite side,
creating an electric field (built-in potential, ψ0), which stops extra diffusion of the
majority carriers [105]. Diffusion of the majority carriers also leaves behind immobile
negatively charged acceptors and positively charge donor ions in the p- type and n-type
silicon respectively. This spatially charged region (p-n junction) is also known as the
depletion region or depletion layer.

When ionising radiation passes through the diode electron-hole pairs will be produced.
The minority carriers (electron on p-type), (holes on n-type) will diffuse toward the p-n
junction and will be swept up by the built-in potential towards the electrodes [105]. The
flow of charge (current flow) can be measured by an electrometer (Figure 2.2).
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Figure 2.2: Schematic diagram of a Si (p-n) diode [105].

Figure 2.3. Silicon / water stopping power ratio.
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In 1984, Grusell and Rickner investigated radiation damage to diodes and the sensitivity
of diodes [106]. They found that a diode’s sensitivity decreased with accumulated dose
whatever the majority of doping material on the diode, whether an n-type diode or a ptype diode, but that the n-type diode was much more affected by radiation damage. Psilicon detectors remain more dose rate independent and show less change in response
with radiation damage. In 1986, Grusel et al. investigated the effect of temperature on
the diode signal, they concluded that the diode signal increased by a factor of 1~3% per
10 C, which may overestimate the response, thus it should be taken into account when
measuring radiation dose within the patient [107]. The specifications of diodes which
are useful for radiation dosimetry have been investigated by Rikner and Grusell (1987);
they confirmed their previous experiences in diode dosimetry [108].
Task Group 62 (TG-62) (Diode in vivo dosimetry for patients receiving external beam
radiation therapy) was formed to provide physicists and medical physicists information
and guidelines for clinical use of in vivo dose verification using diodes [46]. Nilsson et
al. (1988) investigated the factors affecting a diode’s response in radiation therapy
[109]. The energy , angular, temperature, and dose rate dependency also required
adequate characterisation [110]. A diode has a much higher atomic number (Z) than that
of soft tissue. The effective atomic number of a silicon diode is approximately 14, while
that of soft tissue is approximately 7. Due to this difference, the silicon diodes overrespond at low photon energy (<150 KeV) due to an increased photoelectric effect
contribution in this energy region [75, 111, 112]. Many researchers have suggested an
epitaxial diode as it has great stability of sensitivity to radiation dose [113-115]. The
CMRP-UoW epitaxial diode has been investigated and all the general aspects of
radiation dosimetry characterisation have been covered in that research [9, 116].
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Semiconductor devices are a suitable choice for medical radiation detection due to their
many advantages, such as: compared to the ionisation chamber (IC), semiconductor
devices have higher sensitivity (18,000 times than an IC of the same volume ) due to
their higher density; the energy required to produce an ion pair is 10 times less than for
gas in an IC (3.6 eV for silicon and 35 eV for gas); the small size of semiconductor
devices satisfies the Bragg-Grey cavity theory conditions; they have a high spatial
resolution allowing for pin-point dose measurements, can be used for various radiation
fields, and provide good mechanical stability [105, 117]; and they can be operated in a
passive mode like TLDs and in active mode (online) like an IC. Most semiconductor
devices are based on silicon. The main factor which makes silicon diodes an excellent
choice for radiation therapy application is the constancy of the silicon to water electron
stopping power ratio in the mega voltage range (almost energy independent for electron
energies in MV therapy) (as shown in Figure 2.3). However, they do have a number of
disadvantages, including the higher atomic number of silicon as compared with water
that gives rise to a large energy dependence (low energies) [104, 106].
The mass absorption coefficient and the stopping power of the silicon contribute to the
energy dependence for photon and electron beams. Most of the energy dependence in
diodes designed for in-vivo use is due to the material surrounding the die, such as the
electrode attachment, protective housing, and build-up [46]. Moreover diodes exhibit
dose rate dependence due to charge recombination effect at high dose rates, and due to
their construction they also show directional dependence, which has an effect in some
cases [46]. For photon beam in vivo dosimetry, the diode reading increases with
increasing field size. For example, for a large field size (such as 40×40 cm2), the diode
field size dependence can be up to 5% higher compared with the ionisation chamber
measurement for the same field size [46].
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For diodes with a small thickness of build-up (insufficient build-up) electron
contamination is a contributing factor [46].

2.3.2.4

MOSFET dosimetry

Metal-oxide semiconductor field-effect transistor (MOSFET) dosimetry has been
implemented in the field of medical radiation therapy including IMRT, stereotactic,
brachytherapy (internal sealed source radiotherapy), and micro-beam radiation therapy
[104]. The MOSFET was proposed and developed as a radiation dosimeter in 1978 by
Andrew Holmes-Siedle and colleagues [118, 119].
The principal of operation of the MOSFET dosimeter is based on the creation of
‘electron-hole’ pairs on the gate silicon oxide layer (SiO2) by ionising radiation
followed by the build-up and accumulation of the positive charges on the Si-SiO2
interface which causes a permanent shift on the threshold voltage of the MOSFET
[120]. A MOSFET is very small in size [120-122], offers real time reading, is dose rate
independent, and it is an integrator which can store the dose history. Hughes et al.
(1988), Gladstone et al., in their 1991 and 1994 studies proposed the use of MOSFET as
an in-vivo radiation dosimeter or as a surface dose dosimeter [122, 123]. Like any other
semiconductor detector, a MOSFET is expected to have an over-response in low energy
photons as a result of backscattered radiation or the packaging material which causes
the release of secondary electrons [121, 124]. When using MOSFETs there are several
points that should be taken into account such as: temperature dependence, dose
response, limit of life because they lose signal with accumulated dose, sensitivity
changing with bias voltage during irradiation, and MOSEFTs are not tissue equivalent
and their dose response varies accumulated dose [68, 125].
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2.3.2.5

Diamond detectors

Diamond detectors have recently become available for dosimetry of megavoltage
radiation [68, 126-128]. Diamond (Z=6) detectors essentially offer approximate tissue
equivalence (effective Z=7.42 for soft tissue), small physical size, real time
measurement, and have small sensitive volume (1.4 mm3) which is useful for small field
dosimetry [68, 94]. It is also an electrical insulator and insensitive to radiation damage.
The small physical size of a diamond crystal detector gives a good spatial resolution,
and could be a very useful bulk conductivity radiation dosimeter for medical and
radiobiological work. Diamond detectors are also attractive because the carbon water
stopping power ratio remains approximately constant over the energy range of 1–20
MeV, which implies a great advantage for diamond detectors over silicon diodes for
electron dosimetry [127]. They have been successfully used for small field dosimetry
and measuring in high dose gradients [129-131]. Diamond detectors are independent of
photon beam quality for the clinical range [94]. The dose rate dependence of diamond
detectors must be understood and also the pre-irradiation effects [69, 127, 132]. The
reason for the application of diamond not being widespread compared with silicon is
that artificial diamonds of suitable quality are not commonly available [126]. There has
been work for the use of diamond for detection and clinical dosimetry [133, 134].
Since all types discussed above provide point measurements only, a point detector
cannot easily verify multiple points in a plane without repeated measurements. It is
however common practice to verify 3D IMRT plans with single point dose
measurements at some institutions [135-137].
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2.3.3

Two dimensional dose verification systems

The use of 2D array detectors designed to be placed on the treatment couch or attached
to the treatment head for IMRT and VMAT QA, which shows the dose distribution
immediately after the treatment delivery are currently the most common verification
systems in clinical use [138-141]. These dosimeters have advantages in terms of time
saving, since the time required for data acquisition and analysis is shorter than for films
or a single ionisation chamber. However, these 2D array detectors display the dose
distribution only in a single plane Therefore, the dose measured by them cannot provide
information about full 3D dose distribution.
There are several types of dosimeters that can measure dose with high accuracy in a 2D
plane and are considered as suitable tools for QA of IMRT dose verification.
The 2D array detectors can provide a rapid method for dose verification and for daily
IMRT QA. In general, IMRT QA verification 2D detector arrays for planar dose
measurement can be divided into three design philosophies:
(i)

The first has a 2D detector array located on the linac couch, embedded in a

phantom or mounted on the head of the linear accelerator in the absence of the patient.
(ii)

In the second the position of 2D detector array is between the MLC and the

patient (transmission detector) for online and in vivo measurement during treatment
delivery.
(iii)

In the third, the 2D detector array is placed downstream of the patient, such as

in the use of Electronic Portal Imaging Devices (EPID) or mounting the detector array
on an EPID.
Designs (ii and iii) may be used for both in vivo (during treatment), and/or pretreatment.
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2.3.3.1

Ionisation chamber array

A pixel segmented ionisation chamber array (MatriXX, Scanditronix Wellhofer) was
designed by the Torino University and the Instituto Nazionale di Fisica Nucleare
(INFN) [142]. The basic dosimetric properties of the prototype were studied in 2003 by
Amerio et al. and Herzen et al. (2007) to perform a 2D dose verification of radiation
fields with complex shapes and with large gradients [139, 142]. The detector is a 32×32
matrix of 1024 cylindrical ionisation chambers arranged in an area of 24×24 cm2. Each
chamber is 4 mm in diameter and 5.5 mm in height and there is 7.5 mm from the centre
of each detector to the next pitch. The sensitive volume of a single ionisation chamber is
0.07 cm3. Amerio et al. reported good signal linearity with respect to dose and dose rate
[142]. Moreover, the results have shown an excellent reproducibility with values
remaining within 0.5% over one month of daily measurement [142]. Herzen et al.
reproduced these results and extended this work to verification of 2D IMRT plans
[139]. They compared the profiles in the cross plane direction that they measured using
a pyramidal beam arrangement perpendicular to the chamber array to the calculated
profiles and obtained a maximum deviation of 1% [139].
Poppe et al. (2006) undertook a study that examined two different of the 2D ionisation
chambers array manufactured by “PTW” (PTW-Freiburg, Germany) for IMRT plan
verification. These two detectors were version 1 (which consisted of 256 ionisation
chambers in a 16×16 matrix) and version 2 (729 ionisation chambers in a 27×27
matrix)[143].
The distribution of the array signals expected is calculated by convolution of the
planned dose distribution. They have been found to demonstrate an excellent short-time
reproducibility of 0.2%. The long-time reproducibility has been found to be within 1%
over period of 4 months. Poppe et al (2006) examined these detectors for the
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verification of IMRT plan based on one field orientation. This was obtained by setting
the gantry angle of the linac to 0° with the 2D array positioned perpendicular to the
beam axis [143].

2.3.3.2

Film dosimetry

In the realm of radiation therapy, films have been historically a very important way of
acquiring information about the human body and are also an attractive way of
measuring the dose distribution and/or dose verification with high spatial resolution
[144].
There are two types of films: radiographic and radiochromic films. Radiographic films
contains a radiation sensitive emulsion that coats a transparent polyester base [58]. The
emulsion consists of silver halide crystals implanted in gelatine. When the emulsion is
exposed to radiation, ionisation and excitation takes place in the silver halide which
leads to the creation of a latent image. When the film is developed, the affected crystals
are reduced to small grains of metallic silver, which cause the film to become opaque
[68]. Extended dose range (EDR) radiographic film in an excellent dose range is
available from Kodak (EDR2®) as a possible method for 2D dose verification of an
IMRT delivery system. ) Radiographic film use has fallen dramatically due to need for
dark room, and processing to obtain the image.
Radiochromic external beam radiation (EBR) film (Gafchromic® available from the
International Specialty Products (ISP) Group) is self-developing, following absorption
of radiation, without involving any latent thermal, optical or chemical development. It
consists of a radiation sensitive monomer, which upon irradiation, polymerises to form
polymer coloured dye; thus, the film darkens automatically. Radiochromic films have a
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density closer to tissue and offer a large range of doses up to 800 cGy when compared
to radiographic films [145].
All films provide a 2D pixel intensity map that can be converted to a 2D dose map by
using a calibration profile. Films also have some advantages such as: radiographic film
has good spatial resolution [81]. The high resolution of radiographic film combined
with modern film technology has an ability to provide a reasonably accurate and precise
2D distribution from a single exposure.
Films have an excellent spatial resolution, a large sensitive area, and are easy to handle
Films are also useful tools to use for commissioning, for routine QA, and for dose
verification [146], and there is a variety of commercially available types of film [81].
Nevertheless, the disadvantages are the dependence on film scanner readout values,
time delay between irradiation and scanning and chemical processing. These problems
make film dosimetry a very cumbersome procedure for routine treatment verification.
Films also have some disadvantages such as: wet chemical processing where careful
control is needed, their energy dependence for X-rays, their sensitivity to the
environment, blindness to low energy neutrons, and it is acknowledged that absolute
dosimetry is difficult [17, 81, 147]. Films are also disadvantaged by the fact that they
are not a real-time readout dosimeter, and results may not be ideal due to non-uniform
commercial film scanners used for their readout [94, 148-150] .

2.3.3.3

Electronic portal imaging device (EPID)

The original purpose of an Electronic portal imaging devices (EPIDs) was as a
replacement for port films. An EPID consists of a flat panel amorphous silicon detector
array mounted on a retractable arm opposite the linac beam. They can be used for
verification of the proper positioning and set-up of the patient relative to the beam for
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radiotherapy delivery [151, 152]. The use of the EPID has recently been extended to
verify the fluence of IMRT delivery. Verification of the dose delivered to the target
volume can be achieved with in vivo dosimetry [153], and several authors reported on
the use of portal images for measuring 2D dose distributions [154, 155].
There are two approaches to EPID dosimetry and both of them are suitable for pretreatment verification and in vivo dosimetry [156]. The “forward approach,” is a method
where the predicted dose or photon fluence calculated with TPS or an independent
algorithm at the plane of the EPID is compared to the measured portal images [156]. In
the “backward approach,” the portal images are used to reconstruct the dose within the
patient or phantom [157, 158]. This back projection method enables the direct
comparison of the calculated dose with the delivered dose distribution in the phantom or
in the patient. Whereas the dose is verified in only one plane in the forward approach
[156, 159].
A new generation of EPIDs, based on amorphous silicon flat panel technology, can
provide high quality verification images with as little as 2 cGy as compared with 7 cGy
for film dose [160]. Electronic portal imaging devices show many advantages over the
traditional use of film, for instance: ease of use, real time imaging display, and instant
comparison with the planned treatment field. An EPID with a Si flat panel can provide
very high resolution, high quality images, less handling, immediate image viewing, and
less radiation to the patient. On the other hand, where an EPID is used as an IMRT
dosimeter it is difficult to convert the image to dose and it requires a complicated
procedure [151, 161]. Generally, the higher the beam energy used to obtain an image,
the lower the contrast and resolution of the image. The beam used for cancer treatment
(megavoltage) is of higher energy than the one used for regular diagnostic X-ray
(kilovoltage). For this reason, image contrast is lower for megavoltage beams used in
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radiotherapy than for kilovoltage beams used in diagnostic radiography [57, 94, 144,
162]. For this reason most patient setup imaging is now performed with kV x-ray
sources and image detector arrays incorporated into the linac gantry (cf Varian OBI).

2.3.3.4

MapCHECK (Sun Nuclear, Melbourne, FL)

MapCHECK® (from Sun Nuclear, Melbourne, Florida) is a 2D array of diodes that can
be used for measuring the dose produced in a plane by a radiation beam. It consists of
445 n-type diodes distributed over an area of 22×22 cm2. Diode spacing is 7.07 mm in
the 10×10 cm2 central portal of the detector and increases to 14.14 mm outside this area
[163]. These n-type diodes are proprietary designed and are very resistant to damage by
radiation compared to n-types diodes commercially available before 2001. The diodes
have a 2 cm build up region and 2.2 cm water equivalent backscatter region. The entire
array of diodes is easily calibrated to be used for measurement of absolute dose. For
IMRT QA, each beam is measured individually with the beam’s central axis oriented
perpendicular to the plane of the diodes. The advantage of MapCHECK is that it
provides an accurate means of treatment verification and is fast for IMRT QA [71]. The
use of MapCHECK for routine quality assurance for IMRT fields has been found to be
very efficient due to the time needed for various steps in the measurement [71, 104].
In their work Jursinic et al. (2003) found that for the long term (over a period of a
month) reproducibility of MapCHECK measurements was quantified over a 261 day
period of use and The relative standard deviation of these measurements was <0.05%
[71]. These 2D array detectors mentioned above display the dose distribution only in a
single plane. Therefore, the dose measured by them cannot provide information about
full 3D dose distribution.
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2.3.4

Three dimensional dose verification systems

There is a need for a practical 3D dosimetry system, suitable for clinical use, and with
the accuracy and high resolution to allow comprehensive verification of the complex
dose distributions typical of modern radiation therapy treatments. A full understanding
of all 3D conformal radiotherapy generated dose distributions ideally includes
volumetric verification, the verification of IMRT is further complicated by the fact that
the radiation field is continuously changing size and shape (sliding window) or made up
by multiple small beam segments (step and shoot). Thus, a detector with the possibility
for integrating volumetric measurements is needed. Since an IMRT dose distribution
often contains sharp dose gradients, good spatial resolution as well as independence of
dose rate is desirable. Another crucial feature is that the detector response should be
independent of incident radiation direction. This would enable a complete treatment to
be evaluated in a single measurement, as opposed to measuring each beam separately.
In external radiotherapy conventional dosimetry systems such as ion chambers, TLDs,
diodes or film, are unable to satisfy all the above requirements. Volumetric
measurements

are

not

feasible

without

multiple

detectors

and/or

repeated

measurements. In the case of ion chambers, the sensitive volume is too large to obtain
the necessary spatial resolution. Film can be arranged in a stack for 3D measurements,
but suffers from lack of tissue equivalence when packed in this way and exhibits a
dependence on the angular distribution of the radiation [164].

2.3.4.1

Gel dosimetry

The biological effects of ionising radiation demand an increased interest in new
techniques for determining the dose that is delivered to the internal structures [165].
There is a large amount of research into the use of gel dosimetry for clinical dose
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verification in radiation therapy [166]. The use of gels with radiation sensitive material
for dosimetry has occurred since the 1950s [165, 167]. At that time Day and Stein
studied the chemical changes produced by radiation in aqueous solution and the use of
changes for radiation dosimetry in the measurement of absorption of ionising radiation.
For dosimetric applications, the system must be quasi-solid, give a chemical change that
can be observed, and have the same average atomic number and electron density as
body tissue (that is, the same as water). Gel dosimeters have been created from
radiosensitive chemicals dissolved in gelatine material, that then polymerised as a
function of the irradiation dose [94, 166].
Gel dosimetry can be divided into two types: Fricke-based gels[168] and polymer gels
[68, 169, 170]. Gel dosimeters offer advantages such as: having near water equivalence
and high spatial resolution. There are several methods to read out the gel dosimeters: for
example: magnetic resonance imaging (MRI), X-ray computed tomography (CT), or
ultrasound technique [171-174]. Gel dosimeters also exhibit some disadvantages such
as: their high cost and problems that sometimes arise in obtaining access to an MRI
scanner, difficulty in reproducing gels with equal radiation sensitivity in different
batches, and the fact that the method is time consuming (a couple of measurement are
required to get a map of relaxation times) [175].
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2.3.4.2

Delta4® dosimetry system

Figure 2.4: The Delta4® dosimetry system.

The Delta4® (ScandiDos, Uppsala, Sweden) dosimetry system is able to offer a realtime pre-treatment method for volumetric verification of 3D dose distributions for static
angle and dynamic rotational delivery [176]. This device can be placed on the linac
couch for dose treatment verification for both IMRT and VMAT delivery. Delta4®
system is able to provide an effective means of measuring doses at multiple locations in
the field. It consists of 1069 p-type diodes arranged in a matrix along two orthogonal
planes. The p-type detectors have been shown to have little saturation of signal,
especially at high levels of dose per pulse, compared with n-type detectors. Each p-type
diode has a thickness of 0.05 mm and a cylindrical sensitive volume with a 0.78 mm2
area.
The detectors are spaced at 0.5 cm intervals in the central 6 × 6 cm 2 area and at 1 cm
intervals outside of this area, and they cover an area of 20 × 20 cm2. The detector planes
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are placed in an acrylic cylindrical phantom 22 cm in diameter and 40 cm in length (as
shown in Figure 2.4).
The Delta4® system is comprised of a phantom with three removable detector planes
that are arranged in orthogonal planes. The detectors are attached via multichannel
readout circuitry to electrometers with the data displayed using customised software.
The phantom has a cylindrical polymethyl methacrylate (PMMA) structure divided into
quarters by the two detector planes. A main detector board forms one plane running
along the diameter of the cylinder. Two wings sit on either side of the main board at
right angles to form the second detector plane. The two planes are offset from the
vertical; one at +50˚, one at -40˚. The asymmetric arrangement allows the user to
change the angle at which the beam is incident to the board by 10˚. This design enables
the user to avoid beam incidence angles that are parallel to the detector plane for most
static gantry angles. The PMMA has markings in the horizontal and vertical directions
for positioning the centre of the phantom. The markers are two straight lines spaced 1.5
mm apart, between which the lasers in the treatment room can be aligned. For the
Delta4® dosimetry system this corresponds to an isocenter at 88.97 cm source to surface
distance (SSD).
The Delta4® system can be used in a gantry rotation mode for VMAT treatment delivery
verification. As such it cannot be used for in vivo dosimetry [94, 176]. Bedford et al.
found that the uniformity of response of the Delta4® to different segment monitor units
and dose rates was better than 0.5%. Also, the uniformity of angular response was
around 0.5% over the range of gantry angles. For IMRT and VMAT, treatment plans
were assessed. Even though the Delta4® system has detectors in only two planes, it
provides a novel interpolation algorithm that is capable of estimating doses at points
where no detectors are present (Sadagopan et al)[177].
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2.3.4.2.1

Delta4® software tools:

Part of the research work presented in this thesis involves a study of the impact of
the MPTM with both a bare MP and a MP with an encapsulated by a 1 mm solid
water build up layer. The impact on the 3D dose distribution in comparison to the
open field configuration with no MPTM in place was investigated using the Delta4®
system. A brief summary of standard operational procedures for the Delta4® system
is therefore presented below.

2.3.4.2.2

Daily Correction Factor

A daily correction factor (DCF) are applied to measurements in order to account for
differences in treatment conditions between the time of calibration and time of
measurement, for instance changes in linac beam output. The DCF is determined by
comparing the measured dose of all detectors in the central 6 × 6 cm2 of the detector
plates to that of the planned dose in the same area. The DCF is calculated for a
uniform, square field of 20 × 20 cm2 using a 6 MV beam potential. The relevant
DCF has been applied to all measurements. The DCF can be used to identify set up
errors. If the DCF is vastly different from previously stable measurements, the
source of the difference is more often than not a misalignment. Dramatic changes in
DCF can also be indicative of errors with linac beam delivery.
The software also provides a temperature correction that can be applied to
measurements, as p-Si are known to have temperature dependence (as mentioned in
section 2.3.2.3). The correction is calculated relative to the temperature at the time
of absolute calibration. Prior to calculation of the DCF, the temperature is measured
on the surface of the electrometer unit. The temperature is input to the software and
36

a correction applied internally. A more accurate temperature assessment could be
achieved if the temperature was monitored from inside the phantom, as a surface
measurement is not necessarily indicative of the heat transfer to the diodes during
the measurement period [177, 178].

2.3.4.2.3

Pass/Fail Criteria

The software’s default pass/fail criterion was used in section 5.3.2. For dose
deviation analysis, the field will pass if 80% of points have a measured dose within
±3% of the calculated dose. For distance-to-agreement (DTA) analysis, the field will
pass if 90% of the measured points agree with the calculated dose within a radius of
3 mm. For gamma analysis, the field will pass if 90% of measured points have a
gamma index ≤1. The maximum allowable dose and spatial deviation is ±3% and ±3
mm respectively.

2.3.4.2.4

3D Dose Distribution

3D Dose Distribution is an optional feature of the Delta4® dosimetry system that
allows the volumetric verification of treatment plans. A notable advantage of the
feature is its ability to display the location of points that are failing the acceptance
criteria. This allows the medical physicist to ascertain whether the discrepancy
between measured and calculated dose are of clinical significance. This addresses
some concerns that gamma analysis lacks specificity [179]. The 3D dose distribution
is modelled by renormalising the TPS calculated depth dose to fit the measured dose
points registered as the ray traverses the detector plate(s); this process is applied perfield in the case of IMRT plans and per-control point for VMAT plans [37]. Calvo et
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al [180] has verified the accuracy of dose interpolation using ion chamber
measurements. Calvo et al found good agreement (between 0.3% and 2%) among
Delta4 measurement, the pinpoint ion chamber measurement, and the planned dose
[180].

2.3.4.3

ArcCHECK

The ArcCHECK (Sun Nuclear, Melbourne, USA), is a cylindrical diode array,
containing of 1386 diodes in a helical shape with 1 cm inter-diode spacing, 1 cm pitch
and 21 cm diameter. The central 10×10 cm of the ArcCHECK contains approximately
221 detectors; the same as the MapCHECK 10×10 cm. Active detector size of each
diode is 0.8×0.8 mm2. The system was developed to meet the need of rotational therapy
QA. It is well suited for QA of VMAT and IMRT. It allows measurements at arbitrary
gantry angles with sufficient spatial resolution even for the Novalis accelerator with leaf
widths as small as 3 mm. [181] .
The ArcCheck QA system can reconstruct the 3D dose distribution based on sensors
inside a phantom placed on the patient couch. The ArcCHECK detectors are curved to
form the surface of a cylinder inside a doughnut-shaped phantom [182], allowing the
radiation beam to hit at least the central detectors perpendicularly at any gantry angle.
Dose reconstruction in the entire volume of the cylinder is based on the modification of
the dose matrix calculated by the TPS. Without the import of TPS dose data,
ArcCHECK is not able to present 3D dose grids. Therefore, the ArcCHECK method
cannot be considered to be independent of the treatment plan that is to be verified [183,
184].
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2.3.4.4

OCTAVIUS (PTW, Freiburg, Germany)

The Octavius® 4D system consists of a cylindrical, rotational phantom in which the 2D
ionisation chamber array is inserted. The Detector 729 features 10 mm resolution, the
central region of the Detector 1000 SRS features 2.5 mm [185]. An external inclinometer
mounted on the gantry provides constant feedback on the actual gantry angle and allows
the control unit to rotate the phantom accordingly, keeping the 2D array perpendicular
to the beam axis at all times. Thus, the orthogonal beam output can be measured from
all angles and any possible directional dependence of the 2D array becomes irrelevant
[186]. The OCTAVIUS 4D algorithm is based on dose measurements at a certain depth
in the phantom and on PDDs that are used to reconstruct dose values along the ray lines
that connect the relevant detectors and the focus of the beam. As a consequence, the
commissioning of OCTAVIUS 4D is very simple and limited to PDD measurements
and to the adjustment of the phantom’s density in the TPS [185].

2.3.5 Transmission detectors
There is considerable need for real-time in vivo verification of the IMRT and the VMAT
that can be achieved by a transmission-type detector placed in the photon beam
downstream of the MLC during treatment. The idea of a 2D array transmission detector
for real time in vivo QA in EBRT was first proposed by Paliwal et al. The transmission
chamber was an off-the-shelf device called a Dose Area Product Meter (Gammex RMI,
Inc., Middleton, WI 53562) [187] using the concept of dose area product to monitor the
radiation beam in diagnostic applications for the measurement of patient exposure. The
concept of a dose area product was further developed to allow online in vivo comparison
of measured dose area product related to instantaneous MLC leaves opening and
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compare it with pre-recorded data [8, 188].
Two dimensional dosimeter arrays have been used in radiation therapy to measure the
complex dose distribution established by the IMRT and VMAT. These 2D arrays can
measure the dose at multiple locations in the field. Many studies of several ion chamber
arrays are available [140, 142, 189], diode detectors [71, 163], and EPIDs. In general
most systems are not in real-time and still used for pretreatment verification as they
perturb the beam too much to be left in during patient dose delivery. These detectors,
with or without phantoms, are placed on the patient table or in a special gantry mount in
the absence of the patient, or they can be arranged behind the patient.
There is a significant argument regarding the need and the possibility for the on-line
verification of IMRT and VMAT using a transmission-type detector with high spatial
resolution, mounted in the photon beam between the MLC and the patient. Such
technology is not, commercially available.

2.3.5.1 DAVID System (PTW-Freiburg, Germany)
The DAVID® system (PTW-Freiburg, Germany) is non-invasive enough to be able to
perform QA measurement during patient treatment. The DAVID system is a flat,
translucent multi-wire ionisation chamber to be placed in the second accessory holder of
the linear accelerator. The DAVID system comprises a transparent flat ionisation
chamber in order to minimise the interference with the light field of the treatment head,
and multi wire transmission ionisation chamber (there are 37 individual wires that are
positioned exactly below the associated leaf pair of the MLC) [8]. Its signal records the
opening of this leaf pair during patient treatment. As it is at an upstream position in
regard to the patient surface, it can provide a set of values that comes from the MLC
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generated photon fluence. The system also has wireless connection with its software.
The DAVID system has been developed for a standard Siemens linear accelerator. The
transmission properties and characteristics of the DAVID chamber have been measured
by Poppe (2010) [190].

2.3.5.2 COMPASS (IBA Dosimetry, Germany)
The COMPASS® device from IBA Dosimetry, Germany) is a pixel segmented
ionisation chamber. Its 2D array consists of 1600 air vented plane parallel ionisation
chambers with a detector spacing of 6.5 mm, and an active volume of 0.02 cm3. The
active area is which can measure fields of size 40 × 40 cm2 at the isocentre. The
external dimension of this transmission device is 52 cm width, 49 cm length, 11 cm
height, and 15 kg weight. Each chamber is 3.8 mm in diameter and 2 mm in height. The
detector assembly can be attached onto the gantry in the wedge slot of a Varian linac
2100iX which has a source to detector distance of 65 cm. Examinations of the influence
of the transmission detector on the surface dose, and on a dose beyond dmax, have been
carried out [191]. In their work Sankar et al. (2009) describe the influence of this new
transmission detector consisting of a 2D ionisation chamber array on a 6 MV photon
beam. They have found an increase in the surface dose for large field size and small
source skin distances (SSDs), due to the increased surface dose for shorter SSDs. The
impact of the COMPASS transmission detector on a 6 MV photon beam is an increase
in dose particularly in the build-up region. Beyond dmax, the beam parameters of
COMPASS detector and open fields were in good agreement.
COMPASS QA systems can perform a full 3D collapsed cone convolution/
superposition dose reconstruction based on a dose engine developed (algorithm which
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can determine the 3D dose distribution in the patient). COMPASS QA systems need to
be commissioned with individual beam data in order to custom model for each unique
linear accelerator.

2.3.5.3 The Integral Quality Monitoring system (IQM)
The integral quality monitor (IQM) utilises an area integrating energy fluence
monitoring sensor (AIMS) designed to be mounted between the final beam shaping
device, the MLC and the patient. The system consists of spatially sensitive large area
ionisation chamber with a gradient along the direction of the MLC motion in real time.
The signal from the AIMS delivers a simple output for each beam segment, which is
compared in real time to the expected value. The expected signal is calculated by
IQM_CALC based on the field information derived from the TPS and is an independent
of the treatment delivery system. The prototype ionisation chamber, with a physical area
of 22 × 22 cm2, has been made of aluminum with the electrode separations varying
linearly from 2 to 20 mm across the chamber. The sensitive volume of the ion chamber
was approximately 530 cm3. The chamber can monitor a radiation field that projects to a
size of approximately 34×34 cm2 at the isocentre. A calculation method has been
developed to predict AIMS signals based on an integration method, which takes into
account different factors, such as the spatial response function of the chamber, field size
factors, beam transmission through the secondary jaws, and MLC characteristics. Islam
(2009) found out for a 10 × 10 cm2 field size, the chamber attenuates the beam intensity
by 7% and 5% for 6 MV and 18 MV beams, respectively, without significantly
changing the surface dose, depth dose, and dose profile characteristics [188].
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2.3.5.4 Delta4® DiscoverTM (ScandiDose, Sweden)
The Delta4® Discover is a wireless head-mounted p-Si diode array detector, which is
intended to be used during patient treatment. The Delta4® Discover system is designed
to monitor the dose that is delivered to the patient. The delivered dose is then abled to
be compared with the planned dose automatically. The Delta4® Discover detector
system has a detector matrix consisting of 4040 detectors with a detector spacing of 2.5
mm. The thickness of this device is 55 mm, and 10 kg weight. Each detector is 1 mm in
diameter. It allows for an accurate dose and MLC leaf position detection. These
detectors are positioned along the MLC leaves allowing detection of sub-millimeter
positioning errors and dosage errors.
Very recently published work showed that the Delta4® Discover system contributes 1%
to the skin dose and attenuates the beam by 1% [192].

2.3.5.5 Dolphin (IBA Dosimetry, Germany)
Dolphin online treatment monitoring is based on a wireless ionisation chamber. It
measures the real treatment fraction by fraction instead of pre-treatment beam. Its 2D
array consists of 1513 air vented plane parallel ionisation chambers with a detector
spacing of 5 mm in the inner detector area (centre to centre distance), and 10 mm in the
outer area with an active volume of 0.016 cm3. The size of this device is 24.3×24.3 cm2
and with weight of 12 kg [193]. For transmission-type pixelated ionisation chambers
such as the Dolphin device, to reconstruct the dose in a patient requires complicated
algorithms that take into account the perturbation properties of the transmission
detector, which change with the irradiation field geometry.
These systems are advanced in vivo QA dosimetry devices capable of 3D dose
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reconstruction and comparison with the TPS after each treatment fraction. Very recently
with the Dolphin device inside the beam an increase in surface dose was observed
maximum of +11%. Beyond dmax the impact of the Dolphin system on the PDDs was
1%. Measurements showed that the transmission factor depends slightly on the field
size (0.893- 0.921 for 5 ×5 cm2 to 30 × 30 cm2)[194].
Although some of these QA delivery devices are available commercially, they are still
rare in clinical practice for IMRT and VMAT delivery verification during patient daily
treatment.

2.4 Gamma Analysis
Gamma analysis is a form of quantitative acceptance criteria assessment that considers
dose difference and DTA. Its quantitative nature provides a more user-friendly way of
comparing the agreement of calculated and measured dose distributions by providing a
measure of disagreement in the regions that fail the acceptance criteria and an indication
of calculation quality in regions that pass [195]. The -value is found according to
Equations (2.1) and (2.3) below:

𝑟 2 (𝑟𝑚 ,𝑟𝑐 )

Γ(rm, rc) = √

∆𝑑2

𝑀

+

𝛿 2 (𝑟𝑚 ,𝑟𝑐 )
∆𝐷 2 𝑀

(2.1)

Where

r(𝑟𝑚 , 𝑟𝑐 ) = |𝑟𝑐 − 𝑟𝑚 |,

(2.2)

and

𝛿(𝑟𝑚 , 𝑟𝑐 )= Dc(rc) –Dm(rm).

(2.3)
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Dc and Dm are the calculated and measured dose in positions rc and rm respectively. ΔDM
and ΔdM are the acceptable dose difference and DTA criterion respectively. Dose
difference refers to the variation between measured and calculated dose. DTA refers to
the shortest distance between the point of interest corresponding to the measured dose
and the closest point in the calculated distribution with the same dose. If the  -value
has a magnitude greater than 1, the region fails the acceptance criteria.
The  formula assumes that dose difference and DTA are of equivalent importance. In
regions of low dose gradient the dose-difference calculation dominates. In contrast, the
DTA is used in high-gradient regions where the dose-difference may be over-inflated
i.e. a small spatial error (in calculation or measurement) can lead to a large dosedifference [195].
There are no universal guidelines to follow when setting pass/fail criteria or the
percentage of points evaluated in the analysis. Feygelman et al [182] surmises a trend
towards error criteria being chosen on the basis of what can be “reasonably achieved” as
opposed to being based on any strong scientific foundation. This is most likely due to
the fact that  -analysis is yet to be put under rigorous scientific or clinical testing [182].
It is up to the clinic to apply their own judgment of what they deem to be acceptable,
with different thresholds often applied to different anatomical regions. A survey
conducted by Nelms and Simon [196] found that despite the lack of research into the
technique, 3% /3 mm gamma criteria was the most common measure of calculation
quality for 2D diode arrays. The 2009 AAPM TG119 report on IMRT commissioning
used the same criteria [197].
Zhen et al [179] looked into the clinical impact of employing gamma analysis in IMRT
QA, particularly the significance of the location of failing points in plans with high
passing rates. This was performed by introducing an error to establish a relationship
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between passing rate and dose errors in anatomical regions of interest. Zhen et al [179]
found there to be a weak correlation between the two, suggesting that the lack of
information on location, magnitude and sign of dose errors places a significant limit on
the ability of -analysis to predict clinically relevant errors.
As suggested by Horsfield [198], the ease with which -analysis can highlight
discrepancies between planned and measured dose distributions while still pertaining to
an acceptable level of accuracy is advantageous in a clinical setting. It is ultimately up
to the clinic to set high standards for IMRT QA. The popularity of -analysis instils
confidence that these standards can be met through stringent acceptance thresholds.
Thus 3%/3 mm acceptance criteria will be used when necessary throughout the course
of this thesis.

2.5

Skin and surface dose

The skin dose is of interest as the skin is always irradiated during external beam
radiation therapy, and yet, mainly due to voxel resolution constraints, the TPS is
incapable of accurately predicting the dose within 1 mm or 2 mm of the patient’s
surface.
According to the International Commission on Radiological Protection (ICRP) [199]
and the International Commission on Radiation Units and Measurements (ICRU) [200]
the skin depth recommended for practical dose assessments is at 0.07 mm below the
surface. Generally, this depth corresponds to the interface between the epidermis and
dermis layers of the skin “Basal layer” [201].
Many studies conducted with clinical cases in radiation therapy have shown that the
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skin dose is affected by the treatment technique, the accessories and immobilisation
used during radiotherapy, such as thermoplastic masks, wedges, blocks and trays [202210].
It has been found that mask material increased skin dose for 40% to 44% in cases of
head and neck radiation therapy, while tray and blocks can contribute another 3% to
4%. Furthermore, a decrease in the source to surface distance (SSD) also increases the
skin dose [204].
Kim et al, investigated the skin dose by changing the main clinical parameters, such as:
energy, field size, SSD, blocks, physical wedges, dynamic wedges, and beam shaping
with a MLC. They concluded that the skin dose increases for large field sizes of 40 × 40
cm2 for energies of 8 MV and 18 MV, from 6% to 38% and from 5% to 44%,
respectively. In addition, an acrylic block tray increased these values for large field size
by ~19 % for both energies.
Lee et al, investigated skin toxicity as a result of an increase in skin dose from multiple
fields extended intensity modulated radiation therapy for head and neck cancer, and
concluded that this reaction resulted from causes such as the immobilisation masks used
during irradiation, or during the inverse treatment planning system. An 18% reduction
of the skin dose has been observed if the skin is defined as sensitive area during inverse
planning [206].
Butson et al, agreed with previous authors that perspex blocking trays increased the
skin dose of a 6 MV X-ray by about 22%, while an increase that occurred by shortening
the SSD was much lower [207].
Therefore an innovative method to find a suitable radiation detector for skin dose is
necessary in order to obtain accurate and reliable results. Many authors investigated
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several radiation detectors to measure the build-up region, skin, and surface dose for
different radiation modalities [202-204, 211-222].
A variety of dosimeter types can be used, such: a parallel-plate ionisation chamber,
TLD, film, and MOSFET. The Attix chamber is regarded as a reference detector for in
phantom build-up and surface dose measurements, whereas TLD, film, and MOSFET
are less accurate relative detectors that do have potential as in vivo dosimeters due to
their effective depth of measurement. On the other hand, the Attix chamber cannot be
used for skin or in vivo dosimetry with a patient due to its size and high operational
voltage, so other detectors are more convenient with patients for this aim [223].
Each one of the relative detectors has its own advantages and disadvantages that may
make it more favourable than the others in various applications. For instance, TLD is
widely used for in vivo dosimetry due to its tissue equivalency and its lower cost, and it
can also be used for skin dosimetry by using an extrapolation method [213]. However, it
is not suitable for on-line measurements because they take a long time to analyse and
get results. Moreover so many sources of errors may arise from annealing and reading
procedures that can reduce its reliability as a detector [223]. Radiochromic film is also
being used for skin dosimetry because its effective depth is deeper than basal cells and
it can be used with correction against an ionisation chamber for accurate dose
estimation [217], or without correction, to get an approximate dose near basal cells
[224]. However, it cannot be used online and radiochromic film calibration and readout
procedures may introduce some uncertainties especially if the calibration and irradiated
films were scanned after different periods of time [225]. Handling, storage, or
environmental factors such as temperature, humidity, light exposure, or scanning factors
such as film orientation, resolution and scanner light source, can introduce large
discrepancies in its readings, therefor a great deal of care is needed to obtain reliable
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results with radiochromic film. However, film shows excellent results for cavity
measurements, but it underestimates the dose for the distal cavity (by 5 – 6%) as a result
of self-build-up when the film is parallel to the beam direction [226]. Film dosimetery
can give two dimensional dose maps with good resolution (~80 μm WED as for EBT2)
[218, 227]. Rosenfeld et al, Butson et al, [211, 228], promoted MOSFET as a surface
and skin dosimeter in radiation therapy. They found that the bare MOSFET is in
excellent agreement with an Attix ionisation chamber on the build-up region, which
makes it suitable for commissioning the build-up region and for measuring the skin dose
with the patient. It has many advantages, such as its small size, simple reading circuit,
low power operation, ability to store the dose history, and it can be used for online
readout. The sources of uncertainties in MOSFET readings is different than the film, it
is mainly associated with temperature, creep-up effect/instability and angular
dependence. It is not affected by associated issues with cabling such as an ionisation
chamber, as it’s an integrator based on charge build-up on the gate, it can work and
store signal even if there is no wire connected [228, 229].

2.6

Photon Beam Calculation – Convolution

The ICRU defines the absorbed dose as that energy imparted by ionising radiation per
unit mass [68, 230]. In the radiotherapy world, more accurate information about the
absorbed dose that will be received by the patient’s body is very important to the
provision of suitable treatment. For radiation treatment planning people rely on a
predictive method to simulate the energy transport and deposit in the human anatomy
[68, 231]. The TPS requires a dose calculation method, which conforms to correction
based or model based methods [16, 232]. In the correction based methods, the dose can
be determined by correcting water phantom collected data. This data is then held in a
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dose array and is manipulated taking into account patient contours and inhomogeneities
(meaning regions with different tissue densities and composition, such as bone and air).
In the second method (the model based methods), the dose can be determined from the
transportation of radiation from the first principles through the patient.
For photon beams, dose calculations of the patient were historically based on the
correction based methods. The reason behind that is their simplicity [232]. In the 1970s
the correction based dose method was proposed by Milan and Bentley [233].
Due to the huge development of computers and model based algorithms such as various
convolution superposition algorithms including the collapsed cone convolution
algorithm, and the anisotropic analytical algorithm (AAA) have become standard in a
clinical setting to calculate the dose distributions in the patient [234-236]. Monte Carlo
methods are the ultimate model based approach. Monte Carlo methods are approaching
speeds that becoming a viable for use in radiation therapy planning (RTP) calculation
[237].

Figure 2.5: Diagram of general photon interactions with an atom [15, 238].
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Figure 2.5 illustrates photon interactions with the matter in a patient’s body. During the
interaction some of the photon’s energy transfers to electrons, setting them in motion
depositing dose mainly by collisional energy loss. The kinetic energy which is released
in matter is called KERMA. When the electrons travel within the tissue, they will slow
down due to multiple Coulomb collisions, producing ionisation along their pathway.
After that, the excitation of atoms can take place and the molecular bonds will be
broken (biological damage) [239].
The total energy released in the patient through this procedure is called the absorbed
dose. On the other hand, other actions that take energy away from charged particles are
referred to as the bremsstrahlung. ‘Bremsstrahlung’ comprises those photons created
due to the deflection of electrons when approaching the nucleus of the atom. Delta rays
(secondary electrons produced by electron-electron collision) can also take the energy
away. Both braking radiation (bremsstrahlung) and scattered radiation can suffer
multiple interactions in the same way as incident interactions [20, 238-242].
There are several kinds of convolution algorithms. However, all of them have two
important components: Terma, and Kernel. ‘Terma’ is that energy imparted to the
medium by the interactions of primary photons as discussed above (3D distribution of
the total energy released per unit mass). On the other hand, ‘kernel’ is that energy
deposited about the primary photon interaction site.
In the literature, all convolution methods concentrate on the influence of the energy
fluence that comes from the beam. To illustrate that, and in the case of homogeneous
medium, the dose D( r), absorbed at a point r, from energy released at a point r` (Figure
2.6) will be given by the convolution Equations (2.4) and (2.5):
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D (r) = ∫ T (r`) A (r-r`) d3 r`

(2.4)

Where A (r-r`) is the convolution kernel, T(r) represents the TERMA. Also, TERMA is given
by (2.5):

µ

T(r`) = 𝜌 ψ (r`)
Where

µ
𝜌

(2.5)

is the mass attenuation coefficient and ψ (r`) is the primary energy fluence

distribution in the phantom.
In the Cartesian coordinate system this is the (fraction of energy absorbed in each cubic
volume element ‘voxel’ situated at ‘x, y, z’ in a medium). Values in the kernel are the
measurements of energy deposited at vectorial displacement from the interaction site as
a fraction of terma at that site.

Figure 2.6: Vector representation of the convolution scheme: vector r and r` show the
distance from the dose deposition point and the primary interaction site, respectively.
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The convolution method has been widely used to calculate photon dose in beams. The
collapse cone convolution and an anisotropic analytical algorithm are commercially
available. Many studies and articles have discussed these methods in the last past, from
(1985 to 1990s) [232, 236, 242-245].

2.6.1

Convolution/ Superposition Technique

The convolution/superposition technique has been used to calculate photon dose
distributions [232, 236, 242-244]. It takes into account primary radiation and secondary
radiation as well. It calculates the dose a convolution releases at each primary
interaction site (location), which is called ‘TERMA’ (the total energy imparted or
released in the medium by the interaction of primary photon), and the energy deposited
about the primary photons interaction, which is called ’kernel’. Kernel explains the
spread of energy due to a local scattering in the medium. This kernel is the same when
exposing a homogeneous medium by using a mono-energetic beam, however a
collection of weighted kernels are used to account for the energy spectrum for polyenergetic photon beams.
The description above is of what is known as a ‘superposition’ method. In the literature,
kernel can be referred to a different technique based on the geometry of the beam that
delivers the incident energy. For instance, it can refer to a dose spread array, a
differential pencil beam, point kernel, and energy deposition kernel. There is also the
‘planar kernel’, which describes both the forward and backward energy spread from
primary interaction placed in a plane from the laterally oriented broad beam.
Most TPSs these days are using this method for dose calculations. The reason for this is
that this technique takes into account a lot of physics. Most implementations use
empirical factors to account for dose in the build-up region. The superposition method
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has also some drawbacks, and the main one is it takes a long time to do dose
calculations, and it needs empirical parameters that should be determined by dose
measurement in tank water so it is not a pure model based algorithm [20]. The same for
matching Monte Carlo if matched to water data. Lots of details about the convolution
method and its types could can be found in the literature in depth [20, 58, 68, 236, 246].
One weakness is most superposition methods implement rectilinear scaling which
slightly over estimates dose in lung as electrons do not follow rectilinear paths.

The response of the MPDM using a 6 MV photon beam was investigated by Wong et al
[9]. A preliminary characterisation of the array was performed, including radiation
damage study, dose per pulse effect, percentage depth dose comparison with CC13 ion
chamber and build up characteristics with a parallel plane ion chamber measurements,
dose linearity, energy response and angular response. Post irradiated MP detectors
showed a reproducibility of 2.1%. The MP dose per pulse response decreased at higher
dose rates while at lower dose rates the MP appears to be dose rate independent. A good
agreement of the percentage depth dose measurement of the MP with ion chamber depth
dose measurements to within 0.7%.
The MP was shown to have some angular dependency due to the anisotropy of the
silicon diode with the maximum variation in response of 10.8% at a gantry angle of
1800. The angular dependence was within 3.5% for the gantry angles of ±750. Field size
dependence of the MP at isocenter was shown to agree with an ion chamber
measurement to within 1.1%. In the beam perturbation study using MPTM, the
transmission for the MP was 99% at 6 MV while the surface dose increased by 12.1%
for a 30×30 cm2 field size at the source to detector distance (SDD) of 80 cm [9] .
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In summary, although methods are being developed to verify the quality of a treatment
delivery, some cases are quite bulky and they are relatively expensive equipment, and
not provide a comprehensive picture of the beam delivery. There is currently no
complete mainstream method to verify the delivery of the plan, during patient treatment.
The use of silicon diode arrays in QA holds much promise and have the potential to fill
this gap in verification systems due to its desirable qualities, such as the real-time
operation and feedback when compared to other methods e.g. films which are not real
time, its high temporal response and strong radiation response, they have been selected
to be used for the development of a quality assurance system in this thesis.
It was important to verify in this thesis that the surface dose due to electron
contamination from MPTM was not significantly increased. This was mainly performed
by using an original Markus and Attix ion chambers in phantom under the MPTM as
outlined in future sections of this work.
The 2D transmission response data is collected in real-time. This data is then used to
reconstruct the dose in 2D along rays projected from the photon source through each
sensor element. As the data is collected in real-time, the dose, in principle, can be
reconstructed segment by segment for IMRT or even pulse by pulse for VMAT. The 2D
reconstruction could also be extend to 3D reconstruction, however this is beyond the
scope of this thesis. It is extremely exciting for real-time QA of these increasingly
complicated treatment regimes. The reconstruction methodology will also be of great
interest to the wider oncology community as it is applicable to many other forms of
radiotherapy including Stereotactic Radiosurgery, Stereotactic Radiotherapy, Image
Guided Radiotherapy and Motion Adaptive Radiotherapy with dynamic multi leaf
collimator tracking, where real-time radiation treatment monitoring through dose
reconstruction is very important.
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Transmission type detectors can provide a measure of the energy fluence and if they are
real time systems that do not significantly attenuate the radiation beam have a distinct
advantage over the current method as QA could in principle be performed during the
actual patient treatment.
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CHAPTER 3
Methodology
The previous chapter reviewed the current technology used in IMRT and VMAT dose
verification reported in the literature, and concluded with silicon diode detectors being a
very attractive candidate for the development of an IMRT and VMAT QA system. This
chapter goes on to describe the technology proposed for the dose verification in realtime during treatment delivery. It describes the development from the single detector
element to the 2D array of elements, the electronics system as well as other detectors
that have been tested.

3.1

Experimental setup

3.1.1

Linear accelerator and field arrangements

In this thesis, experiments were performed on a linear accelerator Varian model
2100IX; (Varian Medical Systems, Palo Alto, CA), which operates at the energies of 6
MV and 10 MV at the Illawarra Cancer Care Centre (ICCC), Wollongong Hospital,
Wollongong and another medical linac model 2100iX; (Varian Medical Systems, Palo
Alto, CA) producing 18 MV at St. George Hospital in Sydney.
Comprehensive detector characterisation (both in transmission mode and in dosimetry
mode) included; beam perturbation study, IMRT dosimetry, VMAT dosimetry and
verification of dose reconstruction methodology were carried out using the machines.
The linac is capable of variable dose rate and gantry speed rotation during beam
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delivery. Dose rates between 100 MU/min and 600 MU/min can be selected in 100
MU/min increments. Up to 9999 MU can be delivered for any one treatment (i.e. in
service mode). All the irradiation field sizes quoted refer to the field size defined at a
source to surface distance (SSD) of 100 cm. Measurements undertaken for this thesis
were performed with the radiation field defined by the linac jaws (an open field) and the
MLCs; a highly non uniform irradiation field (C shape) and fields with several
programmed MLC movements. The field size was changeable between the limits of 1
× 1 cm2 and 40 × 40 cm2, unless otherwise stated.

3.2

Epitaxial Diodes

This kind of technology consists of a high quality tiny epitaxial film on the top of a
heavily doped bulk silicon wafer, which behaves as a crystal seed for the tiepitaxial
growth and later works as a supporting structure. “Epitaxial means layered upon” as
shown in Figure 3.1.
The epitaxial diode becomes an attractive option in the field of radiotherapy, and differs
from conventional silicon detectors due to the thin epitaxial layer which works to be
more “radiation hard” [247]. The capability to shrink the pixel area (detector sensitive
area), allows a smaller detector thickness to be thinner compared to a silicon detector
with a thickness of 300 µm. Also, thinner detectors would also reduce the required
operational voltage [248].The epitaxial silicon diode has been designed and the
characterisation of this device was reported earlier by Talamonti et al [249], and Bruzzi
et al. [247]. The diodes used in the MP were grown by using the epitaxial growth
technique [103]. The p-epitaxial layer is a 50 µm thick p-Si layer on the top of 375 µm
thick high sensitivity p+ substrate. Comprehensive details and preliminary

58

characterisation of the individual epitaxial CMRP silicon diodes utilised have been
reported elsewhere [9, 94, 250].

3.2.1The “Magic Plate”
The Magic Plate (MP) incorporates an array of 11 × 11 silicon diodes (121 sensors),
covering an area of 10 × 10 cm2 (as shown in Figure 3.2). Each sensor element was
manufactured using epitaxial silicon detector technology. Figure 3.1 represents the single
element structure of the 2 D array which is a diode manufactured by an epitaxial technology.

The epitaxial layer is 50 µm thick, p-type (100 Ω cm) and grown on top of a 375 µm
thick, very low resistivity (0.001 Ω cm) p-type substrate. The p-type substrate was
chosen for its well-known radiation hardness and the epitaxial layer thickness minimises
the radiation damage effects that influence the radiation response of the sensors while
providing adequate sensitivity for the sensor application described in this thesis. The
diodes were produced using ion implantation technology after which they were diced
and embedded in a 0.64 mm thick Kapton® carrier using the ‘drop-in’ technology
developed at the CMRP, UoW [251], so as to be spaced 10 mm apart. This technique is
used to minimise the energy dependence and dose enhancement in a photon field due to
high Z material typically used for packaging of silicon dies. The Kapton® pigtails are
then shielded with thin aluminium foil and grounded to minimise effects from external
radio-frequency noise [252]. The physical size of a single diode is 1.5 × 1.5 × 0.05 mm3
and the individual detectors have a sensitive area of 0.5 × 0.5 mm2.
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Figure 3.1: Schematic diagram of an epitaxial diode (not to scale).

Figure 3.2: The 2 D array Magic plate (MP). The MP uses two
SCSI-2 connectors, with 68 channels each connector, to interface
with the readout electronics. This makes the MP modular, and can
be interchanged with different versions of the front-end data
acquisition systems.
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The MP has been designed to be used as a transmission detector (MPTM) that can be
mounted on the linac head (accessory slot) in line with radiation beam (as shown in
Figure 3.3). In this case, MPTM can be used to verify the dose maps from IMRT and
VMAT in real-time during treatment delivery and to measure the 2D fluence map of the
modulated radiation beam. The MP can also be used in dose mode to measure 2D dose
distribution in a solid water phantom as well (MPDM).

Figure 3.3: Magic Plate in transmission mode (MPTM) mounted in
the accessory tray slot, just below the linac jaw of the medical
linear accelerator on the head of a Varian linac.

When the MP is used in transmission mode (MPTM), the MPTM array is sandwiched
between a black plastic sheet (80 µm), to reduce light leaking to the detector, as a buildup material and/or with an additional 1 mm of solid water covering the entire array, to
remove scattered low energy electrons. Then, the whole assembly is clamped between
two 6 mm acrylic Perspex® slabs. This frame is screwed onto a modified total body
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irradiation (TBI) tray, which can be attached onto the linac accessory slot (this is 58 cm
on a Varian linac from the X-ray source). The field size on a MP is 1.72 times smaller
than that at 100 cm SSD.

(a)

(b)

Figure 3.4: (a) The MPDM was sandwiched between two pieces of 5 mm solid water
plates that were designed to fit the Kapton® substrate. (b) The 2D planar diode array
detector placed in dose mode (MPDM) in a solid water phantom.

When used as a 2D planar diode array in dose mode (MPDM) in a phantom (as shown
in Figure 3.4 (a)), the MPDM was sandwiched between two pieces of 5 mm solid water
plates that were designed to fit the Kapton® substrate. The solid water plate’s width was
1.5 cm. The two solid water plates serve three purposes:
(i)

Shielding the detector from ambient light (optically light tight).

(ii)

For mechanical strength, and protection of the MP diodes.

(iii)

As scattering material, used to increase the signal generated in the diodes.
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This allows the MPDM to be used in combination with an IMRT phantom on the top of
the linac couch (as shown in Figure 3.4(b)). A preliminary characterisation of this
device in dose mode (MPDM) has been reported earlier by Wong et al. [94].
The MP has been shown to possess suitable properties for use as a 2D radiation
transmission detector for radiation therapy treatment verification during patient
treatment. All MP measurements were performed in passive mode (no external bias
applied at the electrodes) to minimise the variation of the leakage current and the
consequent variation of the baseline of the signal which requires time consuming and
frequent recalibration procedures.

3.3

Electronics and software

Each diode in the MP is read out individually by a multichannel fast data acquisition
system (DAS) based on a charge to frequency converter chip named TERA06, designed
by the Instituto Nazionale di Fisica Nucleare (INFN) – Turin Division and University of
Turin microelectronics group. This was originally developed, for readout of pixelated
ionisation or strip chambers for Hadron Therapy as described in detail elsewhere [253].
The device is capable of integrating the photo-induced charge in the detector with zero
dead time over a range of acquisition times (for the experiments described in this thesis,
this was set to 100 ms per frame) and for a fixed total acquisition time. The system
provides the measure of the total charge by a digital value (16 bit) transmitted by a
USB2.0 link; the information is stored on a computer and visualised on the screen in
real-time (48 MB/sec transmission rate). The same readout electronics for the MP
detector array were used in both transmission and dosimetry mode. Figure 3.5 (a) shows
the layout of the Rad-X Doseview software which was utilised in order to acquire all
diode response data. The software was developed by the CMRP. It allows the user to
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see the real time response of up to 128 individual detectors as well as their respective
integral response over the set time of acquisition. Alongside the realtime numerical data
for individual detectors, the software allows for a viewing of an array of devices with a
dynamic relative colour based scale as shown in Figure 3.5 (b). For further information
about the readout system designed for the MP refer to [254, 255].
The MPDM and MPTM measurements were performed in passive mode (no applied
bias) for simplicity of operation and because for all the experiments described in this
thesis, an adequate photogenerated response was measured, leading to an excellent
signal to noise ratio.

(a)

(b)

Figure 3.5: (a) Rad-X Doseview Softwear with individual detector readout and (b)
Rad-X Doseview Softwear for visualization of array readout

3.4

Equalisation procedure

The MP 2D array consisted of 121 detectors implanted on bulk p-type silicon substrate.
The radiation response from each individual diode is different from the adjacent
detectors due to different connections, capacitances, amplifications, etc. Based on that,
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the integral dose between the 121 detectors readout channel will be slightly different.
Therefore, flat field correction or response equalisation is required.

Figure 3.6: The equalisation procedure: the MP at a depth of 10 cm of a 30
× 30 × 20 cm3 solid water phantom and exposed to a 20 × 20 cm2, (field
size defined at an SSD of 100 cm).

Figure 3.6 shows the experimental configuration which was carried out prior to any
measurements by the MP detector array (MPTM and /or MPDM), a flat field correction
was prepared by placing the 2 D array at a depth of 10 cm of a 30 × 30 × 20 cm3 solid
water phantom and exposed to a 20 × 20 cm2, (field size defined at an SSD of 100 cm),
and then irradiated for 20 seconds (200 MU) delivered at 600 MU/min dose rate. The
equalisation procedure was performed for the whole 121 sensor array before performing
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any measurements to generate a flat beam. The flat field correction statistics of MP121
response before and after the equalisation was applied. The differential response for
each energy can be calculated as (3.1):

X (%) =

𝑋𝑒𝑞(𝑖→𝑗)−𝑋𝑒𝑞(6,6)
𝑋𝑒𝑞(6,6)

× 100

(3.1)

where the Xeq (6, 6) is the integral response of the central pixel after equalisation as
described in above, i= detector number (1) and j= detector number (121) .The variation
in the response of all 121 detectors relative to the average response can be then
calculated before and after flat field correction for each desirable beam energy.

3.4.1

Ionisation chambers

PTW original Markus parallel plate ionisation chamber along with four other ionisation
chambers has been used in this thesis. The other four chambers are the Attix, Wellhöfer
compact ionisation chamber (CC13), Farmer and PTW semiflex thimble ion chambers.
Details about the experimental set-up will be explained for specific energy in details in
future chapters.

3.4.1.1 Parallel plate ionisation chamber
There are some limitations of the plane parallel chamber in surface dose measurements.
For plane parallel chambers, the charge measured is produced by the electron fluence
entering from the front window and that by the secondary electrons scattered from the
side wall [256].
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Markus-type chambers (as indicated in Figure 3.7) are known for their over-response
due to their small guard ring [257, 258] and different methods have been developed to
correct for this over-response [259]. To correct for the effect of electrons entering
through the side wall, a factor to correct the chamber reading was derived by Velkley
[260]. Gerbi and Khan [261] reported that an accepted accuracy of ±2% was produced
by the Velkley correction factor, but only for those chambers which have a distance of
(5-11 mm ) between collecting edge and side wall, outside this range the formula did
not predict accurate results. Gerbi and Khan modified the Velkley formula to take into
account the effect of the distance between the collector edges to side wall. Rawlinson et
al. [262] examined the design features of plane parallel chambers and found that the
over response from the side walls is mostly dependent on the ratio of the electrode
separation (s) to the diameter of wall (w), wall angle and wall density. They also
extended the Velkley formula to account for the chamber wall diameter, size of the
guard ring, separation of electrode and the material of chamber. The Velkley correction
formula as modified by Rawlinson is as indicated in equations (3.2),(3.3) and (3.4):

P (d,E)= P`(d,E.G) – ξ(d,E,G)

(3.2)

ξ(d,E,G) = ξ(0,E,G) × e−4.0d/dmax

(3.3)

ξ(0,E,G)= c(E) × (s/w) × ρ0.8

(3.4)

where P is the true percentage depth dose and P` is the measured percentage depth dose,
ξ is the over response correction factor, E is the energy beam, d is depth in phantom, ρ is
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mass density of the ionisation chamber wall, s/w is the ratio of electrode separation (s)
to the diameter of wall (w). For 6 MV photon beam, dmax is 15 mm and c(E) = 27% (as
per Rawlinson et al. [262]).
In this thesis, all in-field dose measurements were therefore corrected using the Velkley
correction as modified by Rawlinson to correct the over response of the Markus
chamber measurements as mentioned earlier [260]. The chamber dimension used for the
correction calculation was obtained from Chen et al [263].

Figure 3.7: Markus plane-parallel ion chamber, model N23343.

Figure 3.8: Gammex RMI 449 Attix parallel plate ion chamber.
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Another parallel plate ionisation chamber is the Attix chamber, which is an air filled
parallel plate ionisation chamber made almost entirely of solid water with a flat plane
towards the beam and an effective point at the surface of the air cavity (as shown in
Figure 3.8). When enclosed in the recommended solid water phantom (design for Attix
IC) perturbations of photon and electron beams by the chamber are negligible. It has a
very thin window to allow the dose at the interface region to be measured. However, it
does have some limitations, which include it’s very large size (6 cm diameter for
Gammex RMI Model 449), so it cannot be used for fields that are smaller than its
diameter (see Figure 13). The ion collector has a minimal thickness colloidal graphite
coating on a 0.13 mm thick polyethylene disc. Therefore, its thickness allows
measurements of dose build-up starting almost at the surface of a phantom.

3.4.1.2 Thimble ionisation chamber
One of the thimble ion chambers used to measure the output factors in this thesis is
called a Farmer chamber (Model 2571). In 1955, Farmer designed a chamber which is
stable and reliable for X-rays and gamma rays for all energies. In the newest design the
thimble central electrode is of aluminium and the wall is made of pure graphite. The
thimble insulator consists of polytrichlorofluorethylene (PTCE). The collecting volume
of the ionisiation chamber is 0.6 cm3. It has three electrodes: the central electrode (the
collector), the thimble wall, and the guard electrode. The role of the collector is to send
the current to the electrometer (charge measuring device which is operated in high
voltage 300 V).
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3.4.2

Delta4® dosimetry system

The impact and the transmission factors of both the bare MPTM and for the MPTM
with 1 mm build up on the open field 2D dose distribution was measured using Delta4®
system to learn more about the dose difference of IMRT/VMAT beams with MP in
place as compared to an open beam.

3.4.3

Conclusion

This chapter provides a description of the 2D detector array, the MP and the TERA
DAQ system that was connected to the MPTM and MPDM which was used to sample
the measured integrated charge and relay the data to the software suite. Delta4® was
also introduced, with the dose calibration procedure presented, as it appears in further
chapters in this thesis.
The following chapter details the feasibility tests performed to characterise the use of
the MPDM associate software system for use in IMRT and VMAT quality assurance
with different beam energies.
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CHAPTER 4
Radiation Response and Basic Characterisation
of the “Magic Plate” when Operated in Dose
Mode with Different Beam Energies

This chapter demonstrates the potential performance characteristics of the MP system
when operated in dose mode (MPDM), i.e. on the patient couch at several linear
accelerator potential differences.

4.1

Introduction

Advances in modern radiotherapy techniques for the treatment of cancer continue to
appear. A recent example is the introduction of VMAT which involves a complex
combination of dose rate variation and beam shaping (to that of the target) while the
treatment beam moves continuously around the patient [264]. The main driver for these
advances is the desire to achieve better tumour control through dose escalation to the
target together with tighter treatment margins. Such advances, need to be made without
increasing the dose to normal tissue so as to avoid undesired treatment related
complications [265].
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Implementation and commissioning of VMAT as well as routine QA of patient plans
and linear accelerators requires an independent dosimetry system, preferably one
capable of measuring a 2D dose distribution.
The MP QA detector system includes a 2D silicon diode array, fast real-time readout
system, and associated software which was first proposed by Rosenfeld from the CMRP
at the UoW. The MP was designed to be placed on the treatment head of the linac as a
transmission detector during the patient treatment (MPTM) as well as to function as a
planar detector for dose distribution measurement in a solid water phantom for the
dosimetric verification of IMRT and VMAT treatment deliveries. The MP has been
previously described and characterised in dose mode (MPDM) to map a 2D dose
distribution in a solid water phantom [9].
This chapter extends some of the work published by Wong et al [9] that was carried out
in dosimetry mode at 6 MV photon beam . In particular the field size dependence, beam
profiles, and the response of the array with different frequency pulses have been
measured for different beam energies such as 10 MV and 18 MV beams to assess the
operation of the MP in these significantly different radiation field environments (e.g.
including neutrons at 18 MV).

4.2

Materials and methods

The MP is designed to be operated in both transmission mode (MPTM) to sense the
actual energy fluence during patient treatment and in dose mode (MPDM) to map the
2D dose distribution at any depth on the solid water phantom. Details of the individual
epitaxial diodes and characterisation of the array in dose mode are published in previous
work [9, 250]. Measurements were performed in the passive mode (zero volts applied
at the electrodes) to minimise the variation of the leakage current and the consequent
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variation of the baseline of the signal which requires time consuming and frequent
recalibration procedures. Prior to any measurements by the MP sensor array a flat field
correction (equalisation procedure) was performed (see section 3.4). It should be noted
that in all cases, irradiation field sizes quoted are referred to the field size defined at the
SSD of 100 cm.

4.2.1

Field size dependent surface doses and output factor measurements

The potential performance of the 2D array in dose mode (MPDM) when measuring the
linac radiation output as a function of the field size was investigated. Effectively this
test assessed the scatter properties of the matrix of detectors, which depend on the
internal design of the device.
In this chapter output factor measurements and surface doses were carried out by
delivering 100 MUs for squared field sizes ranging from 5 × 5 cm2 to 40 × 40 cm2. The
MPDM was positioned in the phantom surface and in standard set-up (depth of dmax at
100 cm SSD). Dose outputs were compared with ion chamber measurements taken at
the same conditions using a Markus ion chamber (Model N23343 ), Attix parallel -plate
(MRI,Model 449) ion chamber, Wellhöfer compact ionisation chamber (Model CC13),
Farmer ionisation chamber (Model 2571) and the PTW semiflex thimble ion chamber
(Model 31010).The ion chamber detectors were connected to a Unidos universal
dosimeter (PTW, Freiburg, Germany) (Model 1300698- T10023) for 6 MV, 10 MV and
(Model 11439- T10001 ) for the 18 MV medical linac.
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4.2.2

Beam dose profile measurements

The beam dose profiles were also measured at different depths (at the phantom surface
and depth of dmax) in the solid water phantom by the MPDM. The MPDM were
compared with those from the CC13 ionisation chamber and the PTW semiflex thimble
ion chamber, at the same depth for field sizes ranging from 5×5 cm2 to 40 × 40 cm2 at
an SSD of 100 cm using the beam energies previously mentioned. For each profile the
MLCs were opened to match the linac jaws. The beam profiles were constructed by
stepping the respective detectors laterally across the beam using the patient couch in
centimetre steps for MP and millimetre steps for the ionisation chambers through each
field.

4.2.3

The response of the array with different frequency pulses

The response of the array with different frequency pulses was measured by varying the
pulse repetition frequency (PRF) of a Varian linear accelerator; the mean dose rate is
changed while dose per pulse remains constant. The average dose rate as seen by the
detector can be varied by either changing the dose per pulse or the pulse repetition rate
of the linear accelerator. The dose per pulse was modified by changing the depth of the
detector in the phantom. The MP diode array detector was placed at different depths on
the solid water phantom at dmax and depth of 10 cm in a 10×10 cm2 beam at an SSD of
100 cm and irradiated with 100 MU for 6 MV, 10 MV and 18 MV beams. The single
diode of the array located on the central axis was used to evaluate the response of the
2D detector array. The dose rate at dmax ranged from 100 cGy/min to 600 cGy/min but
100 cGy was delivered each time.
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4.3

Result

4.3.1

Field size dependent surface doses and output factor measurements

(a) 6 MV
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(b) 10 MV
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(c) 18 MV

Figure 4.1. Surface doses comparison between 2D MPDM and ion chambers
(Markus and Attix ion chambers). The local percentage difference is also shown.
Field size range between 5×5 cm2 and 40×40 cm2. Data were acquired at the
phantom surface using solid water phantom. 6 MV, 10 MV and 18 MV were used for
this study.

Field size dependent surface dose measurement results of MP for 6 MV, 10 MV and 18
MV beams at 100 cm SSD are shown in
Figure 4.1(a , b and c) respectively. The Surface doses measured using the Markus ion
chamber and Attix chamber were also included for comparison. The field size
dependence of the 2D array central axis (CAX) diode values measured at source
detector distance (SDD) 100 cm was measured. The increase in the percentage
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difference of the MP compared to the ion chambers measurements are related to the
water equivalent depth (WED) of MP which is 500 µm. The increase in WED is mainly
caused by the fact that the material above the sensitive volume is not water equivalent but
silicon. So, the additional energy deposited in the sensitive volume scales with the density
of the material (Silicon compare to water). More electrons back scattering due to higher
density which is 2.2 times than water.

Figure 4.2: Output factor comparison between 2D MPDM and ion chambers (Farmer
and CC13 ion chambers). The local percentage difference is also shown. Field size
range between 5×5 cm2 and 40×40 cm2. Data were acquired at dmax in standard set-up
using solid water phantom. 6 MV was used for this study.
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Output factor measurement results of MPDM for 6 MV photons at 100 cm SSD are
shown in Figure 4.2. The output factor measured using the Farmer ion chamber and
CC13 chamber were also included for comparison. The field size dependence of the 2D
array CAX diode values measured at source detector distance (SDD) 101.5 cm (dmax)
agreed well with both the Farmer chamber and CC13 ion chamber. Discrepancies are
within 0.56 % and 1.19 % respectively for all measured field sizes.

Figure 4.3: Output factor comparison between 2D MPDM and ion chambers (CC13
and Markus ion chambers). The local percentage difference is also shown. Field size
range between 5×5 cm2 and 40×40 cm2. Data were acquired at dmax in standard set-up
using solid water phantom. 10 MV beam was used for this study.
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Figure 4.3 shows the field size dependence of the 2D array CAX diode values at SDD
100 cm for a 10 MV beam. The output factor measured using the Markus ionisation
chamber and CC13 chamber were also involved for comparison. MPDM measurements
have been performed at depth of dmax (21 mm in case of 10 MV beam) agreed very well
with the Markus chamber and CC13 measurement within - 0.60 % and 0.32 %
respectively.

Figure 4.4: Output factor comparison between 2D MPDM and ion chambers (Thimble
and Markus ion chambers). The local percentage difference is also shown. Field size
range between 5×5 cm2 and 40×40 cm2. Data were acquired at dmax in standard set-up
using solid water phantom. 18 MV beam was used for this study.

Field size dependent measurement results of MPDM for 18 MV beam at 100 cm SSD
are shown in Figure 4.4. The output factor measured using the PTW thimble ionisation
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chamber was also included for comparison. The output factors of the 2D array CAX
diode values measured at SDD of 103 cm (dmax) fit very well with the thimble ion
chamber within 0.57 % for all field sizes.

4.3.2

Beam dose profile measurements

(a) 6 MV
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(b) 10 MV

(c) 18 MV
Figure 4.5: Beam dose profiles measured at the phantom surface with MPDM. 6 MV,
10 MV and 18 MV linac beams were used for this study. Error bars are not shown
for clarity purposes.
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Figure 4.5(a-c) shows dose beam profiles measured of the MP at the phantom surface in
absolute terms (independently converted to Gy) for 6 MV, 10 MV and 18 MV linac
beams and SSD of 100 cm. Measurements were made with radiation fields from 5×5
cm2 to 40×40 cm2 and fields defined by the linac jaws and the MLCs. The aim of these
measurements is to study the behavior of the array at the surface. Comparison with
some data in transmission mode will be useful to reconstruct the dose in the patient.

(a) 6 MV

(b) 10 MV
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(c) 18 MV
Figure 4.6: Comparison between measured dose profiles using ion chambers (CC13 and
PTW Thimble chambers) and measured doses using Magic Plate in solid water phantom
(MPDM) at dmax. 6 MV, 10 MV and 18 MV were used for this study. Error bars are not
shown for clarity purposes.

Figure 4.6 (a-c) shows dose beam profiles measured of the MPDM (dots) at depth of
dmax in absolute terms (individually converted to Gy) compared with dose beam profiles
of ionisation chambers (lines) measured at the same depth for 6 MV, 10 MV and 18 MV
linac beams and SSD of 100 cm. Measurements were made with radiation fields from
5×5 cm2 to 40×40 cm2 and fields defined by the linac jaws and the MLCs.
The 2D Array data fit very well the ion chamber profiles with a maximum percentage
difference of 3% for all field sizes and for all beam energies tested, both in and out of
the irradiation field. Furthermore, the MPDM detector measurements are accurate also
in the penumbra region. This case is interesting because it shows some limitations of the
2D array sampling capabilities. The well-known dose volume effect due to the superior
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spatial resolution of the MP detector elements easily accounts for the small differences
observed between the data sets in the penumbra region of the beam profiles. It can be
noted that for all field sizes the dose on the thin end of the profiles is not measured in
the completed dataset. This is because the field edges actually fall between two adjacent
detectors. This is due to the detector design having a 1 cm spacing of the MPDM.
Nonetheless the agreement between the two datasets is very good with the 2D array data
accurately matching the ion chamber profiles. Above results prove that MPDM is
validated against the ion chambers and no perturbation of the field caused by MPDM in
a solid water phantom. This demonstrates that the robustness of the 2D array when
operated in dose mode.

4.3.3

The response of the array with different frequency pulses

In previous work the MPDM was irradiated with a 10 × 10 cm2 field size and showed
decreased dose per pulse response at higher dose rates (dose per pulse >1 × 10−4
Gy/pulse) due to the Auger recombination effect. However, at lower dose rates typical
for IMRT deliveries the MPDM appears to be dose rate independent [94].
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(a) 6 MV

(b) % STDEV (6 MV)

(c) 10 MV

(d) % STDEV (10 MV)
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(e) 18 MV

(f) % STDEV (18 MV)

Figure 4.7: The response of MPDM with changing dose rate with comparison with Farmer
chamber and 0.125 CC chamber. The local percentage difference is also shown. The variation
of the response of 2D MPDM at dmax with changing dose rate was also shown. 6 MV, 10 MV
18 MV were used for this study. The data has been normalised to the 600 cGy/min response at
each energy.

Figure 4.7 (a, c and e) shows the response of the array CAX diode value with different
frequency pulses measured of the MPDM (black squares) at depth of dmax
(independently normalised to 600 MU/Min) compared with normalised data from an
ionisation chamber (red dots) measured at the same depth for 6 MV, 10 MV and 18 MV
linac beams and SSD of 100 cm. Measurements were made with radiation field size of
10×10 cm2 and fields defined by the linac jaws and the MLCs. The 2D Array data
(CAX) diode value agreed very well with the ion chamber measurements with a
maximum percentage difference within 2.5 % for 10×10 cm2 field size and for all beam
energies tested.
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Figure 4.7 (b, d and f) show a 2D presentation of the percentage standard deviation of
all dose rates tested on the MPDM array which was within 1% (one standard deviation).

(a) 6 MV

(b) % STDEV (6 MV)

(c) 10 MV

(d) % STDEV (10 MV)
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(e) 18 MV

(f) % STDEV (18 MV)

Figure 4.8: The response of MPDM with changing dose rate with comparison with Farmer
chamber and 0.125CC chamber. The local percentage difference is also shown .The variation
of the response of 2D MPDM at depth of 10 cm with changing dose rate was also shown. 6
MV, 10 MV and 18 MV were used for this study. The data has been normalised to the 600
cGy/min response at each energy.

The response of the 2D array (MPDM) (CAX) diode value with different frequency
pulses measured of the MPDM (black squares) at a depth of 10 cm (independently
normalised to 600 MU/Min) was investigated in
Figure 4.8 (a, c and e). MPDM results compared with normalised data of ionisation
chambers (red data points) measured at the same depth for 6 MV, 10 MV and 18MV
linac beams and SSD of 100 cm. Measurements were performed with radiation field
size of 10×10 cm2 and fields defined by the linac jaws and the MLCs. The 2D Array
(CAX) diode data value agreed very well with the ion chamber measurements with a
maximum percentage difference less than 2.8 % for 10×10 cm2 field size and for all
beam energies tested.
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Figure 4.8 (b, d and f) also show that a 2D presentation of the percentage standard
deviation of all dose rates tested on the MPDM array which was within 1% (one
standard deviation).

4.4

Discussion

In a phantom, the response of the silicon diode array (MPDM) is determined by a
combination of photon interactions directly in the diode as well as energy depositions
within the diode resulting from secondary electrons produced in the phantom that reach
the diode. The primary component of the energy dependence observed using silicon
diodes for dosimetry is due to the low energy component of the scattered photon
radiation in the phantom combined with the increase in the photoelectric cross-section
of silicon compared to water. Such energy dependence is therefore not critical here
where the beam energy is 6 MV, 10 MV, and 18 MV. However for out-of-field (OOF)
measurements it is expected to be more significant and therefore must be taken into
consideration.
At small field sizes (< 5×5), it is well known that the lack of electronic equilibrium a
lower dose delivered per monitor unit, whereas for field sizes >10 × 10 cm2, electronic
equilibrium is reached and so the dose delivered per monitor unit is constant. One of the
main interests in using detectors such as MP for IMRT and VMAT dose verification is
that the dimensions of the detector is very small so they are usually regarded as an
excellent choice for output factor measurements especially for small field sizes. It is
well known that ionisation chamber measurements for field sizes less than 5×5 cm2 may
not be accurate because of the volume averaging effect. This highlights one of the major
advantages of the MP detector since the IMRT segment sizes in clinical treatments
continue to decrease, which is out of scope of this thesis. In this chapter, the dosimetric
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characteristics of the 2D array MPDM have been investigated. In Wong et al [9] the
measurements performed using a 6 MV photon beam showed that the 2D array response
(MPDM) was very reproducible, within 2.1 % and the system’s linearity to dose was
also verified for the measured dose range of 0.05-10 Gy. Output factor comparison with
ion chamber measurements was also very good. In this work output factors agreed very
well with reference dataset for field sizes ranging from 5 × 5 cm2 to 40 × 40 cm2. The
2D MPDM successfully detected centimeter positional movements of the linac
secondary collimators. Moreover, dose profiles matched very well with ion chamber
measurements. As pointed out in this chapter, the MP spacing of 1 cm may result in a
limited sampling of the radiation beam. This may be an issue if high resolution for
asymmetric profile edges are needed, e.g. in high dose gradient regions. However, this
is an efficiency problem common to other planar detectors currently available.
Promising devices for IMRT verification and in vivo dosimetry include EPIDs [151,
161], Delta4® [176], ArcCHECK [181-183, 266] and OCTAVIUS [267]. These
detectors can provide very high resolution and highly efficient planar dose maps.
However, further investigations are under way for the deployment of this technique into
in vivo routine clinical practice [268, 269]. With the 2D MPDM the workload can be
remarkably reduced when compared to conventional verification techniques. One of the
attractive points of this class of devices is that dose distributions are acquired, shown
and potentially processed in real-time. The data acquisition software provides a
graphical environment where dose maps can be compared and evaluated pulse by pulse.
Alternatively, measurements may be exported to any files format and loaded in other
applications. MPDM sensor is very thin compared to other commercially available
detectors and easy to use for daily radiotherapy plan verification. The experimental
positioning and set-up procedures were also straightforward (see section 3.4). The
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average time required to arrange the system in the standard measuring set-up was <5
min which is similar to the setup time for a Delta4® system.

4.5

Conclusion

The radiation response of the MPDM was characterised. The 2D array of epitaxial
silicon based detectors with “drop-in” packaging showed properties suitable to be used
as a simplified multipurpose and non-perturbing 2D radiation detector for radiation
therapy dosimetric verification. On the basis of the of tests performed in this chapter,
one can conclude that the 2D array is a dosimetrically accurate and sensitive tool and
that it can be a useful device for QA and verification of clinical radiotherapy beams.
The possibility of obtaining higher efficiency dose maps with the 2D array is currently
under investigation.
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CHAPTER 5
Beam Perturbation and Surface Dose
Characteristics in 6 MV, 10 MV and 18 MV
Photon Beam Energies
This chapter describes and discusses the performance characteristics of the MP system
when operated upstream of the patient in transmission mode (MPTM). The MPTM is an
essential component of a real-time QA system designed for operation during
radiotherapy treatment. Of particular interest is a quantitative study into the influence of
the MP on the radiation beam quality at several field sizes, several treatment
configurations and linear accelerator potential differences. The impact is measured
through beam perturbation effects such as changes in the skin dose and/or PDD (both in
and out of field).

5.1

Introduction

The Magic Plate has been previously reported in dose mode (MPDM) to map a 2D dose
distribution in a phantom [9] and further investigation with different beam energies has
been performed in the previous chapter. However, for the real-time QA system the MP
is placed in the accessory slot on the head of the linac and must be operated as a
transmission detector during the patient treatment with minimal perturbation of the
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incident radiation field, requiring a detailed study of its influence on the treatment
beam. The surface dose in particular can be one of the limiting factors in treatment plans
with high doses to a target and is the focus of this chapter [217]. Similar studies in the
past have been completed for beam modifiers such as wedges, MLC and block trays
[205, 270-272].
Beam perturbation can be quantified by measuring changes in the PDD profiles
particularly in the build-up region including surface dose, with the transmission MP
placed in the beam. Ideally, such a device would have no significant impact on the
treatment delivery, either to the target dose or surrounding normal tissues. Therefore,
the main objective of this chapter is to quantitatively determine whether or not the
presence of the MP upstream of the patient has a significant effect on the surface dose
and PDD during patient treatment.

5.2

Materials and methods

For the MPTM investigation, two potential operational conditions were examined in
this chapter:
(i) The MP array sandwiched between black plastic sheets, 80 µm thick, here in
referred as “bare MPTM” as shown in Figure 5.1(a). The role of the black plastic is to
remove light from the background detector response.
(ii) The MP array with an additional 1 mm of solid water covering the entire array as
shown in Figure 5.1(b). The role of the 1 mm solid water was to remove scattered low
energy electrons.
Condition (i) is designed for minimum attenuation of the primary linac beam; however
precise sampling of the energy fluence may be adversely affected by contamination
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electrons. To better sample the energy fluence, the 1 mm of solid water was introduced
in condition (ii) to filter a large component of these contamination electrons.
Experiments were performed on two Varian linear accelerators (Model 2100EX), one of
which operated at the energies of 6 MV and 10 MV, and another which was operated at
18 MV. Irradiation field sizes of 5 × 5 cm2 and 10 ×10 cm2 and a constant SSD of 100
cm were used for both linac experiments.

5.2.1

Surface dose and percentage depth dose measurements

The surface dose and PDD for each set-up (i.e. (i) and (ii) above) were measured and
compared to the corresponding surface dose and PDD with no MP in place (i.e. open
field). These measurements were carried out both in-field (on the beam CAX) and outof-field (OOF) for different field sizes. Ionisation chamber measurements were
normalised to the maximum dose at a depth of 15 mm for 6 MV, 21 mm for 10 MV and
30 mm for 18 MV beam energies. With the MPTM mounted on the linac accessory slot,
PDD up to a depth of 10 cm were measured on the CAX and OOF 11cm laterally to
CAX as a function of the irradiation field size. For the OOF measurements, the solid
water phantom and detector on the linac patient couch were moving laterally from the
central axis position. The phantom size was 60 × 30 × 30 cm3 with the lateral movement
in the direction of the 60 cm phantom length to maintain consistent scattering conditions
(see Figure 5.3 (a and b)).
The depth dose profile and surface dose were measured with Markus type (PTW,
Freiburg, Germany) parallel plate ionisation chamber Model N23343. The chamber was
connected via a tri-axial cable to a PTW UNIDOS model T10002-20713 electrometer
with -300 V bias voltage applied. The Markus chamber is designed for the measurement
of surface and build-up dose. Markus-type chambers are known for their over-response
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due to the large separation and their small guard ring [257, 258] and different methods
have been developed to correct for this over-response [260-262, 273]. In this chapter, all
measurements using the Markus ionisation chamber were corrected using the Velkley
correction as modified by Rawlinson to correct the over-response of the Markus
chamber. The chamber dimension used for the correction calculation was obtained from
Chen et al. [263]. A dose of 200 MU was used for all measurements.
All measurements were performed with MPTM (Source to Detector Distance (SDD) of
58 cm) for the two different set-up conditions mentioned above and without MP (open
field) as shown in Figure 5.2 (a and b). All measurements were repeated at least three
times in order to calculate the average value and standard deviation.
The depth dose as a function of field size in the solid water phantom were carried out
using the Markus chamber mentioned above with some data compared with that using
an Attix chamber, RMI model 449 for the same measurements.

5.2.2

The influence of the MPTM on the beam quality using Delta4® system

In the second part of this chapter, the influence of both the bare MPTM and the MPTM
with 1 mm build up on the open field 3D dose distribution (measured change as a
percentage) was measured by the Delta4® QA system.
Several IMRT test plans (the 3×3 cm2, 5×5 cm2, 10×10 cm2, the beam segments and
modulated IMRT beam for a patient lung tumour with seven segments) were verified
using a Delta4® phantom both with and without the MP located in the beam. A daily
calibration factor was determined using a standard 20×20 cm2 field.
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5.2.3

The transmission factor measurements

In the third part of this chapter, the transmission factor of the MP was investigated. The
transmission factor was derived from any dose change measured at dmax and at a depth
of 10 cm for radiation field sizes 10 × 10 cm2 and 5 × 5 cm2 and an SSD of 100 cm for 6
MV, 10 MV and 18 MV photon fields. A Farmer ionisation chamber (Model 2571A)
was used for 6 MV, 10 MV and an Attix chamber, Model 449 was used for the 18 MV.
A Delta4® system was also used to measure the transmission characteristics for 6 MV
photon beam using different treatment configurations for both MP versions in
comparison with the open field configuration.

(a)

(b)

Figure 5.1: MP with two possible setup conditions: (a) the bare MP array
(sandwiched between black 80µm thick plastic sheets) and (b) the bare MP
array (covered by 1 mm solid water through entire MP).
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(a)

(b)

Figure 5.2: MPTM, mounted in the accessory tray slot just below the linac jaw of the
medical linear accelerator with a prototype version of the MP readout system on the
head of a Varian linac. MPTM with two possible setup conditions: (a) the bare MP
array (sandwiched between black 80µm thick plastic sheets only and (b) the bare MP
array (covered by an additional 1 mm of solid water MP).

(a)
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(b)
Figure 5.3: The out-of-field (OOF) measurements for (a) MP mounted in transmission
mode and (b) no MP in place (i.e. open field). The solid water phantom and ionisation
chamber detector on the linac patient couch were moved laterally from the central axis
(CAX) position. The phantom size was 60 × 30 × 30 cm3 with the lateral movement in
the direction of the 60 cm phantom length.

5.3

Results

5.3.1

Surface dose and percentage depth dose measurements

99

(a)

(b)

(c)

(d)

Figure 5.4: Depth dose measurements at 6 MV. Depth dose and dose difference
distributions in a solid water phantom for a 6 MV linac field, SSD 100 cm, with and
without MPTM for different field sizes on the CAX (a) 10 ×10 cm2, (c) 5 ×5 cm2;
and OOF (b) field sizes 10 ×10 cm2, (d)5 ×5 cm2.The solid circles indicate that the
response of ionisation chamber when MP was operated in transmission mode and the
open circles indicate the response of the ionisation chamber without MP in
transmission mode.
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Figure 5.4 shows the depth dose profile of a 6 MV photon beam on the CAX and OOF
for a 10 × 10 cm2 and 5 × 5 cm2 field size, respectively, with the bare MPTM (setup (i))
mounted in the linac accessory.
Error bars (where visible) represent three standard deviations from the mean. The
square symbols in each graph show the measured change (plotted separately) in the
depth dose curve (DDC) caused by the MPTM in the beam.
Figure 5.4(a, c) demonstrate that the perturbation effect of the radiation beam by MPTM
is negligible. The change in the surface dose with the MPTM placed in the beam was a
reduction of 0.0751 cGy (0.2270 %) for 10×10 cm2 and an increase of 0.1553 cGy
(0.6125 %) for 5×5 cm2 field sizes. For all depths investigated, the maximum measured
change in the absolute dose was a reduction of less than 0.2839 cGy (0.1647 %) for
10×10 cm2 and 0.2769 cGy (0.2363 %) for 5×5 cm2 field sizes. The majority of the
change occurs within 5 mm of the surface. The measured changes in the CAX dose at
any depths with MPTM in a beam were less than 1% of the equivalent open field value.
The similar experiments on the 6 MV beam using the MPTM with additional 1 mm
build-up showed an increase of the surface dose 0.9776 cGy (2.9554 %) for 10×10 cm2
and 0.1001 cGy (0.3910 %) for 5×5 cm2 field sizes.
In the case of the OOF, the effect of the MPTM on radiation field perturbation is greater
in terms of percentage change than for the equivalent CAX measurements. In addition,
the majority of the change occurs within 10 mm below the phantom surface. With
MPTM placed in the beam, the surface dose increased by 0.1076 cGy (1.4997 %) for
the 10×10 cm2 and 0. 1051 cGy ( 6.2561 %) 5×5 cm2 field sizes as shown in Figure 5.4(
b, d). The equivalent using the MPTM with an additional 1 mm solid water build-up
showed 0.8031 cGy (10.8580 %) for 10×10 cm2 and 0. 2914 cGy (16.9675 %) for 5×5
cm2 field sizes.
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(a)

(b)

(c)

(d)

Figure 5.5: Depth dose measurements at 10 MV. Depth dose and dose difference
distributions in a solid water phantom for 10 MV linac field , SSD 100 cm, with and
without MPTM for different field sizes on the CAX (a) 10 ×10 cm2,(c) 5 ×5 cm2; and
OOF(b) field sizes 10 ×10 cm2,(d) 5 ×5 cm2. The solid circles indicate that the response of
ionisation chamber when MP was operated in transmission mode and the open circles
indicate the response of the ionisation chamber without MP in transmission mode.
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Figure 5.5 shows the depth dose profile of the 10 MV photon beam on the CAX and
OOF for 10×10 cm2 and 5×5 cm2 field sizes with the bare MPTM (setup (i)) mounted in
the linac accessory.
Similar to the 6 MV X-ray beam, the perturbation effect of the bare MPTM is small.
The change in the surface dose by the introduction of the MPTM was a reduction of
0.3576 cGy (1.5604 %) for 10 cm x10 cm and 0. 1097 cGy (0.7140 %) for 5 × 5 cm2
field sizes.
From Figure 5.5 (a , c) one can see that for all depths investigated, the maximum
measured change in absolute dose was less than - 0.9138 cGy (- 0.5778 %) and - 0.3045
cGy (- 0.2322 %) for the 10×10 cm2 and 5×5 cm2 field size, respectively. The greatest
dose change occurs within 7 mm of the surface. The perturbation effect of MPTM on
the depth dose change in the CAX is less than 1% for all measured depths. A similar
experiment with 1mm solid water build-up placed above the MPTM showed an increase
of the surface dose by + 0.3280 cGy (+ 1.4345 %) and + 0.0552 cGy (+ 0.3576 %) for
10×10 cm2 and 5×5 cm2 field size, respectively.
In OOF, the perturbation effect of the MPTM on depth dose distribution is slightly
higher than for the same dose in a CAX. Most dose change is within 10 mm from the
surface. The surface dose with MPTM in the beam decreased slightly - 0.0938 cGy (1.2412 %) for 10×10 cm2 and increased +0.0702 cGy (+ 3.7167 %) for the 5×5 cm2
field sizes. The equivalent experiments using the MPTM with an additional 1 mm buildup showed an increase of the surface dose +0.5858 cGy (+7.5330 %) and +0. 3749 cGy
(+20.2024 %) for 10×10 cm2 and 5×5 cm2 field size, respectively.
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(a)

(b)

(c)

(d)

Figure 5.6: Depth dose measurements at 18 MV. Depth dose and dose difference
distributions in a solid water phantom for 18 MV linac field, SSD 100 cm, with and without
MPTM for different field sizes in CAX (a) 10 ×10 cm2,(c) 5 ×5 cm2 ; and OOF(b) field sizes
10 ×10 cm2,(d)5 ×5 cm2. The solid circles indicate that the response of ionisation chamber
when MP was operated in transmission mode and the open circles indicate the response of
the ionisation chamber without MP in transmission mode.
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Figure 5.6 shows the depth dose profile of an 18 MV photoneutron beam on the CAX
and OOF for 10×10 cm2 and 5×5 cm2 field sizes with the bare MPTM (setup (i))
mounted in the linac accessory.
As for 6 MV and 10 MV X-ray beams, the perturbation effect of the bare MPTM is
small. The change in the surface dose by the MPTM was - 1.8991 cGy (- 6.3814 %) for
10 ×10 cm2 and - 0.8535 cGy (- 6.2781 %) for 5 ×5 cm2 field sizes.
From Figure 5.6 (a, c) one can see that for all depths investigated, the maximum
measured change in absolute dose was less than + 0.4773 cGy (+ 0.3013 %) and +
0.3947 cGy (+ 0.2025 %) for the 10×10 cm2 and 5×5 cm2 field sizes, respectively. The
most dose change occurs within 10 mm from the surface. The perturbation effect of
MPTM on depth dose change in the CAX is less than 1% for all measured depths. A
similar experiment with 1mm solid water build-up placed above the MPTM showed an
increase of surface dose of -2.4356 cGy (-8.1842 %) and -1.0862 cGy (- 7.9895 %) for
10×10 cm2 and 5×5 cm2 field size, respectively.
In OOF, the perturbation effect of the MPTM on depth dose distribution is slightly
higher than in a field. Most dose change is within 10 mm of the surface. The surface
dose with MPTM in the beam slightly decreased by 0.3169 cGy (-3.4432 %) for 10 ×10
cm2 and decreased by 0. 04476 cGy (-1.9931 %) for the 5×5 cm2 field sizes. The
equivalent experiments using the MPTM with additional 1 mm build-up showed a
decrease in the surface dose of 0.1804 cGy (-1.9631 %) and an increase of 0. 08228
cGy (+3.6623 %) for 10×10 cm2 and 5×5 cm2 field size, respectively.

105

Table 5.1: Summary of the Percentage Depth Dose (PDD) measurements with different
energies. The change in dose at the surface measured at the central axis (CAX) and out
of field (OOF) with open fields and an MP field in position. Values measured using an
original Markus chamber and compared with an Attix ionisation chamber for 6 MV, 10
MV and 18 MV beam energy at the surface of the phantom. The values are in
percentage relative to the maximum dose (dmax= 15 mm, 21 mm and 30 mm). The
source-to-surface distance (SSD) was 100 cm and 2 Gy was delivered to dmax in each
case.
Energy
(MV)

6

10

18

Original Markus ionisation chamber
CAX- (%)
OOF- (%)
MP
MP
MP fieldMP
fieldfield- no with
field- no with
build
1mm
build up
1mm
up
build up
build up

Attix ionisation chamber
CAX- (%)
OOF- (%)
MP
field-no
build
up

MP fieldwith
1mm
build up

MP
field- no
build up

MP
fieldwith
1mm
build up

10×10

- 0.0375

0.4888

0.0538

0.4015

0.0767

0.4610

0.0485

0.3563

5×5

0.0776

0.0500

0.0525

0.1457

0.0157

0.1505

0.0312

0.1473

10×10

-0.1780

0.1640

-0.0469

0.2929

-0.2559

0.1444

-0.0483

0.2428

5×5

-0.0548

0.0276

0.0351

0.1874

-0.0720

0.0527

0.0221

0.1195

10×10

….

….

….

….

-0.9495

-1.2178

-0.1584

-0.0902

5×5

….

….

….

….

-0.4267

-0.5431

-0.0223

0.0411

Field
Size
(cm2)

Table 5.1 summarises the findings of the beam perturbation by MPTM at dmax for all the
above- presented radiation fields.

Table 5.2: Summary of the response (sensitivity) (two standard deviation) of the MP in
transmission mode (MPTM). The absolute response (in nano-Coulombs per 100 MU) of
the central detector (CAX) of the MPTM located on the central axis of the 6 MV, 10
MV and 18 MV radiation fields, as a function of field size.
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MPTM central diode response (nC)

Energy (MV)

Field Size (cm2)
10×10

6
5×5

10×10
10
5×5

10×10
18
5×5

MP field- no build up

MP field- with 1mm build up

68.0281

72.4019

(±0.0257)

(±0.1270)

57.0172

65.3595

(±0.2208)

(±0.0253)

55.0714

73.5076

(±0.0779)

(±0.0372)

39.1567

59.1128

(±0.0053)

(±0.0056)

53.8847

61.9483

(±0.2306)

(±0.1526)

34.7484

46.4496

(±0.0304)

(±0.0776)

The quantitative absolute response (in nC per 100 MU) of the bare MPTM and the
MPTM array with the additional 1 mm of solid water were measured for a 10×10 cm2
and 5×5 cm2 field sizes and beam energies of 6 MV, 10 MV and 18 MV. The data are
presented in

Table 5.2. As expected 1mm build up is increasing response of the diodes however
signal is enough in both cases to reliably measure signal with accuracy better than 0.1%
with the monolithic diode array Magic Plate 512 channel electrometer [274] .
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bare MPTM (Wings)

bare MPTM (Main board)

MP with 1mm build up
(Wings)

MP with 1mm build up
(Main board)

(A) Field size 3×3 cm2

bare MPTM (Wings)

bare MPTM (Main board)

MP with 1mm build up
(Wings)

MP with 1mm build up
(Main board)

(B) Field size 5×5 cm2

bare MPTM (Wings)

bare MPTM (Main board)

MP with 1mm build up
(Wings)

MP with 1mm build up
(Main board)

(C) Field size 10×10 cm2

bare MPTM (Wings)

bare MPTM (Main board)

MP with 1mm build up
(Wings)

(D) Beam segments using the Varian linac test
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MP with 1mm build up
(Main board)

bare MPTM (Wings)

bare MPTM (Main board)

MP with 1mm build up
(Wings)

MP with 1mm build up
(Main board)

(E) Modulated IMRT beam for lung tumour
Figure 5.7: Impact on the measured dose (in percentage difference) by Delta4® phantom for a
variety of treatment field configurations. All data shown is with MP in transmission mode (bare
MPTM or MPTM with 1 mm build up) comparison with no MP in place (i.e. open field).

5.3.2

The influence of the MPTM on the beam quality using Delta4®system

Figure 5.7 shows the effect of having the MPTM system in place on the measured 2D
dose mapping by the Delta4® phantom diode array for a range of treatment field
configurations. All data presented here is with the MP in transmission mode (the bare
MPTM or MPTM with 1 mm build up) with the data compared to the open field
configuration with no MPTM in place. The measured changes in percent difference
across the entire Delta4® detectors have been displayed in (Figure 5.7). In the case of the
bare MPTM the measured change in-field in percent difference averaged over all
Delta4® detectors (two standard deviation) were ±3.24%, ±2.77%, ±1.97%, ±2.75% and
±2.72% for the 3×3 cm2, 5×5 cm2, 10×10 cm2, the beam segments and modulated IMRT
field configurations, respectively for 6 MV photon beam. A similar experiment with
1mm solid water build-up placed above the MPTM showed that the in-field measured
change in percent difference (two standard deviation) were ±3.47%, ±0.62%, ±2.05%,
±3.39% and ±3.10% for the 3×3 cm2, 5×5 cm2,10×10 cm2, the beam segments and
modulated IMRT beam configurations, respectively for 6 MV photon beam.
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Gamma analysis was performed using 3% and 3mm criteria. By comparing the planned
dose to the delivered dose a plan will fail the criteria if <90% of all data points have a
gamma index ≤1. Gamma analysis criteria (±3% dose deviation, ≤3 mm distance to
agreement and ≤ 1 gamma index) for both MPTM setups (i and ii) and open field for all
configurations of delivered radiation fields was carried out based on comparison of 3D
doses reconstructed by the Delta4® system in comparison with 3D dose predicted by the
TPS. The gamma index gave 100% (90%) pass criteria for all treatment configurations.
Hence, showing this gamma threshold was not sensitive to the inclusion of the bare
MPTM or MPTM with 1 mm build up.

Table 5.3: Gamma analysis output of the Delta4® system for a variety of field size
configurations. All data shown is with MP in transmission mode (bare MPTM or
MPTM with 1 mm build up) comparison with no MP in place (i.e. open field). Gamma
analysis criteria used was ((80%) with ±3% dose deviation, (90%) with ≤3 mm distance
to agreement and (90%) with index ≤ 1 gamma index).
Field Size
(cm2)

Beam statistics

Dose deviation

Open field

MPTM fieldno build up

MPTM fieldwith 1mm build up

83.7 % (80 %)

83.5 % (80 %)

88 % (80 %)

100 % (90 %)

100 % (90 %)

3 ×3
Distance to
agreement
Gamma index
Dose deviation

5 ×5

Distance to
agreement
Gamma index
Dose deviation

10×10

Distance to
agreement
Gamma index

100 % (90 %)
100 % (90 %)

100 % (90 %)

100 % (90 %)

89.5 % (80%)

91.1 % (80 %)

93.4 % (80 %)

100 % (90 %)

100 % (90 %)

100 % (90 %)

100 % (90 %)

100 % (90 %)

100 % (90 %)

97.8 % (80 %)

97.8 % (80 %)

97.6 % (80 %)

100 % (90 %)

100 % (90 %)

100 % (90 %)

100 % (90 %)

100 % (90 %)

100 % (90 %)
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Table 5.3 shows gamma analysis criteria (±3% dose deviation, ≤3 mm distance to
agreement and ≤ 1 gamma index) for both MPTM setups (i and ii) and open field which
was measured by the Delta4® system compared with the TPS. The data indicated that
both versions passed the standard clinical gamma analysis. The numbers outside of the
brackets are the percentage of data points which fall within the criteria specified for
each histogram (i.e. points with a dose deviation of less than 3%, points with a DTA of
less than 3 mm and points with a gamma index of less than 1). The number inside the
brackets is the tolerance that has been specified for that particular beam to "pass". Both
the limits for each metric and the percentages can all be specified within software. By
analysing this way, a measured beam will not fail if the vast majority of points pass, but
a small number does not; this is actually quite helpful for beams which traverse the
couch on an oblique angle.

5.3.3

The transmission factor measurements

The transmission factor related to the dose change at dmax and 10 cm depth in a solid
water phantom for two field sizes (10x10 cm2 and 5x5 cm2) for 6 MV, 10 MV and 18
MV energy beams were measured and are presented in Table 5.4. Transmission factors
at dmax and a depth of 10 cm were all within 1.630 % of open field. This result increases
the rigidity and potential life-time reliability of the MP system. In the case of
transmission detectors, both the IQM system and the DAVID system attenuate a 6 MV
photon beam by 7% while the COMPASS system reported a 3.3 % beam attenuation,
which are both greater than the values measured for the MP system. The recently
introduced ScandiDos Delta4® DiscoverTM system attenuates the beam up by to 1% [7]
whereas a maximum of 11% increase in the surface dose has been reported for the IBA
DolphinTM detector [194].
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The transmission characteristics for 6 MV photon beam using different treatment
configurations for both MPTM versions in comparison with the open field configuration
was measured by Delta4® system at isocentre by finding difference in signals measured
by all corresponding diodes in a field . In the case of the bare MPTM the measured infield transmission factors (two standard deviation) were 0.9902 (±3.24%), 0.9931
(±2.76%), 0.9950 (±1.96%), 0.9968 (±2.74%) and 0.9984 (±2.72%) for the 3×3 cm2,
5×5 cm2, 10×10 cm2, the beam segments and modulated IMRT field configurations,
respectively for 6 MV photon beam.
A similar experiment with 1mm solid water build-up placed above the MPTM showed
that the in-field measured transmission factors (two standard deviation) were 0.9835
(±3.46%), 0.9829 (±0.62%), 0.9850 (±2.04%), 0.9863 (±3.38%) and 0.9873 (±3.1%)
for the 3×3 cm2, 5×5 cm2,10×10 cm2, the beam segments and modulated IMRT beam
configurations, respectively for 6 MV photon beam.
These transmission characteristics measured are similar to those measured by an
ionisation chamber as quoted in Table 5.4.
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Table 5.4: The transmission factor (two standard deviations) at depth of dmax and at
depth of 10 cm for 6 MV, 10 MV and 18 MV energy beams. The Farmer ionisation
chamber was used for 6 MV and 10 MV and the Attix chamber was used for 18 MV.
At depth of maximum dose
Energy
(MV)

At depth of 10 cm

Field
Size
(cm2)

MPTM field- no
build up

MPTM field- with
1mm build up

MPTM field- no
build up

MPTM field- with
1mm build up

10×10

0.9937
(±0.0026)

0.9841
(±0.0021)

0.9944
(±0.0068)

0.9855
(±0.0028)

5 ×5

0.9951
(±0.0028)

0.9853
(±0.0017)

0.9967
(±0.0030)

0.9845
(±0.0019)

10×10

0.9944
(±0.0012)

0.9863
(±0.0022)

0.9949
(±0.0003)

0.9867
( > ± 0.0000)

5 ×5

0.9948
(±0.0010)

0.9865
(±0.0006)

0.9951
(±0.0005)

0.9865
(±0.0006)

10×10

0.9930
(±0.0006)

0.9856
(±0.0007)

0.9959
(±0.0002)

0.9901
(±0.0001)

5 ×5

0.9943
(±0.0004)

0.9902
(±0.0006)

0.9964
(±0.0002)

0.9853
(±0.0004)

6

10

18

5.4

Discussion

Two potential operational set-up conditions of the MPTM were considered to
investigate the perturbation of the radiation field, the first with a Magic Plate covered by
a thin 80 m layer of light protection plastic and the second with an additional 1mm
solid water build-up on top of the MPTM. The 1mm solid water build-up was
introduced to reduce the sensitivity of the MPTM response to contamination electrons
from the source and scattered from the jaws, thus making correlation with the energy
fluence less challenging.
Results suggest that for the majority of the radiation fields studied, the electrons
produced from the interaction of the 6 MV and the 10 MV photons with the jaws are
scattered. Most of these electrons are peaked forward and located close to the jaw
surfaces, minimising any contribution to the centre of the 10 × 10 cm2 field at the
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phantom surface. This is supported by the increase in the relative surface dose when
adding a 1mm solid water slab above the MP which acts as a build-up for photons and
an attenuator of scattered low energy electrons. However, in the case of a 5×5 cm2 field,
the role of electrons scattered from the jaw to the centre of the field is significant. This
is supported by a small change in the relative surface dose caused by the addition of the
1mm slab above the MP. This effect is a combination of the attenuation of the low
energy electrons scattered from the jaws and the generation of electrons from direct
photon interactions within the 1mm solid water build-up.
It was demonstrated that the OOF surface dose enhancement produced by a 1mm buildup was greater than when the bare MPTM was used. This result is consistent with the
CAX measurements and supports the radiation field perturbation interpretations on the
CAX. The CAX and OOF dose with depth with the bare MPTM (Figure 5.4 to Figure
5.6 ) in place shows that the MPTM has negligible effect otherwise for all investigated
fields and photon energies. The depth dose distribution perturbation is less than 1% at
any depth less than 10 cm in a solid water. Perturbation factors at dmax and at a depth of
10 cm were found to be less than 1.63 % of the open field for all energies tested. The
MPTM therefore produces very minimal distortion of the field and skin dose, both in
field and OOF. Monte Carlo simulations are required for a detailed explanation of the
observed dose reduction and enhancement due to the MPTM, which will form part of
future work.

5.5

Conclusion

The impact of the black plastic sheet and the 1mm of solid water on the changes in the
skin dose and full PDD have been investigated. The results showed that in general, both
versions of the MPTM detector array could potentially be used as a 2D transmission
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detector. However, if the surface dose considered as an important factor to be
considered for the cancer treatment, then the bare MPTM proved to be the best
candidate as the increase to the surface dose was the least of the two systems tested.
It has been demonstrated that at 6 MV, 10 MV and 18 MV the MPTM in the beam
minimally perturbs the radiation field both in a field and out of field, leading to a < 0.5
% increase in dose at the surface relative to dose at dmax and <1% in depth of the
phantom. This change is minimal and within any dosimetry budgeted error, while
potentially allowing for real-time verification of VMAT and IMRT during patient
treatment. Further chapters will be directed to the conversion of the response of MPTM
directly to the absorbed dose in a patient without using the beam model.
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CHAPTER 6
Characterisation of the Magic Plate in
Transmission Mode (MPTM)
This chapter describes the characterisation of the radiation response of a silicon diode
array called the MP when operated in transmission mode (MPTM). This mode of MP
operation is designed to be used to verify the dose from IMRT and VMAT treatment
delivery, in real-time and during patient treatment delivery by measuring the equivalent
of the 2D energy fluence map of the modulated radiation beam.

6.1

Introduction

Energy fluence measurements can be made and logged using the ionisation chamber
upstream of the MLC. This combined with comparison of the measured and planned
MLC leaf positions provides some level of in vivo QA [182]. However, there is no
direct measurement of the 2D spatial distribution of the energy fluence downstream of
the MLC yet upstream of the patient.
There are other transmission detectors that have been presented in the literature; the
IBA COMPASS detector [275], the Integral Quality Monitoring system (IQM) [188],
the DAVID system [8, 276] and more recently the IBA dolphin online treatment
monitoring. All these detectors are ionisation chamber based except the IBA dolphin
(which is based on diodes) and some of them significantly attenuate the beam, increase
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the surface dose and some can only provide online treatment evaluation after each
fraction; not in real-time [194].
The MP system is designed so as to be able to make measurements representative of the
energy fluence from which the dose can be reconstructed and compared with the
planned patient treatment dose. If this can be done in real-time, the feedback would lead
to a very high level of QA in cancer treatment delivery.
This chapter describes the performance characteristics of a 2D silicon detector array
system that have been developed, when operated in transmission mode to monitor the
fluence during patient treatment for real-time QA of megavoltage photon radiotherapy
on a medical linear accelerator using three different energies 6 MV, 10 MV and 18 MV.
Characterisation of this detector in transmission mode is essential and must be carried
out prior to clinical use.

6.2

Materials and methods

The MP was utilised as a transmission detector by mounting it on the linear accelerator
head (in the accessory slot) normal to the radiation beam as shown in Figure 3.3.
In this chapter, the MPTM was sandwiched between black plastic sheets (80 m), to
minimise light leaking on the detector. The MP detector array is located on the linac
accessory slot, and is 58 cm from the linac X-ray source. The source to detector distance
(SDD) of 58 cm indicates the position of MP when used as a transmission detector,
attached to the linac’s accessory slot. Prior to any measurements by the MPTM detector
array, a flat field correction was performed.
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6.2.1

Linearity measurement

Measurements were performed in free air geometry at 58 cm SDD. A single diode
located at the central axis was used to evaluate the response linearity of the MP for
10×10 cm2 field size. The setup was irradiated with 6 MV photon beam from 1 to 800
MUs delivered with 75 MU/min, 150 MU/min, 300 MU/min, 600 MU/min repetition
rates.

6.2.2

MPTM Detector Reproducibility

The reproducibility of the MPTM signals was investigated. The setup was field size
20×20 cm2 and irradiated with 6 MV, 10 MV and 18 MV beam energies. The detector
was irradiated six times with a constant number of MUs, in our case both 100 MU/min
and 600 MU/min dose rates. The average response for each detector element across the
entire 2D array was calculated and the percentage standard deviation obtained. The final
result is then displayed as a response distribution.

6.2.3

Effect of scattered electrons on the MPTM response

To investigate the effect of the MLCs on the MPTM response a systematic study of
square fields defined by the linac jaws with either the MLC fully retracted or matching
the jaws has been studied. This investigation was carried out for field sizes ranging from
1×1 cm2 to 40×40 cm2. The transmission mode measurements were performed in free
air geometry with the MP positioned at 58 cm SDD. The MPTM was sandwiched
between black plastic sheets, 80 µm thick or with a thin passive contamination electron
filter (1 mm solid water). The SDD of 58 cm indicates that the position of the MP when
operated in transmission is such that it is mounted in the accessory slot of the Varian
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linac utilised. For this study only the response of the diode located on the central axis of
the linac beam was used.

6.2.4

The response of the array with different frequency pulses

For this setup, the MP was placed in transmission mode and the dose rate range used
(100-600) MUs/min; 100 MUs were delivered. The field size was 10 ×10 cm2 at 100
cm SSD and MLC was matching the linac jaws. The setup was irradiated with 6 MV, 10
MV and 18 MV beam energies. The total time required to deliver 100 MUs was
recorded by the CMRP MP readout system.

6.2.5

Energy response measurement

To study the energy response of the MPTM, the 2D array was irradiated with energies
of 6 MV, 10 MV and 18 MV and 100 MUs were delivered each time. Measurements
were performed in transmission mode. All diodes across the array were used to evaluate
the energy response of the MP for 40×40 cm2 field size.

6.2.6

MP in transmission mode versus full scatter conditions

The effect of back scattering from the patient and/or a phantom on the MPTM response
was carried out. A systematic study of small and large square field sizes of 2×2 cm2 and
10×10 cm2 were analysed. The response from a single row of MPTM detectors passing
through the central axis of the 6 MV radiation field with and without a phantom which
centered at the isocentre in place was investigated. The phantom was used to mimic the
patient and back scattering effect. 100 MUs were delivered under each operation
condition studied.
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6.3

Result

6.3.1

Equalisation

Figure 6.1 (a, b and c) shows the flat field correction statistics of MP121 response
before and after the equalisation was applied (see section 3.4). The differential response
is calculated according to Equation (3.1).

(a)

(b)

(c)

(d)

(e)

(f)

Figure 6.1 : (a, b, c) The MP response before and after the equalisation applied for
different energies (6 MV, 10 MV and 18 MV), (d, e, f) the differential response of
MP121 after equalisation. MP was placed at depth of 10 cm on the solid water
phantom, 100 SSD and 20×20 cm2 field sizes.
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The variation in the response of all 121 detectors relative to the average response was ±
2.708 % (1 SD) and ± 0.151 % (1 SD), ± 2.710 % (1 SD) and ± 0.145 % (1 SD), ±
2.693 % (1 SD) and ± 0.1009 % (1 SD) before and after flat field correction for 6 MV,
10 MV and 18MV beam energies respectively. Figure 6.1 (d, e and f) shows also the
differential response of the 2D MP121 after equalisation which was less than ± 0.6% for
all beam energies mentioned above.

6.3.2

Linearity measurement

(a)

(b)

(c)

(d)

Figure 6.2 : MPTM response linearity with different dose rate of the central pixel,
for 6 MV photon beam and 10×10 cm2 field size.
121

The response of the MPTM array was found to be linear with clinically useful range of
1 MU to 800 MU for 6 MV photon beam with different dose rate repetitions range from
75 MU/Min to 600 MU/Min. The adjusted regression coefficient R2 found to be 1 and
error bars are calculated by two standard deviations over three repetitions as shown in
Figure 6.2.

6.3.3

Reproducibility

(a)
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(b)

(c)
Figure 6.3: The distribution of the percentage variation (the reproducibility) of all
121 detectors across the 2D array signals when operated in transmission mode. Field
size was 20×20 cm2 and irradiated with 6 MV, 10 MV and 18 MV beam energies.
The detector was irradiated six times with a constant number of MUs.
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All the 121 pixels, in transmission mode, present a reproducibility better than 1.27%
(2SD), 1.18 (2 SD) % and 0.40 (2SD) % for 6 MV, 10 MV and 18 MV beams
respectively as shown in Figure 6.3.

6.3.4

Effect of scattered electrons on the MPTM response

Part of this chapter focuses on how having the MLCs fully retracted or matching the
shape of the linac jaws impacts on the MPTM response with photon field size. Such
information is important in the context of the intended use of the MP array when used in
transmission mode, which is to be able to reconstruct the dose in the phantom.

(a)
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(b)
Figure 6.4 Normalised response of bare MPTM defined by the jaws only or jaws
and MLCs for 6 MV, 10 MV and 18 MV beam energies: (a) MPTM with no build
up and (b) MPTM with 1mm solid water. Lower panels: percentage change of the
central detector response with field size when the MLCs are retracted compared to
when the MLCs match the jaws.

The 6 MV, 10 MV, and 18 MV radiation fields that were used here are made up of
photons, electrons, positrons and photo-created neutrons (in the 18 MV case). All data
has been normalised to the response of the MP detector in a 10×10 cm2 field size. The
central detector response of the MPTM in the both cases (where the MLCs fully
retracted and MLCs match the jaws) is seen to increase logarithmically with increasing
field size. Significant differences (> 10%) are observed for both measurement scenarios
for field sizes less than 2×2 cm2, with the MPTM response with the MLCs retracted
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being higher than when the MLCs match the jaws in all cases. The position of the
MLCs (being between the jaws and the MPTM) is the reason for the change in response
of the MP detector that is observed. The consistent decrease in MPTM response when
the MLCs are matching the jaws indicates that the MLCs effectively act to reduce the
amount of scattered radiation (electrons, photons and where relevant, neutrons) that
reaches the central detector of the MP. It is envisaged that utilisation of the MLCs (as
such is the case in IMRT and VMAT where numerous small fields are incorporated in
the treatment plan) will have a positive impact on the ability of the MPTM to correctly
reconstruct the dose and discussed more in (section 6.3.4) below.

6.3.5

The response of the array with different frequency pulses

Figure 6.5 : The response of MP in transmission mode with changing dose
rate for 6 MV, 10 MV and 18 MV photon beam , field size 10×10 cm2 at
100 cm SSD.
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The MP diode array detector was placed in transmission mode at 58 cm SSD in a 10×10
cm2 beam and irradiated with 100 MU. Figure 6.5 shows the pulse repetition frequency
and continuous dose rate of MP array when operated in transmission mode. This show
the detectors and the readout system are not subject to the saturation effects over this
dose rate range.
The percentage standard deviation across the array of frequency pulses range from 100
MU/min to 600 MU/min was 2.384%, 1.711% and 3.325% for 6 MV, 10 MV and 18
MV respectively.

6.3.6

Energy response measurement

(a)
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(b)

(c)
Figure 6.6: (a, b, c) The distribution of the MPTM response of all 121 detectors
across the array in different photon energies modes (6MV, 10MV and 18MV). Field
size was 40×40 cm2 at 100 cm SSD.
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Figure 6.6 presents the MPTM response with increasing beam energy (6 MV, 10 MV
and 18 MV beams). The histogram data presented includes the response data for all 121
diodes in the MP array. The field size was 40×40 cm2 at SSD 100 cm, with 100 MU
delivered at each energy. The sensitivity of the MPTM increases by ~20% when the
beam energy is increased from 6 MV to 10 MV, however remains almost constant
(decrease of ~5%) when further increased to 18 MV.

6.3.7

MP in transmission mode versus full scatter conditions

The response from a single row of MPTM detectors passing through the central axis of
the radiation field with and without the phantom in place for a field size of 2×2 cm2 and
10×10 cm2 was carried out.
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Figure 6.7: Influence of back scatter on the MPTM response in 2×2 cm2 and in
10×10 cm2 field sizes. MP was operated in transmission mode.

The phantom was used to mimic a patient and the difference between the two
measurements (with and without the phantom) in the case of the two field sizes studied
is shown in Figure 6.7. The variation of the response of the MP detector array elements
within the radiation field is less than 0.5%. For MP detector array elements outside the
radiation field varied by less than 3.5%, which is indicative of the small contribution
that backscattered photons from the phantom, make to the measured response for a 2×2
cm2 field size.
The MPTM is not design to measure water equivalent tissue dose but rather the MPTM
response should be proportional to energy fluence. While it is intuitive that transmitted
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energy fluence should be much higher than that scattered from the phantom (mimicking
a patient) in the field, it was not obvious that this effect will be negligible for the
MPTM detector array elements in out of the radiation field. The presented results
quantify and clarify this point by demonstrating that placement of the phantom (patient)
does not significantly influence the response of the MPTM.

Figure 6.8: The frequency as a function of variation across the array in 2×2 cm2 and
in 10×10 cm2 field sizes.

Figure 6.8 shows also the frequency distribution of the percentage variation across the
array for the same field sizes when the phantom in place and without. The response of
MP was not significantly affected by scattered radiation from the phantom for both
radiation fields as expected.
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6.4

Discussion and conclusion

The radiation response and basic characterisation of the MPTM for QA during patient
treatment delivery was carried out. Variation of the response between the diodes in a
flat field was ± 0.151 %, ± 0.145 % and ± 0.1009 % after the equalisation technique for
6 MV, 10 MV and 18 MV energy beam respectively. The dose and dose rate linearity of
the MP in transmission mode was excellent. The effect of scattered electrons and
photons from the jaws (and MLCs to a minor extent) which contribute to the central MP
detector response is different in case of the bare MPTM compared to the case with 1mm
build up. The 1 mm build-up acts as a passive filter to reduce the scattered low energy
electron contribution to the MPTM response. The MLCs, when placed so as to match
the jaws, reduced scatter response contribution from jaws to the central detector for all
photon energies. The highest efficiency will be expected for the 6 MV photon beam as
the average energy of scattered electrons is lowest. The effect is more pronounced for
small fields of 2×2cm2 or less. The effect of the scattered electron contribution to the
response of the MPTM vs field size should be taking into account when MPTM is used
for photon energy fluence map measurements.
The percentage variation of the response of in-field MPTM detector array elements for a
field size of 2×2 cm2 and 10×10 cm2 with and without the phantom in place was less
than 0.5%. For array elements outside the radiation field the variation was less than
3.5%. These results indicate that the backscattered photons from the phantom, make a
very small contribution to the measured response of the MPTM with field size,
(particularly in-field). A significant contribution (>10%) would have to be taken into
consideration in the dose reconstruction procedure.
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It was therefore concluded that this contribution could be ignored in the dose
reconstruction process. Small contribution that backscattered photons from the
phantom, make to the measured response as a function of field size.
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CHAPTER 7
2D Mapping of the 6 MV Photon Fluence and
3D Dose Reconstruction during Radiotherapy
Treatment
This chapter discusses the development of an algorithm that predicts (reconstructs) the
dose in a homogenous phantom based on the measured 2D fluence map during patient
delivery and independently of the linac settings. This can be checked against the
intended plan dose and if they disagree the treatment can be stopped automatically and
immediately.

7.1

Introduction

During radiotherapy treatment, reconstruction of the 2D and 3D dose maps for
comparison with the treatment plan (TP) is significantly challenging. Commercially,
radiosensitive film technology can be used for such 2D dose mapping, however no
comparison with the TP can be made in real time [68]. Electronic portal imaging
devices, have recently been used for such 2D dose map reconstruction [151, 162, 277,
278]. The reconstruction procedure however, is not clinically common and is complex
for IMRT. One might expect the reconstruction to be extremely difficult for VMAT
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where the beam attenuation and scatter conditions change continuously as the beam
rotates around the patient.
Some QA systems (e.g. ArcCheck and Delta4®) reconstruct the 3D dose distribution
based on sensors inside a phantom placed on the patient couch. However, they require
the dose distribution calculated by the TPS in the phantom as an input parameter in their
software for comparison, which detracts from their independence as a QA device [183,
184]. Independent tools that provide the 3D dose distribution are the OCTAVIUS® 4D
(in a phantom only) and COMPASS transmission detector [185, 279]. New
transmission-type detectors incorporating wireless readout (e.g. Delta4® DiscoverTM
[192] and Dolphin [193]) are based on 2D diode or ionisation chamber arrays. These
systems are advanced in vivo QA dosimetry devices capable of 3D dose reconstruction
and comparison with TPS after each treatment fraction. The clinical impact of these
systems, particularly their effect on the skin dose, perturbation of the radiation field and
accuracy of 3D dose reconstruction, is important. Therefore, real-time, in vivo QA
devices that are able to provide 3D dose reconstruction in a patient, while being both
independent of the TPS and non-perturbing of the treatment beam are still required.
This chapter aims to quantitatively demonstrate reconstruction of the real-time radiation
dose from the irradiation response of the 11×11 silicon MP detector array operated in
transmission mode.

7.2

Materials and methods

Figure 7.1 shows a schematic diagram of the linac with the relevant positions of the MP
detector (MPTM and MPDM). When mounted in the accessory slot of the linac the
MPTM (is 58 cm from the X-ray source) and the field size on a MP is 1.72 times
smaller than that at 100 cm SSD.
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For the MPTM investigation in this chapter two potential operational set-up conditions
were studied , (i) The bare MPTM and (ii) the MPTM with 1mm buildup (see Chapter
5).
Prior to mounting on the linac head the MP for transmission operation flat field
equalisation in a phantom of all MP detector elements and readout channels is
performed (see section 3.4).
Figure 7.1 also illustrates the divergence of the radiation field with distance from the
X-ray source, which obviously must be taken into account when reconstructing the dose
at any given depth in the phantom from the response of the MPTM detector.

7.2.1

Surface dose and buildup measurements

The influence of the MPTM detector on the PDD profile and in particular the surface
dose (both in-field and out-of-field) was first determined. With the MPTM mounted in
the linac accessory slot, percentage depth dose curves were therefore measured both on
the CAX and 11 cm OOF as a function of the irradiation field size to a depth of 100
mm. The CAX and OOF measurements were performed as described in chapter 5.2.1.

7.2.2

MPTM response as a function of field size

In the second part of this chapter the MPTM response was therefore investigated for
different irradiation field sizes that ranging from 5×5 cm2 to 40×40 cm2. These
measurements were performed with the radiation field defined by the linac jaws only or
both the MLC and linac jaws in order to determine the significance of the known
different electron contamination and photon scattering conditions and the corresponding
effect these conditions may have on the response measured by the MPTM in the
accessory mount [280]. Measurements were performed in transmission mode at 58 cm
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SDD which is the standard MPTM accessory position for the two different set-up
conditions mentioned above.

7.2.3

Dose reconstruction technique using MPTM response

The radiation field incident on the patient is a complex mixture of Bremsstrahlung
photons from the target modified by a flattening filter, scattered electrons from the linac
jaws and MLC and electrons generated in air. All of these components, including their
dependence on the radiation field size are taken into account by the dose simulation
engine component of the linac beam model in the TPS. It is possible to convert the
MPTM response to dose via beam modelling assuming that MPTM does not perturb the
radiation field downstream. Such a method, is used for transmission-type pixelated
ionisation chambers e.g. Dolphin device, and requires complicated algorithms that take
into account the perturbation properties of the transmission detector, which change with
the irradiation field geometry.
Assuming that the MPTM is effectively transparent to the radiation field it is reasonable
to assume that a direct correlation may exist between MPTM response and the patient
dose. Ideally this correlation would be independent of field size. In order to empirically
determine whether a simple conversion factor exists to convert the MPTM detector
response to dose in the phantom, the dependence of the central detector response, Rc, in
the 11×11 MPTM detector matrix (also referred to as the (6,6) detector), on the
irradiation field size was investigated for simple square fields and SSD 100 cm. The
hypothesis here was that there exists a particular depth in the homogeneous solid water
phantom for which the response of the (6,6) detector located at 58 cm SSD is
proportional to the dose and is also independent of field size (i.e. proportionality
coefficient is the same). This depth will be referred to as the “Sweet Depth” (SwD) and
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ideally, is the same for all MPTM detector array elements (i,j) and their projected dose
positions at the SwD. The relationship between the response of the MPTM to the
projected dose at the SwD on a central axis can be defined as DSwD= α Rc, where α is a
constant and ideally DSwD (i,j) = α Ri,j, where Ri,j is the response of detector element (i,j).
It is then possible to find the relation between R i,j and the dose at any depth, r, in the
phantom along the projected ray from the centre of the source through the particular
diode (i,j) using the PDD in water or scaled to the phantom material for a given field
size. In this case dose at depth r given by (7.1):

Di,j(r) = DSwD (i, j)

𝑃𝐷𝐷(𝑟)
𝑃𝐷𝐷 (𝑆𝑤𝐷)

= α Ri, j

𝑃𝐷𝐷(𝑟)
𝑃𝐷𝐷 (𝑆𝑤𝐷)

(7.1)

This approach to 3D dose reconstruction based on point dose information measured by a
diode at particular depth in a cylindrical phantom have been used in Delta4® and
OCTAVIUS® 4D [185] while the experimentally derived dose at SwD point can be
considered as the dose measured by a “virtual diode”. In a megavoltage photon beams,
the average energy decreases with increasing distance from the CAX. Such lateral
energy variation has an influence on the attenuation and scattering properties of photon
beams at a point located a significant distance away from the CAX and it has to be
taken into account. This effect is known as off-axis softening and can be explained by
selective attenuation of photons by the flattening filter. The effect leads to a reduction of
the PDD at off-axis points. In this case, for non-central axis dose, the reconstruction is
based on correction of the “virtual diode” reading using a tissue phantom ratio (TPR)
and correction factor provided in the case of a flattening filter in Tailor et al [281] or
without one in Georg et al [282] as suggested in Allgaier et al [185].
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The validity of this approach to dose reconstruction in a phantom is demonstrated by
reconstructing the 2D dose at dmax and different depths based on the “virtual diode”
response for different field sizes followed by comparison with the 2D dose map
measured on the dmax plane with an ionisation chamber at the same reconstruction
points. The depth dose measurements and related PDD(r) as a function of field size in
the solid water phantom were carried out using a Markus chamber. This information is
not known for a patient and will be part of future studies. Beam profiles and output
factor measurements at a few depths were separately measured using a Wellhöfer
Compact ionisation chamber (Model CC13) for each field size and used for dose
reconstruction comparison at dmax (i,j) in a phantom according to the equation (7.1).

In addition to the 2D dose distributions reconstructed for several square field geometries
and depths, an asymmetric multileaf collimator configuration within a 20×20 cm2 field
size has also been reconstructed. In the asymmetric MLC configuration case, the
reconstructed 2D dose map of the radiation field at dmax was quantitatively compared at
the same reconstructed sampling points with the equivalent dose map exported from the
PinnacleTM dose planning system as well as from directly measured dose profiles at the
same depth using the MP placed in the solid water phantom i.e. (MPDM as indicated in
Figure 7.1).
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Figure 7.1: Schematic diagram of a typical linac with the various in situ operating
positions of the MP detector.

7.3

Results

7.3.1

Surface dose and buildup measurements

The percentage depth dose profiles shown in Figure 7.2 were measured in the solid
water phantom, with and without (open field) the MPTM detector array mounted on the
linac accessory tray. Error bars (where visible) represent three standard deviations from
the mean. At the phantom surface and on the CAX, the change in the dose relative to
dmax measured with the MPTM in place was - 0.040 % and + 0.080 % for 10×10 cm2
and 5×5 cm2 field size respectively. In the case of the OOF measurements change in the
measured surface dose relative to dmax with MPTM in position was + 0.054 % and +
0.052 % for the 10×10 cm2 and 5×5 cm2 field size respectively.
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(a)

(b)

Figure 7.2: Measured percentage dose profile measured (Markus IC) as a function of depth in solid
water phantom with and without bare MPTM in situ together with the difference between the two
for (a) CAX and (b) OOF. Field sizes were 10×10 cm2 and 5×5 cm2. A 6 MV photon beam was used
for measurements in both field sizes.

7.3.2

MPTM response as a function of field size

Figure 7.3(a) shows the absolute response of the central detector of the MPTM (in nanoCoulombs) located on the CAXs of the 6 MV radiation field, as a function of field size.
Only the response of the diode located on the CAX of the linac beam was used for this
chapter since for small field sizes only the central diode is fully exposed to the beam
due to the divergence of the photon beam (illustrated in Figure 7.1).
The MPTM was sandwiched between either two sheets of 80 µm thick black plastic
(triangles) and 1 mm of solid water (dots). The observed decrease in absolute MPTM
response when the MLC matches the linac jaws is due to the MLCs effectively
shielding the MP from contamination electrons created high-up inside the head of the
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linac. No such decrease is observed for the case where the MP detector is encapsulated
by 1 mm of solid water, which indicates that the solid water attenuates the bulk of the
above mentioned contamination electrons. For the case where the MLCs match the linac
jaws, adding the 1 mm solid water leads to a consistent increase in the absolute response
of the MP detector for all field sizes. Such an increase could be significant as it
indicates that the MP response seems not to be dominated by the contamination
electrons that make up the primary radiation field. The increase is analogous to that
when approaching electronic equilibrium (the well-known build-up curve observed with
MV photon fields). One would expect a decrease in the measured response if the
response was dominated by the component related to contamination electrons and this
has been confirmed by detailed radiation transport simulations presented elsewhere
[280].

(a)

(b)
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(c)

(d)

Figure 7.3: (a) Response of MP in transmission mode (MPTM) with different field sizes. MP
was sandwiched between two sheets of 80 µm thick black plastic or 1 mm of solid water. (b)
Normalised response of MP in transmission mode together with a Farmer IC measured field
factor for different irradiation field sizes. (c) Ratio of the measured (Markus chamber) dose at
several depths and MPTM (with no build up) response for different irradiation field sizes. The
data has been normalised to 1 for a 10×10 cm2 field size at each depth. (d) Ratio of the
measured (Markus chamber) dose at several depths and MPTM (with 1 mm build up) response
for different irradiation field sizes. The data has been normalised to 1 for a 10×10 cm2 field
size at each depth. The 6 MV photon beam was used for all measured field sizes.

The data in Figure 7.3 (b) has implications for the final intended application of the MP
when used in transmission mode, which ideally, would be to measure the real-time
energy fluence so as to be able to reconstruct the dose along rays defined by the line
emanating from the photon source through each MP detector during a patient treatment.
In this case, a decrease in the measured response with decreasing field size is to be
expected. Ideally, the in-field response of the MP would scale with the linac output
factor. The observed difference between the MP response and the Farmer chamber
measured output factors (OF) observed in Figure 7.3 (b) is to be expected as the MPTM
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positioned in the accessory mount is in free air geometry. The response of MP is
therefore significantly affected by the make-up of the primary radiation field which
includes a significant proportion of low energy scattered electrons created in the linac
head (jaws etc.) [283, 284] and the influence of the MLCs on the measured response as
mentioned above. As such, a scaling or correction (conversion) factor could be used in
order to reconstruct the dose in vivo from the MP response. This is especially important
for small field sizes as they are more commonly utilised in modern clinical radiotherapy
treatments such as IMRT and VMAT etc. On the other hand, it may be possible to find a
SwD where the MP response better mimics (proportional to) the dose as a function of
field size. This has been investigated for the fields where the MLCs match the linac
jaws for the MP detector array (with and without the build-up layer).

7.3.3

Dose reconstruction technique using MPTM response

Figure 7.3 (c) illustrates the procedure used to determine the Sweet Depth (SwD). The
ratio of dose measured by the Markus ionisation chamber to the MPTM response, R c, is
plotted for 5 × 5 cm2 to 40 × 40 cm2 irradiation field sizes and normalised to the ratio at
10×10 cm2 field size. This normalised ratio is plotted and produced for various
measurement depths (between the surface and 15 mm). The Markus IC data used was
taken with the MLCs matching the jaws and has been corrected for its well-known over
response, and is consistent with previous published data [285].
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Table 7.1: The ratio of the measured (Markus chamber) dose at several depths and
MPTM (with no build up) response for different irradiation field sizes. The data has
been normalised to 1 for a 10×10 cm2 field size at each depth. Ion chamber
measurements were performed at SSD 100 cm and 6 MV photon field.
Depth (mm)
Field size
(cm2)

0 mm

1 mm

2 mm

3 mm

4 mm

5 mm

15 mm

5

0.896

1.058

1.107

1.107

1.113

1.120

1.144

10

1.000

1.000

1.000

1.000

1.000

1.000

1.000

15

1.130

0.999

0.960

0.955

0.946

0.940

0.921

20

1.292

1.026

0.958

0.948

0.933

0.922

0.886

30

1.595

1.099

0.978

0.962

0.936

0.919

0.863

40

1.857

1.168

1.011

0.991

0.959

0.938

0.876

Table 7.1 summaries the ratio of the measured (Markus chamber) dose at several depths
and MPTM (with no build up) response for different irradiation field sizes. The data has
been normalised to the deduced ratio for a 10x10 cm2 field size at each depth.
Measurements were performed at SSD 100 cm and 6 MV photon field. One can
conclude that 1 mm is almost the best candidate sweet depth that shows less dependent
on field size.
From Figure 7.3 (c) it follows that the SwD is 1 mm where the response is almost
independent of field size (<5% for FSs <20 × 20 cm2) with the average conversion
factor for these field sizes being α = 7.3 ± 0.22 x10-3 Gy/nC (one standard deviation).
The 1 mm depth was therefore chosen as the sweet depth so as to best match the main
application for the MPTM which is with IMRT and VMAT treatments that mostly use
small field sizes (see Table 7.1).
The data presented above utilised the response of the central detector (6,6) in the MP
array made up of 11 ×11 detector elements operated in transmission mode. The
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following results focus on extending the above data to make an assessment of all 121
detector elements of the MPTM. For example, to reconstruct the dose at dmax for a
10×10 cm2 and 100 MU delivered, the tissue-phantom-conversion factor (TPCF) for
conversion of the “virtual diode (6,6)” response to dose at dmax (6,6) =

𝑃𝐷𝐷(𝑟)
𝑃𝐷𝐷𝑆𝑤𝐷

which

is 2.361 and then the dose at dmax(6,6) is 2.361 × 7.3x10-3 Rc (Gy), where Rc (nC) is the
MPTM response for the central diode. For different field sizes the TPCF will be
different but is measured and well tabulated for each linac for the solid water phantom
used. For non-central axis projections, corrections were considered but insignificant.
The same conversion factor is then applied to all detector elements (i,j) to reconstruct
the dose from the response of all in-field MP detector elements at the SwD.
In the case of the MP with the 1 mm build-up layer Figure 7.3 (d) indicates that the
SwD is between 1 mm and 2 mm. However, in this case, the field sizes over which the
MP could be used increases to 30×30 cm2. Table 7.2 summaries all the measured dose
at several depths and MPTM (with 1 mm build up) response for different irradiation
field sizes.
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Table 7.2: The ratio of the measured (Markus chamber) dose at several depths and
MPTM (with 1 mm build up) response for different irradiation field sizes. The data has
been normalised to 1 for a 10×10 cm2 field size at each depth. Ion chamber
measurements were performed at SSD 100 cm and 6 MV photon field.
Depth (mm)
Field size
(cm2)

0 mm

1 mm

2 mm

3 mm

4 mm

5 mm

15 mm

5

0.826

0.974

1.020

1.020

1.026

1.032

1.053

10

1.000

1.000

1.000

1.000

1.000

1.000

1.000

15

1.165

1.030

0.990

0.985

0.976

0.970

0.950

20

1.350

1.072

1.000

0.990

0.974

0.964

0.926

30

1.685

1.162

1.034

1.017

0.990

0.972

0.912

40

1.932

1.215

1.051

1.031

0.997

0.976

0.911

All of the data presented above utilises the response of the central detector in the
MPTM array (made up of 11×11 detector elements) operated in transmission mode. The
following results focus on extending the above data to make an assessment of all
detector 121 elements of the MPTM. Such an assessment is clinically very relevant as it
is well-known that the contamination electron distribution, photon flux and photon
energy spectrum is not uniform in the X-Y plane which affects the corresponding dose
delivered [280].
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(a)

(b)

Figure 7.4: (a) 2D response map of the bare MPTM, field size 30×30 cm2 at SSD 100
cm and (b) 2D dose map of MPDM, at 15 mm depth, field size 30×30 cm2 at SSD 100
cm for a 6 MV photon field.

Figure 7.4 (a and b) excellently illustrates the above point, showing the variation of the
MPTM (the bare MP with no build up) response in the X-Y plane and the response of
the MP operating in dose mode at 15 mm depth in a 30×30×20 cm3 solid water
phantom. For both plots a 6 MV photon field was used and the radiation field size
defined at SSD100 cm was 30 × 30 cm2. The fraction of the field cross-section sampled
by the MPDM is obviously a lot smaller (~10%) than that for MPTM (~40%) due to the
divergence of the field with distance from the source. Regardless of this the trend
observed in the MPTM 2D data which shows increase in response as one moves away
from the centre of the field can also be observed in the MPDM plot.

Equalization of MPTM is different to MPDM due to different nature of the response of
the diodes in both modes. The response of the diode in MPTM is proportional to Ѱ

µen/ρ

where Ѱ is photon energy fluence and
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µen/ρ

is a mass energy absorption

coefficient in silicon. In a dosimetry mode the MPDM response is driven by secondary
electrons and is proportional to DwS, where Dw is the dose to water and S is a ratio of
silicon -to-water stopping powers for electrons which is almost constant (within in 5%)
for the electron energies of interest in this thesis work.
Assuming that at depth of 10 cm the dose to water is uniform taking into account
scattering radiation as well, equalization will therefore take into account any intrinsic
difference in the charge collection or sensitive volume size of the diodes, which is
important for the response in a transmission mode as well. However the effect of slight
variation of photon energy of the beam out of the CAX on the response of the MPTM is
not accounted in this equalization that potentially can lead to the error in dose derivation
in a phantom based on the response of the MPTM.
However good agreement in the beam profiles measured by IC and derived from the
MPTM response including the penumbral region at different depths is confirmation of
appropriateness of the current equalization procedure. It is possibly due to the effect of
softer photon fields on the edges of the radiation field which is contributing to

the

response of the diode in the same way as in MPTM making equalization suitable for
both MPMD and MPTN modes. Further confirmation of that should be investigated
further using Monte Carlo simulations and comparison of the response of the MPDM
and MPTM for the same beams including for 1mm buildup for MPTM.
The noise in Figure 7.4 (a) and (b) is similarly, within ± 2%, with a tendency of the
reduced response in a CAX in both cases. Relevant experimental data for MPTM with 1
mm build up has been shown elsewhere (See Figure 6.4, Figure 7.3 and Figure 8.3).
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(a)

(b)

150

(c)

(d)

151

Figure 7.5: Beam dose profiles measured at different depth with CC13 IC in comparison
with reconstructed profiles from the bare MPTM response dose for all diodes in row 6
of the MP array: a) depth dmax, c) depth 5cm, d) depth 10cm. The variation for each
depth shown is for the in-field comparison only. (b) Frequency histogram of the
variation of measured and reconstructed dose at depth of for in-field points for all field
sizes tested. Reconstructed dose points can be compared with those experimentally
measured for field sizes less than about 20×20 cm2 only as determined by the current
size of the MPTM. Error bars are not shown for clarity purposes.

Figure 7.5 (a) shows a comparison of the dose profile of the reconstructed point doses at
dmax(i,j) from the measured Ri,j MPTM data with measured IC (CC13) data for several
square field geometries along the centre of the field at this depth. To make this
comparison a correction of the “virtual diode” response at non central axis at depth 1
mm was taken into account as was mentioned earlier. The observed decrease in the
reconstructed and measured dose at dmax at the centre of the field with decreasing field
size corresponds perfectly to the well-known dose reduction (output field factor) since
for each field size 100 MU was delivered by the linac corresponding to 1 Gy delivered
in the centre of a 10×10 cm2 field at dmax.

Figure 7.5 (b) shows a frequency histogram of the percentage difference between the
reconstructed point doses and the measured point doses for all in-field MPTM detector
elements for all radiation field sizes investigated (over 230 measurement points). For all
field sizes the in-field point doses reconstructed from MPTM response was shown to
correlate extremely well to measured point doses with less than 1.24 % variation (1
standard deviation). To demonstrate the robustness of the reconstruction method the
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MPTM data has been used to reconstruct the dose at several depths in a phantom along
the projected rays from the source through each MPTM detector element.
Based on the same MPTM raw data, in
Figure 7.5 (c) and (d) a comparison of the dose profiles of the reconstructed dose profile
at a depth of 5 cm and 10 cm in the solid water phantom were shown. Measured IC
(CC13) data for several square field geometries along the centre of the field (row 6) at
these depths are shown for comparison. For all field sizes point doses reconstructed
from MPTM response was shown to correlate extremely well to the measured point
doses. Accurate 2D dose mapping in a phantom using MPDM was confirmed earlier,
demonstrating the agreement with the ionisation chamber is within 0.7 % after
equalisation [9].

(a)

(b)
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(c)

(d)

(e)

(f)

(g)

(h)
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(i)

(j)

(k)

(l)

(m)

155

Figure 7.6: a) Reconstructed and b) planned 2D dose map at depth dmax for a highly asymmetric
radiation field geometry; (c-m) dose profiles along the lines indicated in (a) and (b) as planned,
reconstructed and measured by MPDM in the phantom at dmax .

Figure 7.6 demonstrates the application of MPTM for dose reconstruction in the case of
an asymmetric MLC leaf configuration.
Figure 6 (a) shows the reconstructed dose map generated at dmax from all MPTM
detector elements within the 20×20 cm2 irradiation field (defined at SSD of 100 cm).
The equivalent dose map planned using the PinnacleTM TPS is shown in Figure 7.6 (b).
Figure 7.6 (c) -6(m) show profiles of the planned dose in the phantom (red solid lines),
reconstructed dose in the phantom (blue dots) and measured dose with MPDM in the
phantom (green squares) along the column numbers indicated in Figure 7.6 (a). The
CC13 ionisation chamber was not used for 2D dose mapping in a solid water phantom
for the case of a strongly asymmetric field (Figure 7.6) as the chamber is not suitable for
small field dosimetry and in any case such 2D mapping would be a very time
consuming process.
For most dose profiles good agreement (better than 5%) between the MPDM and the
planned dose is observed, except for column #7. The column #7 is between blocked and
non-blocked fields and any small misalignment of MPDM along the leaf direction will
lead to large discrepancy due to the present MPDM sensor element pitch, which is 10
mm. Prediction of the dose profile out of field using the same reconstruction algorithm
as in-field is impossible at this stage and will be part of future development.
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7.4

Discussion

The 6 MV primary radiation field used here is made up of photons, electrons and (to a
much lesser extent) positrons [286]. The MP detectors are constructed of silicon and
sense all charged particles traversing the sensitive volume of the detector, whereas their
sensitivity to photons depends on the interaction cross section [287, 288]. The
proportion of the three primary field components is well-known to change slightly with
the field size defined by the linac jaws. Further, minor changes are expected depending
on the configuration and position of MLC leaves relative to the jaw position due to
changes in the scattering and shielding conditions resulting from the MLC leaves.
When the MP is mounted in the block tray the response of the silicon detectors used in
the MPTM will obviously be determined by the make-up of the primary field
components. However, due to the active thickness of the silicon detectors being only 50
µm, one might expect the corresponding response to be less sensitive to the photons (i.e.
weighted more towards charged particles) within the primary radiation field. The
electrons directly interact with the silicon detectors whereas the interactions cross
section for photoelectric, Compton and pair production are not significant in the
detector volume for clinically relevant (6 MV) photon spectra [288].
The results obtained in this chapter, represent an exciting development toward real-time
QA for IMRT and VMAT during treatment delivery using the MPTM.
MPTM measurements lead to direct dose derivation at any depth in a homogeneous
phantom using a “virtual diode” response concept effectively placed in the build-up or
pre-electronic equilibrium regions. The impact of MPTM on beam perturbation was
investigated both in-field (central axis) and out-of-field (OOF) for square field sizes 5×5
and 10×10 cm2 for 6 MV radiation field from medical linac.
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All data presented demonstrated that the design of MPTM produced negligible
perturbation of the radiation field reflected in less than 1% skin dose variation and less
than 0.1% in dose variation below depth 1 cm in -field when MPTM is in a beam. This
net decrease implies that the additional scatter dose created by having the MPTM
detector array in beam is not significant.
For OOF a similar decrease in dose at depth where electronic equilibrium exists was
measured except at the phantom surface which showed a small increase in dose when
the MP was placed in the beam. This difference however remains insignificant relative
to the dose at dmax. While the out of field dose is small one needs to consider it over the
full course of radiotherapy treatment and it should be minimised as much as possible,
consistent with the well-known ALARA principle. The small change of the OOF dose
measured can be attributed to a net increase electron contamination caused by the
MPTM detector in the beam acting as an extended source.
It is important to investigate this in more detail (i.e. whether the increase truly is due to
an increase in electron contamination or a change in the average LET of the
contamination electrons that traverse the MP detector). All data presented demonstrated
that the design of MPTM produced negligible perturbation of the radiation field as
reflected by the < 1% variation of in-field doses measured depth 1 cm when the MPTM
is placed in the beam.
The term “sweet depth” (SwD) and the “virtual diode” corresponding to that depth,
were coined to describe the depth at which the ratio of the central axis MPTM response
and absorbed dose at SwD in the phantom was approximately constant with field size.
The SwD that has identified for a 6 MV photon field was found to be at 1 mm depth in
the phantom for the bare MPTM detector on the central axis. Applying the same
response-to-dose conversion factor for all in-field MPTM detector elements (i,j) gives
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the dose measured by the “virtual diode” (i,j) and it has been demonstrated that the 2D
reconstructed dose correlated to within less than ±2.48 % (2 standard deviations) of the
measured by ionisation chamber 2D dose at dmax in the solid water phantom for all
square field sizes investigated.
The well-known effect of energy dependence of commercially packaged silicon diodes
used for direct dosimetry in a phantom or on a patient is minimised in this method by
using the transmission response of the MP to reconstruct the dose at any depth in a
phantom. This has been achieved in the MP design by utilising the “drop in” packaging
technology, developed at CMRP, which avoids any high Z materials, gold wire bonding
and thick over layers in contrast to packaging in commercial diodes [289]. Additionally,
the relative response of MPTM in free air geometry associated with silicon diode energy
dependence is not changing with an MLC determined field size significantly due to
minimal change in the photon spectra. This is in contrast to application of silicon diodes
for direct dosimetry in a phantom, where the silicon diode response is affected by
photon spectral changes with depth due to the contribution of lower energy scattered
photons to the dose which increases with increasing depth.
The sweet depth could be further refined in the future depending on the desired
precision and is certainly expected to be different for different linac operating
conditions (e.g. 10 MV or 18 MV photon fields), which will be the focus of a future
chapter.
Reconstruction of the dose under MLC blocked area using the same method as
developed for in-field dose is not feasible because the dose under the blocked area is
determined not only by the leakage through the MLC (as measured by the bare MPTM)
but also by scattered photons from in-field . This dose depends on the size of the MLC
opening and can be modelled using a beam model. The geometry of MLC opening is
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easily determined by the response of the MPTM and can be incorporated into a dose
reconstruction algorithm, similar to what was done in OCTAVIUS® [8].
An attempt was made to reconstruct the dose under MLC blocked regions using the
same procedure for the in-field reconstructed dose, however differences between the
reconstructed and measured doses were observed. This difference was 6 % in the case
of the 5x5 cm2 square field at depth of dmax (but 5 mm outside of the field – see
Figure 7.5 (a)) and up to 50 % (Figure 7.6) for the asymmetric MLC leaf configuration.
It is clear in the profiles shown in Figure 7.6 (c) – Figure 7.6 (m) that for the
asymmetric field case our simple analysis breaks down significantly when the MPTM
detector array elements are blocked by the MLC leaves. A systematic study of the dose
reconstruction under for fields partially blocked by the MLC leaves will be a part of
future work.
The proposed SwD method leads to the corresponding “virtual diode” at particular
depth in a phantom gives rise to in-field dose reconstruction at any depth for any gantry
angle during the treatment delivery and this allows application of the MPTM for 3D
dose reconstruction in a phantom for comparison with TPS using algorithms such as
those developed for OCTAVIUS® 4D [8]. However, OCTAVIUS® 4D can be used for
pre-treatment QA only and requires a cylindrical phantom and a real 2D detector array
and its synchronisation with a gantry angle. In comparison with existing transmission
mode detectors placed on a linac head for dose verification during treatment; the MPTM
is neither perturbing the beam nor increasing the skin dose. The “virtual diode” method
also leads to a direct, experimentally based, derivation of the in-field depth dose
distribution for any shape of MLC opening, i.e. independent of any beam model and /or
TPS having to be utilised in one or another way as required by other transmission
detectors that have recently appeared on the market. However for accurate dose
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reconstruction under blocked fields, the separate beam model is required, and this will
improve the overall 3D dose reconstruction for IMRT and VMAT.
The proposed SwD method leads to the corresponding “virtual diode” depth allows
immediate and simple application of the MPTM for 3D dose reconstruction. Using a
homogeneous virtual solid water cylindrical phantom for IMRT or VMAT delivery, it
has been shown by OCTAVIUS® 4D [185] that 3D reconstruction followed by
comparison with TPS predicted 3D dose in the same phantom is possible.
This virtual cylindrical phantom should be placed at SSD =100 cm, and other simple
corrections should be performed for points not on the central axis of the “virtual
diodes”. This is distinctly different to the slab phantom used in this thesis. In contrast, to
the OCTAVIUS® 4D QA phantom, the proposed method does not require a physically
cylindrical phantom with rotated 2D ionisation chamber arrays and their
synchronisation with the linac gantry rotation. This makes the virtual phantom mode
QA simple and robust. Due to “virtual diodes” (as opposed to the 2D ionisation
chamber array inserted in a OCTAVIUS® 4D phantom) the proposed system does not
have a “dead layer” on the surface of the phantom where the dose reconstruction is
impossible due to the absence of detectors close to the surface (mechanical constraint).
Additionally, due to very fast and high dynamic range of the readout electronics, the
dose reconstructed along the projected rays can be compared to the predicted dose by
the TPS in pulse-by-pulse or integrated within 200 ms as in case of OCTAVIUS® 4D
for each gantry angle for application during patient treatment. Another advantage is in
the small size of the diodes in MPTM allowing more accurate reconstruction of the
point dose along the projection. However, it has been recognised that better spatial
resolution (10 mm in the prototype MPTM) is required.
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MPTM is therefore a universal QA tool which could potentially be used for 2D dose
reconstruction in phantom or for QA during patient treatment and is fully independent
of the TPS.
The MPTM combines the advantages of transmission detectors which allow dosimetry
during the treatment with those of the OCTAVIUS® 4D QA tools that provides
dosimetry based on direct dose measurements in a phantom. In the future is planned to
extend the 2D dose reconstruction of MPTM to 3D similar to OCTAVIUS®.
Additionally, the same MP can be used for 2D dose mapping mode in a phantom, which
is some economic benefit.

7.5

Conclusion

It has been demonstrated that in a 6 MV linac photon field that the MPTM in the beam
minimally perturbs the radiation field leading to < 0.1 % increase (relative to dmax) in
the skin dose to the patient, and does not significantly change the PDD (less than 1% for
depths below 1.5 cm) for the investigated field sizes, while potentially allowing for realtime verification of VMAT and IMRT treatments.
The first stage of development of a dose reconstruction procedure based on the sensing
of the energy fluence and identifying the Sweet Depth (SwD), and corresponding
“virtual diode” depth, was successfully completed. Based on the reading of “virtual
diode” response found empirically, which is in the same proportion for all field sizes
measured at 1mm depth, the dose map can be reconstructed for each open field and
compared with the prescribed dose from the TPS. In this chapter it has been
demonstrated in a 6 MV, that for several square field irradiation geometries the in-field
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reconstructed dose correlates with the directly measured dose at dmax to be within ± 2.48
% (2 standard deviations) for all in-field MP detector elements.
The small in-field variation measured demonstrates the robustness of the reconstruction
method of using the MPTM in field data to reconstruct the dose along the projected rays
from the source through each MPTM detector element at the given depth in the
phantom. Similar results are obtained for in-field dose reconstruction in an asymmetric
field. The reconstructed dose methodology in its current form is more than adequate to
detect gross errors of in-field IMRT or VMAT radiotherapy treatment during patient
treatment in real time using in-field MPTM diodes only.
Determination of which conversion factor to be used for each ray is selected based on
absolute response of the MPTM diodes. Diodes which are in open fields have
essentially higher and identical response than diodes under blocked fields. It will
provide an open field effective area and selection of the conversion factors for each
diode in real time pulse by pulse by the fast data acquisition system (DAQ) system.
Reconstructed in-field and blocked field projected doses for each gantry angle will
allow 3D dose reconstruction.
Straight forward application of MPTM for QA on a virtual cylindrical phantom utilising
“virtual diodes” which have angular independent response for 3D dose reconstruction is
possible without delay applying similar to existing OCTAVIUS® 4D or ArcCheck
software packages.
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CHAPTER 8
Dose Reconstruction in 10 MV and 18 MV
Radiation Fields
This chapter extends the work described in the previous chapter to different beam
qualities commonly used in clinical radiotherapy, namely 10 MV and 18 MV radiation
fields. It is important to demonstrate that the MPTM can be used in these radiation
fields as they differ significantly from 6 MV with the production threshold of
photoneutrons being surpassed at 10 MV. The impact on the ability of the MPTM to
operate as a transmission detector in terms of beam perturbation is discussed in the
context of a QA system for VMAT and IMRT treatment modalities. The methods
undertaken here are similar to those described in the previous chapter and MPTM
measurements performed in real-time are used to reconstruct the dose for simple field
geometries in a uniform phantom.

8.1

Materials and methods

The divergence of the radiation field with distance from the X-ray source must be taken
into account when reconstructing the dose at any given depth in the solid water phantom
from the response of the MPTM. At the position (i.e. in the accessory slot of the linac)
of the MPTM (58 cm from the X-ray source) the actual field size is 1.76 times smaller
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than that at 102.1 cm SSD, and 1.77 times smaller than that at 103 cm SSD for 10 MV
and 18 MV beam energies respectively.
For the MPTM study two operational set-up conditions were tested (i) the bare MP
array (sandwiched between black plastic sheets, 80 µm thick) (ii) the bare MP array
with an additional 1 mm of solid water covering the entire array.
In addition, the two set-ups were chosen to determine the influence of the unavoidable
contamination electron component within the linac radiation field on the ability to
reconstruct the dose from the MPTM response under similar irradiation conditions.

8.1.1

Surface dose and buildup measurements

The effect of the two MPTM set-ups on the surface dose (both in-field and out-of-field)
is of primary importance since it is at the surface where the maximum impact of the
MPTM is expected. Depth dose curves were then measured on the CAX and OOF as a
function of the irradiation field size to a depth of 10 cm as explained in previous
chapter. All dose measurements were made with a Markus chamber and Attix ionisation
chamber in a solid water phantom. The Markus chamber was connected via a triaxial
cable to a PTW UNIDOS model T10002-20713 electrometer with -300 V bias voltage
applied. Additionally, the Attix chamber was connected via a triaxial cable to a PTW
UNIDOS model T10001-11678 electrometer with -300 V bias voltage applied. All
measurements were repeated at least three times to calculate the average and standard
deviation. All Markus ionisation measurements were corrected for over response for the
chamber measurements [260, 263] .
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8.1.2

MPTM response as a function of field size

In the second part of this chapter the MPTM response for different irradiation field
sizes ranging from 5×5 cm2 to 40×40 cm2 was investigated similarly to that described in
the previous chapter.

8.1.3

Dose reconstruction technique using MPTM response

All 10 MV dose measurements as a function of field size and depth in the solid water
phantom were carried out using the same ionisation chamber mentioned above under
the same geometric conditions with the data compared with independent extrapolation
chamber data (Far West Technology) [285].
A Wellhöfer Compact ionisation chamber (model CC13) and the Farmer ionisation
chamber (model NE 2571) were used for complimentary output factor measurements at
depth of 2.1 cm (dmax) in the solid water phantom.
The final part of the work presented in this chapter demonstrates the ability of all 121
pixels of the MPTM (operating under set-up condition (i and ii) mentioned above) to
reconstruct the 2D distribution of the dose delivered at any depth in the phantom.
The 2D dose distribution of the radiation field at 2.1 cm depth (dmax) for a 10 MV
photon field and at 3 cm depth (dmax) for 18 MV beam for field sizes ranging from 5×5
cm2 to 40×40 cm2 at an SSD of 100 cm was separately measured using the MPDM in
the solid water phantom as explained in details in chapter 4.
As the MPTM is effectively transparent to the radiation field it is reasonable assume
that a direct correlation may exist between MPTM response and the patient dose and
this correlation would ideally be independent of field size. The MPTM response may
then be used to reconstruct the 2D or 3D dose without using any information from the
treatment planning system.
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8.2

Results

8.2.1

Surface dose and buildup measurements

Figure 8.1 shows the PDD profile for both the (a and c) in-field on the CAX and (b and
d) OOF for a 10×10 cm2 and 5×5 cm2 field size respectively with the bare MPTM.

(a) 10 MV (CAX)

(b) 10 MV (OOF)

(c) 18 MV (CAX)

(d) 18 MV (OOF)

Figure 8.1: 10 MV and 18 MV percentage depth dose profiles measured using a Markus
IC (10 MV) and Attix IC (18 MV) as a function of depth in solid water phantom with
and without the bare MPTM in place, together with the difference between the two to
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highlight the differences. (a) and (c) are for CAX and (b) and (d) are OOF. The field
size was 10×10 cm2 and 5×5 cm2 as indicated.

Error bars represent three standard deviations (3 SD) from the mean. The square
symbols in each graph show the percentage deduced change (plotted separately) in the
percentage depth dose curve caused by the MPTM. The influence of the bare MPTM is
insignificant. At the phantom surface and on the CAX, the change in the dose relative to
dmax with and without the MPTM in position was measured by an ionisation chamber to
be less than 0.50% for all beam energies tested. In the OOF positions measured, the
effect of the MPTM on PDD distribution at the phantom surface relative to dmax (21mm
depth for 10 MV and 30 mm depth for 18 MV) was negligible, < 0.30% for all field
sizes at both energies.

(a)

(b)

168

(c)

(d)

Figure 8.2: 10 MV radiation field analysis with (a) Response of the MPTM with treatment field
size; (b) Normalised response of the MPTM together with CC13 IC for different irradiation
field sizes; (c) Ratio of the measured IC (Markus chamber) dose at several depths and MPTM
(i.e. no build up) response for different irradiation field sizes. The data has been normalised to
the 10×10 cm2 field size response at each depth; (d) Ratio of the measured IC (Markus
chamber) dose at several depths and MPTM (with 1 mm build up) response for different
irradiation field sizes. The data has been normalised to the 10×10 cm2 field size response at
each depth.

(a)

(b)
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(c)

(d)

Figure 8.3: 18 MV radiation field analysis with (a) Response of the MPTM with treatment field
size; (b) Normalised response of the MPTM together with CC13 IC for different irradiation field
sizes; (c) Ratio of the measured IC (Markus chamber) dose at several depths and MPTM (i.e. no
build up) response for different irradiation field sizes. The data has been normalised to the 10×10
cm2 field size response at each depth; (d) Ratio of the measured IC (Markus chamber) dose at
several depths and MPTM (with 1 mm build up) response for different irradiation field sizes. The
data has been normalised to the 10×10 cm2 field size response at each depth.

8.2.2

MPTM response as a function of field size

Figure 8.2(a) and Figure 8.3(a) shows the absolute response of the central detector of
the MPTM (in nC) located on the CAX of the 10 MV and 18 MV radiation field
respectively, as a function of field size. The bare MP was sandwiched between either
two sheets of 80 µm thick black plastic (triangles) or 1 mm of solid water (dots).
The observed small reduction in absolute MPTM response when the MLC positions
were chosen to match those of the linac jaws is due to the MLCs shielding the MP from
some contamination electrons created inside the head of the linac. No such decrease is
observed for the case where the MP detector is encapsulated by 1 mm of solid water,
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which indicates that the solid water attenuates the bulk of the above mentioned
contamination electrons.

8.2.3

Dose reconstruction technique using MPTM response

For the case where the MLCs match the linac jaws, adding the 1 mm solid water leads
to a consistent increase in the absolute response of the MP detector for all field sizes.
Such an increase could be significant as it indicates that the MPTM response seems not
to be dominated by the contamination electrons that make up the primary radiation
field, but rather the primary photons. This has important ramifications for the ability of
the MP system to deduce the reconstructed dose for complex treatment fields as
discussed below.
The MPTM response data has implications for the final intended application of the MP
when used in transmission mode, which ideally, would be to measure the real-time
energy fluence so as to be able to reconstruct the dose along rays defined by the line
emanating from the photon source through each MP detector during a patient treatment.
A decrease in the measured MPTM response is expected with decreasing field size as it
is well-known that the linac output monitor units (MUs) must be compensated
(increased) as the irradiation field size is increased in order to maintain the delivery of a
given prescribed dose to a target at a given source to target distance. The linac MU
output factor is used to ensure the dose at dmax is independent of field size. Ideally the
in-field response of the MPTM would scale with the linac output factor.
The data in Figure 8.2(b) and Figure 8.3(b) are normalised to the response of the MP
detector in a 10×10 cm2 field size in Figure 8.2(a) and Figure 8.3(a) respectively. The
data is shown together with the linac output field factor (OF) measured independently
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using both CC13 chamber for 10 MV and thimble IC for 18 MV at dmax measured with
the MLCs retracted (crosses).
The observed difference between the MP response and the OOF observed in
Figure 8.1(b) and Figure 8.2(b) is to be anticipated as the MP (positioned in the block
tray) is mounted in a free air geometry. The response of MPTM OOF significantly
affected by the make-up of the primary radiation field at the position of the MPTM
which will include a significant proportion of low energy scattered electrons created in
the linac head [283, 284]. Likewise, the influence of the MLCs on the measured MPTM
response is expected to be more significant OOF.
For in-field elements of the MPTM array a simple conversion factor could be used in
order to reconstruct the dose during patient treatment from the MPTM response. It may
also be possible to find a SwD where the MPTM response is proportional to the dose as
a function of field size, which could be different from that found for the 6 MV case.
This has been investigated for the fields where the MLCs match the linac jaws for the
MPTM detector array (with and without the build-up layer).
Figure 8.2(c) and Figure 8.3 (c) show the dose measured by the Markus and Attix ICs at
various depths divided by the MPTM response (without the 1 mm solid water cover).
The dose values were obtained for irradiation field sizes between 5×5 cm2 and 40 × 40
cm2. The Markus and Attix ICs data used were taken with the MLCs matching the jaws.
Table 8.1and Table 8.3 show the ratio of the measured (Markus &Attix chambers) dose
at several depths and the bare MPTM (without build up) response for different
irradiation field sizes.
If one focuses on using the MPTM in the block tray position for small field irradiation
geometries (i.e. applications in IMRT and VMAT) then the graph indicates that the
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SwD appears to be between 1 and 2 mm, but only if the application is restricted to field
sizes of less than 20×20 cm2.

Table 8.2 and Table 8.4 show the ratio of the measured (Markus &Attix chambers) dose
at several depths and MPTM (with 1mm build up) response for different irradiation
field sizes. In this case the MPTM with the 1 mm build-up layer as shown in Figure
8.2(d) and Figure 8.3(d) indicate that the SwD is 2 mm. The data also indicates that the
field sizes over which the MP could be used for this set-up increases to 30×30 cm2.

(a)

(b)

Figure 8.4: (a) 2D response map of MPTM, field size 40×40 cm2 at SSD 100 cm and (b)
2D dose map of MPDM, at 21 mm depth, field size 40×40 cm2 at SSD 100 cm for a 10
MV photon field.
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(a)

(b)

Figure 8.5: (a) 2D response map of MPTM, field size 40×40 cm2 at SSD 100 cm and (b)
2D dose map of MPDM, at 30 mm depth, field size 40×40 cm2 at SSD 100 cm for an 18
MV photon field.

Figure 8.4 and Figure 8.5 illustrates the above point very well, showing the variation of
the MPTM response (in nC) in the X-Y plane for a 40×40 cm2 field size at SSD100
together with the response (in nC) of the MP operating in dose mode at 21mm and 30
mm depths for 10 MV photon and 18 MV beams respectively (MPDM-dmax), in a
30×30×20 cm3 solid water phantom. The trend observed in the MPTM 2D data can also
observed in the MPDM plot even though the field cross-section sampled by the MPDM
is smaller than that for MPTM due to the divergence of the field with distance from the
source.

174

(a) 5×5 cm2

(b) 10×10 cm2

(c) 20×20 cm2

(d) 30×30 cm2
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(e) 40×40 cm2
Figure 8.6: The beam dose profiles measured by the MPDM were compared with those from
the CC13 IC and reconstructed doses at dmax 21 mm in case of 10 MV. The SwD used was 1mm
(bare MPTM with no build up).

Figure 8.6 shows a comparison of the dose profile of the measured MPDM,
reconstructed point doses at dmax(i,j) from the measured Ri,j MPTM data (with no build
up) with measured IC (CC13) data for several square field geometries along the centre
of the field at 21mm depth for 10 MV photon beam. The observed offset in the profiles
is due to the field factor as 100 MU was delivered at each position and the graphs are
displayed in term of measured dose in Gray (Gy). Excellent agreement exists between
the two sets of data for all of the field sizes, both in field and out of the irradiation field
with all MPDM data. The percentage difference between the reconstructed dose and the
measured dose at the central row (row no.6) for all in field MP detector elements for all
field sizes was less than 3%, however, for 20×20 cm2 field size was 9 % at the edge of
the field only. This could be related to the blockage of the MLC and will require future
development investigation.
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(a) 5×5 cm2

(b) 10×10 cm2

(c) 20×20 cm2

(d) 30×30 cm2
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(e) 40×40 cm2

Figure 8.7: The beam dose profiles measured by the MPDM were compared with those from the
CC13 IC and reconstructed doses at dmax 21 mm in case of 10 MV. The SwD used was 2 mm
(bare MPTM with no build up).

Figure 8.7 shows a comparison of the dose profile of the measured MPDM,
reconstructed point doses at dmax(i,j) from the measured Ri,j MPTM data (with no build
up) with measured IC (CC13) data for several square field geometries along the centre
of the field at 21mm depth for 10 MV photon beam. The SwD depth of 2 mm was
investigated as well. Results show that the same percentage difference indicated in Fig 5
was obtained at 2 mm sweet depth.
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(a) 10×10 cm2

(b) 20×20 cm2

Figure 8.8: The 10×10 cm2 and 20×20 cm2 beam dose profiles measured by the
MPDM were compared with those from the CC13 IC and reconstructed doses at
dmax (21 mm in case of 10 MV). The SwD used was 1 mm in this case and the
MLCs were retracted (i.e. open) for the MPTM data.

Figure 8.8 shows a comparison of the dose profile of the measured MPDM,
reconstructed point doses at dmax(i,j) from the measured Ri,j MPTM data (with no build
up and MLC was retracted) with measured IC (CC13) data for 10×10 cm2 and 20×20
cm2 field geometries along the centre of the field at 21mm depth for 10 MV photon
beam. A SwD depth of 1 mm was utilized in this case. The percentage difference
between the reconstructed dose and the measured dose at the central row (row no.6) for
10×10 cm2 field sizes was less than 4%, and less than 8% for 20×20 cm2 field size.
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(a) 5×5 cm2

(b) 10×10 cm2

(c) 20×20 cm2

(d) 30×30 cm2

(e) 40×40 cm2
Figure 8.9: The beam dose profiles measured by the MPDM were compared with
those from the CC13 IC and reconstructed doses at dmax (21 mm in case of 10 MV).
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The SwD that used was 1 mm for field sizes < 10×10 cm2 and 5 mm for field sizes
> 10×10 cm2. The MPTM with 1 mm build up was used here.

Figure 8.9 shows a comparison of the dose profile of the measured MPDM,
reconstructed point doses at dmax(i,j) from the measured Ri,j MPTM data (with 1mm
build up) with measured IC (CC13) data for several square field geometries along the
centre of the field at 21mm depth for 10 MV photon beam. It has been taken into
account correction of the “virtual diode” response off the central axis at depth 1 mm for
field sizes < 10×10 cm2 and 5 mm for field sizes > 10×10 cm2 by implementing an
additional coefficient to α, which is an inverse distance squared ratio geometry based
correction coefficient. The percentage difference between the reconstructed dose and
the measured dose at the central row for all in field MP detector elements for all field
sizes was less than 3%. However, for 20×20 cm2 field size was 4 % at the edge of the
field only.

(a) 5×5 cm2

(b) 10×10 cm2
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(c) ) 15×15 cm2

(d) 20×20 cm2

(e) 30×30 cm2

(f) 40×40 cm2

Figure 8.10: Beam dose profiles measured at a depth of dmax (30 mm for 18 MV field) with the
PTW thimble IC in comparison with both the measured MPDM and reconstructed profiles from
the MPTM response dose for all diodes in row-6 of the MP array. The SwD that was used was 1
mm for field sizes < 10×10 cm2 and 6 mm for field sizes > 10×10 cm2. The MPTM with no build
up was used here.

Figure 8.10 shows a comparison of the dose profile of the measured MPDM,
reconstructed point doses at dmax(i,j) from the measured Ri,j MPTM data (with no build
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up) along with the measured IC (PTW thimble) data for several square field geometries
along the centre of the field at 30 mm depth for 18 MV beam.

(a) 5×5 cm2

(b) 10×10 cm2

(c) 15×15 cm2

(d) 20×20 cm2
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(e) 30×30 cm2

(f) 40×40 cm2

Figure 8.11: Beam dose profiles measured at depth of dmax (30 mm for 18 MV beam
energy) with the PTW thimble IC in comparison with both the measured MPDM and
reconstructed profiles from the MPTM response using all diodes in row-6 of the MP
array. The SwD that used was 2 mm for field sizes < 10×10 cm2 and 15 mm for field
sizes > 10×10 cm2. The MPTM with 1mm build up was used here.

Figure 8.11 shows a comparison of the dose profile of the measured MPDM,
reconstructed point doses at dmax(i,j) from the measured Ri,j MPTM data (with 1mm
build up) with measured IC (PTW thimble ) data for several square field geometries
along the centre of the field at 30 mm depth for 18 MV beam. The correction of the
“virtual diode” response on the non-central axis has been taken into account by
implementing a coefficient additional to α which is an inverse distance square ratio
geometry based correction coefficient.
Similarly, for the MPTM (no build up device) the correction of the “virtual diode”
response has been taken into account on the non-central axis at a depth of 1 mm for
field sizes < 10×10 cm2 and 6 mm for field sizes > 10×10 cm2 and at a depth of 2 mm
for field sizes < 10×10 cm2 and 15 mm for field sizes > 10×10 cm2 for MPTM (with
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1mm build up) by implementing a coefficient additional to the α which is an inverse
distance square ratio geometry based correction coefficient.

Table 8.1: Ratio of the (Markus chamber) dose and MPTM (no build up) response for
different irradiation field sizes, measured at several depths. The data has been
normalised to that for the 10×10 cm2 field size at each depth. Ion chamber
measurements were performed at an SSD of 100 cm and in a 10 MV photon field.
Depth (mm)

Field
size
(cm2)

0 mm

1mm

2 mm

3 mm

4 mm

5mm

10mm

15mm

21mm

25mm

30mm

100mm

5

0.922

1.138

1.220

1.242

1.263

1.275

1.315

1.337

1.350

1.355

1.356

1.315

10

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

15

1.114

0.980

0.928

0.910

0.899

0.892

0.866

0.854

0.847

0.845

0.844

0.858

20

1.265

1.022

0.928

0.899

0.879

0.866

0.82

0.803

0.792

0.789

0.787

0.808

30

1.523

1.113

0.927

0.905

0.874

0.854

0.788

0.760

0.746

0.743

0.742

0.770

40

1.705

1.186

0.987

0.927

0.890

0.866

0.793

0.764

0.750

0.747

0.746

0.775

Table 8.2: Ratio of the (Markus chamber) dose and MPTM (1 mm build up) response
for different irradiation field sizes, measured at several depths. The data has been
normalised to that for the 10×10 cm2 field size at each depth. Ion chamber
measurements were performed at an SSD 100 cm and in a 10 MV photon field.
Depth (mm)

Field
size
(cm2)

0 mm

1 mm

2 mm

3 mm

4 mm

5 mm

10mm

15mm

21mm

25mm

30mm

100mm

5

0.815

1.006

1.078

1.098

1.116

1.127

1.181

1.181

1.193

1.197

1.1989

1.162

10

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

15

1.218

1.072

1.014

0.995

0.982

0.975

0.934

0.934

0.926

0.924

0.923

0.937

20

1.415

1.143

1.039

1.006

0.983

0.969

0.898

0.898

0.886

0.883

0.881

0.904

30

1.760

1.287

1.072

1.047

1.011

0.987

0.878

0.878

0.862

0.859

0.857

0.890

40

1.966

1.368

1.139

1.070

1.027

0.999

0.881

0.881

0.865

0.862

0.860

0.894
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Table 8.3: Ratio of the (Attix chamber) dose and MPTM (no build up) response for
different irradiation field sizes, measured at several depths. The data has been
normalised to that for the 10×10 cm2 field size at each depth. Ion chamber
measurements were performed at an SSD of 100 cm and in an 18 MV photon field.
Depth (mm)

Field
size
(cm2)

0 mm

1mm

2mm

3mm

4mm

5mm

6mm

15mm

21mm

30mm

33mm

35mm

5

0.642

1.010

1.174

1.229

1.270

1.295

1.316

1.413

1.446

1.476

1.483

1.487

10

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

15

1.389

1.172

1.080

1.046

1.022

1.010

0.995

0.933

0.915

0.899

0.894

0.892

20

1.695

1.321

1.160

1.102

1.058

1.038

1.011

0.904

0.875

0.849

0.844

0.841

30

2.166

1.556

1.292

1.197

1.126

1.091

1.051

0.887

0.847

0.813

0.807

0.803

40

2.467

1.703

1.369

1.253

1.1678

1.125

1.076

0.892

0.848

0.814

0.806

0.803

Table 8.4: Ratio of the (Attix chamber) dose and MPTM (1 mm build up) response for
different irradiation field sizes, measured at several depths. The data has been
normalised to that for the 10×10 cm2 field size at each depth. Ion chamber
measurements were performed at an SSD of 100 cm and in an18 MV photon field.
Depth (mm)

Field
size
(cm2)

0 mm

1 mm

2 mm

3 mm

4 mm

5 mm

6 mm

15mm

21mm

30mm

33mm

35mm

5

0.537

0.845

0.982

1.028

1.062

1.083

1.1003

1.182

1.209

1.235

1.240

1.243

10

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

1.000

15

1.462

1.233

1.137

1.101

1.075

1.063

1.047

0.982

0.963

0.946

0.941

0.939

20

1.811

1.411

1.239

1.177

1.131

1.109

1.080

0.966

0.934

0.907

0.901

0.898

30

2.361

1.695

1.408

1.305

1.227

1.189

1.145

0.967

0.923

0.886

0.879

0.875

40

2.696

1.861

1.496

1.370

1.276

1.230

1.176

0.975

0.926

0.889

0.881

0.878
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8.3

Discussion

Two versions of the MPTM were investigated with the intention of demonstrating the
optimization of the trade-off between primary radiation field attenuation/scattering and
best response repress
entation of the energy fluence.
The results showed that in general, both versions of the MPTM detector array could
potentially be used as a 2D transmission detector, however, the MPTM with 1mm build
up proved to be the best candidate for 10 MV and 18 MV beams. For the same field
sizes the OOF dose was measured to be insignificant compared to the in-field dose but
slightly increased at the surface with increasing irradiation field dimensions. The small
change (<1%) of the in-field surface dose measured can be attributed to a net increase
electron contamination caused by the MPTM detector acting as an extended source
when in its operating position within the block tray.
The best correlation between the measured MPTM 2D response (representative of the
2D energy fluence) and the 2D dose was coined as the SwD and was characterised for
both the versions of the MPTM array. The sweet depth that has been identified for a 10
MV photon and 18 MV fields indicates that the MPTM response data correlates with
the 2D energy fluence distribution of the modulated radiation beam and the
reconstructed dose at a given depth within a homogeneous phantom for IMRT treatment
delivery verification. For all field sizes investigated the deduced in-field 2D dose plan
correlated very well with the actual in-field 2D dose plan measured in the solid water
phantom. The sweet depth may be further refined in the future if better precision is
desired, and is certainly expected to be different for different linac operating conditions
(e.g. 10 or 18 MV photon fields).
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8.4

Conclusion

The new real-time method with the potential to monitor the patient dose during
treatment has been demonstrated using the MPTM. It has been demonstrated in a 10
MV and 18 MV linac fields that the MPTM minimally perturbs the radiation field
leading to < 1 % increase in the skin dose to the patient. The dose can then be
reconstructed along rays projected from the photon source through each MPTM detector
element and compared with the prescribed dose from the TPS system. This potentially
allows for real-time verification of IMRT or VMAT treatments.
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CHAPTER 9
Conclusion and Future Work
Over the last 15 years, more sophisticated methods for tailoring the radiation
distribution to conform to the target and avoid healthy tissue irradiation have come into
routine clinical use. Methods such as IMRT, VMAT and SABR rely on collimating the
radiation beam to millimeter accuracy using over 100 independently controllable
tungsten leaves which are driven by servo-motors to multiple positions at precise times
during the treatment to shape the radiation beam correctly and thus better optimise
clinical radiation treatment.
A sophisticated computer algorithm calculates all the treatment parameters to optimise
the dose distribution in the patient. A single patient treatment plan may contain
thousands of treatment parameters defining all of these variables. This complexity
makes it imperative that processes are in place to check and verify that the parameters
are correct and that the X-ray equipment delivers the dose accurately.
As there is a significant need for online detectors to be used during patient treatment a
2D detector array “Magic Plate” was developed by the CMRP to measure 2D radiation
dose distributions.
In this thesis, the MP detector, developed for verification of complex radiotherapy
treatment plans, was investigated in terms of its operational performance in many
different irradiation geometries and irradiation beam qualities. An algorithm was
developed as part of this thesis work that would allow the MP detector to be attached to
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the linear accelerator during a patient treatment so that it can continuously record a 2D
map of the radiation dose being delivered for comparison with the intended dose plan.
Traditionally most verification of a patient treatment plan occurs before the patient
commences treatment and relies on measuring doses at multiple points in a phantom
(effectively a plastic dummy patient). This is an intensive task and a significant
workload for clinical physicists. The assumption is then that all of the subsequent
patient treatments execute as planned and without differing from the pre-treatment
verification test. This is generally, a reasonable assumption due to the high levels of QA
that are applied to all systems involved. However, there is always a very small
probability that mechanical, electronic, human or data corruption issues could lead to
inaccurate treatment delivery in subsequent patient treatments. There are many layers of
safeguards already in place to reduce this risk but the concept of measuring the radiation
dose distribution every day as it is delivered to the patient is elegant and appealing.
Using the method developed, the MP detector sits in the radiation path, in transmission
mode, (MPTM) before the X-ray beam hits the patient and records millisecond by
millisecond a 2D map of the intensity of X-rays directed at the patient. Because of its
very thin design there is almost no perturbation to the X-ray beam due to the presence
of the detector.
In this thesis, an algorithm has been developed that predicts the dose in the patient
based on the measured intensity of the X-ray distribution in the beam using MPTM.
This can be checked against the intended plan and if they disagree the treatment can be
stopped automatically and immediately. This requires additional interfacing, hardware
and software decision systems that are not addressed in this thesis.
The result is a method that could be used to ensure patient treatment safety and accuracy
on a day to day basis. In the clinic, doctors are always looking for ways to provide
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improved quality and safety with increased efficiency and automation. Incorporation of
this system (MPTM system) into an automated daily dose data log could provide a
higher level of assurance with minimal workload impact for clinicians.
In transmission mode, two MP operational set-ups were presented in this thesis (the
bare MPTM and the MPTM with 1mm build up). This thesis involved the assessment of
the potential of the MP sensor array for small and large X-ray field transmission and
dosimetry measurements on a medical linac.
The 2D array of epitaxial silicon based detectors with “drop-in” packaging showed
properties suitable to be used as a simplified multipurpose and non-perturbing 2D
radiation detector for radiation therapy dosimetric verification (MPDM) (i.e. in
dosimetry mode). The broad range of tests performed in this thesis, concluded that the
2D array is a dosimetrically accurate and sensitive tool and that it can be a useful device
for QA and verification of clinical radiotherapy beams.
The output factor of the treatment field and beam profiles in a solid water phantom at
different depths and different treatment configurations were measured and compared
with different types of ionisation chambers. Discrepancies are within 1% for all
measured field sizes and beam energies. The MP measurements were able to be
extended to smaller field sizes less than 5×5 cm2 since the active volume of the MP
sensors are much smaller than the ionisation chamber. This highlights one of the major
advantages of the MP detector since the intra-fraction treatment field sizes in clinical
treatment continue to decrease. The 2D MPDM successfully detected centimeter
positional movements of the linac secondary collimators. Furthermore, dose profiles
matched very well with ion chamber measurements. Both in and out of the irradiation
field, a maximum percentage difference of 3% for all field sizes and for all beam
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energies tested has been reported in this thesis. Furthermore, the MPDM detector
measurements are accurate also in the penumbra region.
The basic characterisation of the MPTM was performed, including equalisation,
response linearity, reproducibility, energy response, the response of the array with
different dose rates, the response of the array as a function of field size, transmission
factors, and attenuation of the beam by MP, back scattering effect. Discrepancy of the
response between the diodes in a flat field was ± 0.15 %, ± 0.14 % and ± 0.10 % after
the equalisation technique for 6 MV, 10 MV and 18 MV energy beam respectively. The
response linearity of MPTM was excellent (R2 =1). The effect of the backscattered
photons from the phantom to the response of the MPTM vs field size was investigated.
The percentage variation of the response of in-field MPTM detector array elements for a
field size of 2×2 cm2 and 10×10 cm2 with and without the phantom in place was less
than 0.5%. For array elements outside the radiation field the variation was less than
3.5%. These results indicate that the backscattered photons from the phantom, make a
very small contribution to the measured response of the MPTM with field size,
(particularly in-field). A significant contribution (>10%) would have to be taken into
consideration in the dose reconstruction procedure. It was therefore concluded that this
contribution could be ignored in the dose reconstruction process. Small contribution that
backscattered photons from the phantom, make to the measured response as a function
of field size.
The performance characteristics of the MPTM system upstream of the patient were
demonstrated. Of particular interest is a quantitative study into the influence of the
MPTM on the radiation beam quality at several field sizes and linear accelerator
potential differences. The impact is measured through beam perturbation effects such as
changes in the skin dose and/or PDD (both in and out of field). The change in the
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surface dose relative to dmax was measured to be less than 0.5 % for the 6 MV, 10 MV
and 18 MV energy beams. Therefore, MPTM does not provide a significant increase in
skin dose to the patient and the PDDs showed an excellent agreement with and without
MPTM for 6 MV, 10 MV and 18 MV energy beams. Compared to the transmission
detectors, both the IQM system and the DAVID system attenuate a 6 MV photon beam
by 7% while the COMPASS system reported a 3.3 % beam attenuation, which are both
greater than the values measured for the MP system. The recently introduced ScandiDos
Delta4® DiscoverTM system attenuates the beam up by to 1% whereas a maximum of
11% increase in the surface dose has been reported for the IBA DolphinTM detector.
Transmission factors measured for both set ups (with different build up) with 6 MV, 10
MV and 18 MV at a depth of dmax and a depth of 10 cm were all within 1.6 % of open
field (see section 5.3.3). The effect of both the bare MPTM and the MPTM with 1 mm
build up on 3D dose distribution in comparison to the open field investigated using the
Delta4® system and both the MPTM versions passed standard clinical gamma analysis
criteria. The results indicate that both versions may be suitable for the new real-time
megavoltage photon treatment delivery QA system under development. However, the
bare MPTM appears to be the slightly better suited of the two MP versions as it
minimally perturbs the radiation field and does not lead to any significant increase in
skin dose to the patient. However, if the surface dose considered as an important factor
to be considered for the cancer treatment, then the bare MPTM proved to be the best
candidate as the increase to the surface dose was the least of the two systems tested.
The photon irradiation response of a 2D solid state transmission detector array mounted
in a linac block tray is used to reconstruct the projected 2D dose map in a homogenous
phantom along rays that diverge from the X-ray source and pass through each of the 121
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detector elements. A unique diode response-to-dose scaling factor, applied to all
detectors, is utilised in the reconstruction to demonstrate that quantitatively real-time
QA during radiotherapy treatment is feasible.
The development of a dose reconstruction procedure based on the sensing of the energy
fluence and establishing the sweet depth was successfully completed. The sweet depth
that has been identified for different MV photon beams proves that the MPTM response
data can be used to both correlate with the 2D energy fluence distribution of the
modulated radiation beam and proportional to the dose at a given depth within a
phantom. It has been found that the MPTM response is proportional to the projected 2D
dose map measured at a specific phantom depth, the “sweet depth”. A single factor, for
several irradiation field sizes and depths, is derived to reconstruct the dose in the
phantom along rays projected from the photon source through each MPTM detector
element. It has been demonstrated that for all field sizes using the above method, the 2D
reconstructed and measured doses agree to within ± 2.48 % (i.e. 6 MV photon beam) (2
standard deviation) for all in-field MP detector elements.
Currently several QA devices working in transmission mode for real-time dose
verification during the patient treatment are available. One of them is Delta4AT
transmission device from Delta 4 family products [290]. However this device should be
used in conjunction with Delta 4 pre-treatment QA device and should be first calibrated
for each particular plan delivery for which 3D dose delivery verified by Delta 4. This
makes device expensive and not independent.
Recently IBA Dosimetry introduced the transmission device Dolphin which is based on
array of 1513 ionisation chambers with pitch of 5 mm [193] . The device measures
photon energy fluence which is used to reconstruct 3D dose in a patient or phantom
using the beam model, i.e. not fully machine independent.
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Another transmission QA device is IQM based on transmission wedge type ionization
chamber which is placed on a linac head [291]. The device is measuring the area dose
product in real-time during the patient treatment. It is assumed that response of the
wedge ionization chamber is unique for particular MLC opening size and position.
While the device provides control of the correctness of MLC opening driven by the TPS
is not reconstructing the 3D dose independently of the machine.
All mentioned above transmission devices are not ideally transmitting radiation and
have different degrees of beam perturbation and increasing the skin dose to the patient.
The proposed MPTM is very thin and does not perturb the beam, providing
transmission of 1.6 % of the open field for all beam energies tested and no significant
skin dose increase < 0.5 %.
The proposed method of the response of the MPTM to dose in the patient is independent
of the machine and TPS and is based on a virtual diode (sweet point) response and PDD
for particular photon energy. It makes this device convenient for independent QA
during the patient treatment.
The advantage of MPTM compared to the EPID based system is that the algorithm does
not need to cater for patient perturbation of the beam or patient motion effects.
The reconstruction methodology will also be of great interest to the wider oncology
community as it is applicable to many other forms of radiotherapy including
Stereotactic Radiosurgery, Stereotactic Radiotherapy, Image Guided Radiotherapy and
Motion Adaptive Radiotherapy with dynamic multi leaf collimator tracking, where real
time radiation treatment monitoring through dose reconstruction is very important.
Future work will be directed to the application of the MPTM for 3D dose reconstruction
in a phantom for patient relevant plans and its comparison with the TPS and other
devices such as Delta4® or ArcCHECK.
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